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Extracellular matrix acts as the supporting structure of a tissue and dynamically changes in a 
reciprocal relationship with cells of that tissue. ECM changes with aging and disease and can 
affect the responses of cells in these altered states. ECM can be used as a model for aged 
microenvironments to more fully understand their effect on cellular function. Macrophage 
polarization has been shown to be necessary for appropriate skeletal muscle healing. This study 
used decellularized skeletal muscle ECM from young and aged mice to determine 
microenvironmental effects on macrophage phenotype both in vitro and in vivo using an 
abdominal wall injury reconstruction model.  
The first objective of this work was to characterize muscle ECM from young and aged 
mice and to observe its effect on macrophage phenotype and function. Bone marrow-derived 
macrophages treated with muscle ECM showed increases in iNOS immunolabeling and nitric 
oxide production with aged muscle ECM indicative of a shift to a pro-inflammatory phenotype. 
The second objective of this work was to characterize the macrophage response to 
artificially glycated ECM. Young muscle ECM was artificially glycated with low and high 
concentrations of glucose, ribose or fructose. The macrophage response to glycated muscle ECM 
showed an increased nitric oxide production compared to young ECM. ECM glycation caused 
pro-inflammatory phenotypes from bone marrow-derived macrophages. 
AGED MUSCLE ECM RECAPITULATES ALTERED HOST RESPONSE 
OBSERVED IN AGED MUSCLE INJURY 
 
 Samuel Traxler LoPresti, Ph.D. 
University of Pittsburgh, 2018
 
 v 
The third objective of this work was to characterize the in vivo host response to young, 
aged and glycated muscle ECM implanted into an abdominal muscle injury. The host response to 
aged and glycated ECM was characterized by reduced infiltration of host cells including F4/80+ 
macrophages and delayed or prevented activation of macrophage polarization markers iNOS and 
arginase-1. Glycation led to increased collagen staining and reduced fast:slow muscle fiber type 
ratio by 90 days. In vivo results suggest that aged ECM delays inflammatory cascades while 
glycated ECM inhibits macrophage activation overall. 
Aging and glycation of the skeletal muscle ECM microenvironment had direct effects on 
the macrophage response in vitro and in vivo. This provides evidence for a cell-extrinsic 
mechanism of aging which is separate from known changes in stem cell function and population 
with age. 
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1.0  INTRODUCTION 
1.1 AGING 
1.1.1 Aging and Muscle Physiology 
Aging is a multifactorial process that all organisms experience through time which eventually 
results in the loss of normal physiological function [1]. Aging is a major risk factor for many 
disease pathologies including cancer, obesity, diabetes, as well as cardiovascular and 
neurological diseases. As we age, our skeletal muscles atrophy and our ability to regenerate 
injured muscles declines [2]. Many factors have been implicated with the diminished ability of 
our muscles to regenerate with age including satellite cells (muscle stem cells), vascularization, 
denervation, hormonal decline, oxidative stress, and the immune system [3-8]. However, the 
direct effects of changes in the muscle microenvironment with aging has only begun to be 
investigated [9]. With an increasing percentage of the population living to advanced age, reduced 
independence due to sarcopenia (weakened muscles) poses a large healthcare burden [10].  
1.1.2 Clinical significance of sarcopenia 
The world’s percentage of people over the age of 65 is expected to double by 2050 [11]. 
Sarcopenia, the age-related increase in muscle weakness, is estimated to affect 22.6% of women 
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and 26.8% of men over the age of 64 with 31.0% and 52.9% in women and men over the age of 
80 [12]. Sarcopenia leads to a 30-50% reduction in muscle mass from age 40 to 80 and up to 3% 
annual decline in muscle function [13]. Incidence of sarcopenia is associated with increased 
mortality, functional decline, falls and hospitalization [14]. This has a profound impact on the 
quality of life of patients with sarcopenia as their independence declines. This is also associated 
with an estimated $18.5 billion cost in 2000 which is a staggering economic burden on the 
healthcare system [15]. 
1.1.3 Healthy muscle regeneration 
Muscle fibers consist of hundreds of nuclei shared within one connected cytoplasm, making 
them syncytial cells formed from the fusion of many individual cells [16]. Satellite cells, also 
known as muscle stem cells, are the major cell type that contributes to skeletal muscle 
regeneration following injury [17]. Satellite cells are located in the basal lamina of muscle fibers 
next to the cell membrane under normal conditions [18]. Quiescent satellite cells are 
characterized by being Pax7+/Myf5+ [19]. Upon muscle injury, satellite cells are activated and 
proliferate, transforming into myogenic progenitor cells or myoblasts [20]. Activated satellite 
cells express MyoD1 and Myf5 which control commitment to a differentiation fate [21]. Known 
activators of satellite cells which are produced from damaged cells or infiltrating cells are 
hepatocyte growth factor (HGF), fibroblast growth factor (FGF), insulin growth factor (IGF), 
and nitric oxide (NO) [22-25]. Terminal differentiation of myogenic precursor cells (MPCs) to 
myocytes is regulated through expression of myogenin [26]. Myocytes are then able to fuse 
together or fuse with damaged muscle fibers to propogate muscle regeneration [27]. 
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Nuclear positioning during muscle injury and regeneration plays an important role in 
myofiber fusion. During regenerative fusion, new myoblasts are incorporated by adding their 
nucleus to the center of a damaged myofiber [28, 29]. This provides a histological metric for 
regeneration of muscle fibers, by quantifying the percent of fibers with centralized nuclei [30]. 
Once many myoblasts have been added to regenerating myofiber, the myofiber matures and the 
nuclei migrate from the center to the periphery [31]. Once nuclei relocate to the periphery, they 
space out to maximize the distance between nuclei [32]. Some myonuclei will also migrate from 
the periphery to the neuromuscular junction in order to establish synaptic transmission [33, 34]. 
Interestingly, biopsies of muscle disorders show predominant centralization of nuclei in muscle 
fibers [35, 36]. In muscle dystrophy, the absence of functional dystrophin leads to destabilization 
of muscle fiber cellular membranes. This leads to chronic damage and repair, which is observed 
histologically by a centralized nuclei phenotype [35]. 
1.1.4 Effect of Aging upon Muscle Regeneration 
Muscle regeneration is known to decline with aging [37]. The number of satellite cells per 
muscle fiber decreases with increased age [38]. The proliferation, response to proliferative 
signals, and ability to replenish the supply of quiescent stem cells all are responsible for declined 
muscle stem cell function [39, 40]. Stem cell differentiation is also inhibited with advanced age 
due to reduced proliferation [38]. Expression of the myogenic regulatory factors (MRFs) MyoD, 
Myf5, and myogenin are reduced in aged muscle and muscle stem cells [41, 42]. The number of 
regenerating myofibers as assessed by nuclei centralization also reduces [39, 43]. Furthermore, 
the number of immune cells, including neutrophils and macrophages, decreases during muscle 
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regeneration in aged individuals [44]. All of these factors lead to reduced muscle mass and 
strength with aging. 
The immune system aging also has an effect during muscle regeneration. Macrophage 
dysfunction impairs their normal role in preventing satellite cell apoptosis, contributing to 
declines in satellite cell population [45, 46]. At steady state, there are reduced numbers of pro-
inflammatory macrophages but similar numbers of anti-inflammatory macrophages in aged 
muscle [47]. Following exercise, the number of pro- and anti-inflammatory macrophages 
increased in young individuals but not in old [47]. Aged muscles experienced increases in the 
pro-inflammatory cytokine gene expression of IL-6, IL-8 and MCP-1 following exercise [48]. In 
additions to alterations in immune cell activation, aged muscle stem cells are less sensitive to 
immune cell signaling [49]. 
Macrophage polarization is involved in the normal muscle regeneration process following 
injury [50]. Pro-inflammatory and anti-inflammatory macrophages are associated with satellite 
cell proliferation and differentiation, respectively [51]. Macrophage polarization has been shown 
to be deficient with aging [52]. Macrophages in aging muscle have been shown to skew towards 
anti-inflammatory phenotypes which was associated with fibrosis [53]. There also have been 
shown to be reduced numbers of macrophages in diabetic and aged human muscle [54]. These 
altered macrophage phenotypes in aging muscle have been shown to impair muscle regeneration 
[55].  
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1.2 MACROPHAGE POLARIZATION 
Sections of this chapter are adapted from: 
Brown BN, Haschak MJ, Lopresti ST, Stahl EC. Effects of age-related shifts in cellular 
function and local microenvironment upon the innate immune response to implants. Semin 
Immunol. 2017 Feb;29:24-32. doi: 10.1016/j.smim.2017.05.001. Epub 2017 May 20. 
 
Macrophages are classified as mononuclear phagocytes that serve as one of the primary 
components of the innate immune system [56]. Macrophages are known to exist in a spectrum of 
phenotypes known as macrophage polarization [56]. This spectrum ranges from pro-
inflammatory (M1) macrophages tasked with the clearance and uptake of foreign cells or debris 
to a range of anti-inflammatory (M2) phenotypes associated with immune resolution, wound 
healing and angiogenesis [57]. The shift in macrophage polarization from pro- to anti-
inflammatory is associated with the successful host response to injury or biomaterials [58, 59].  
1.2.1 Macrophage origins 
Macrophages have both embryonic and bone marrow origins [60]. Embryonic macrophages 
originate in the yolk sac and then populate many tissues throughout the body, including the liver, 
lung, heart, spleen and intestine [61-66]. Once hematopoiesis begins in the bone marrow, 
monocytes are recruited to the blood stream. These monocytes are then recruited to tissues 
during injury and regeneration where they differentiate to macrophages [67]. Over the course of 
aging, bone marrow-derived macrophages slowly replace tissue resident macrophages [68-70]. 
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As monocyte-derived and tissue resident macrophages have different functional profiles, this is 
hypothesized to be a reason for diminished regenerative potential with advanced aging. 
The response to abdominal muscle injury can involve peritoneal or monocyte-derived 
macrophages based on the severity of injury [50]. Peritoneal macrophages are known to exist as 
two subsets: large peritoneal macrophages (LPMs) and small peritoneal macrophages (SPMs) 
[71]. Large peritoneal macrophages are thought to originate from the embryonic yolk sac like 
many tissue-resident macrophages and undergo self-renewal [72]. Small peritoneal macrophages 
are derived from circulating monocytes [73]. Both populations have been shown to be replaced 
by bone marrow-derived monocytes as seen by bone marrow chimera experiments [73]. SPMs 
rapidly proliferate during infection or injury and are known to secrete NO, IL-1, TNFα, and IL-
12 [74]. LPMs, however, secrete MCP-1, MIP-1β, and G-CSF [73]. These two distinct 
macrophage population can heavily influence the host response to abdominal muscle injury. 
Macrophages that respond to muscle injury are mainly monocyte-derived [75]. 
Monocytes derive from hematopoietic stem cells (HSCs) which give rise to monoblasts, which 
differentiate into promonocytes and then mature monocytes [76]. Monocytes are known to exist 
in two subsets in the mouse: a CX3CR1hi/Ly6clo which infiltrates tissue rapidly during infection 
and a CX3CR1lo/Ly6Chi population which does not [77]. There is now known to be a Ly6Cmed 
population that has been termed intermediate monocytes while CX3CR1lo/CCR2hi are termed 
classical monocytes and CX3CR1hi/CCR2lo are termed non-classical monocytes [78]. Non-
classical monocytes have been shown to be more mature and derived from classical monocytes 
[78]. Non-classical monocytes have higher expression of TNFα following TLR activation, as 
well as lower CD14 and higher CD16 expression compared to classical monocytes [79, 80]. 
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Tissue resident macrophages are also known to exist within muscles themselves [81]. 
These cells are known to secrete cytokine induced neutrophil chemoattractant (CINC) and 
monocyte chemoattractant protein 1 (MCP-1) [81]. While these tissue-resident macrophages, 
which expressed Ly6Chi/CX3CR1lo/CD11c-, dominate the early muscle inflammatory response, 
monocytes recruited from the blood were the predominant type thereafter [81]. All three 
macrophage populations, tissue-resident, peritoneal and monocyte-derived can play a role in 
abdominal muscle regeneration, depending on the type of injury. 
1.2.2 Macrophage polarization  
Macrophages were classically described as immune cells that phagocytosed pathogens and killed 
invading cells through the production of reactive oxygen and nitrogen species [82]. Following 
the discovery of the T helper 1 / T helper 2 (Th1/Th2) paradigm in T cells, macrophages were 
found to exist in a similar spectrum between classically activated (M1) and alternatively 
activated (M2) macrophages [83-85]. Pro-inflammatory (M1) macrophages are described as 
being stimulated with interferon-γ and lipo-polysaccharides [86]. They are associated with 
upregulation of IL-12 and IL-23, increased antigen presentation, and production of nitric oxide 
and reactive oxygen species [87]. Anti-inflammatory (M2) macrophages were originally 
described as being activated with interleukin-4 (IL-4) and/or IL-13 [88]. Alternative macrophage 
activation can also be caused by exposure to IL-10, glucocorticoids or secosteroid hormones 
[89]. Alternative activation has further been broken down into M2a (exposure to IL-4 or IL-13), 
M2b (activation with immune complexes (ICs) and TLR-agonists or IL-1R), and M2c (exposure 
to IL-10 or glucocorticoids) [90]. Due the increasing complexity of macrophage classes and 
many inconsistencies, new nomenclature has been proposed focused around the specific 
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activators used to stimulate the macrophages being studied [91]. Regardless, macrophages have a 
complex spectrum of phenotypes based on a large pool of activators that can polarize them 
anywhere between commonly described extremes of M1 and M2. 
1.2.3 Macrophage polarization and muscle regeneration 
Macrophage polarization has been implicated in the host response to injury of many tissues. 
Muscle regeneration is intimately tied in with macrophage activation and resolution [92]. 
Depletion of macrophages prior to muscle injury prevents muscle regeneration [93]. Pro-
inflammatory macrophages are found in the first few days of muscle injury, at the same time of 
satellite cell activation and proliferation [94]. Alternatively activated macrophages arrive around 
day 4, co-current with myotube regeneration [94]. M1 macrophages lead to a Pax7+/MyoD+ 
proliferative satellite cell while M2 macrophages lead to MyoD+/Myogenin+ post-mitotic 
myocytes [94]. Following immune resolution, myotubes will fuse in order to form new muscle 
fibers [95]. Chronic inflammation from macrophages can impair skeletal muscle regeneration 
[51]. The dysfunction of the immune system with aging directly impairs the ability of muscles to 
heal following injury [96]. 
1.2.4 Macrophage populations and polarization with aging 
The output of immune cells from the bone marrow is weighted towards myeloid lineage with 
aging, the absolute monocyte number is unchanged between young and aged individuals [97, 
98]. However, an increased percentage of non-classical monocytes (CD14+ CD16++), and a 
reduction in classical monocytes (CD14+ CD16-) has been reported in elderly individuals [97, 
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98].  Like other innate immune cells, macrophage recruitment is delayed in aging, possibly due 
to a reduction in expression of the integrin very late antigen-4 (VLA-4) on monocytes, and 
vascular cell adhesion molecule-1 (VCAM-1) on endothelial cells [99]. Furthermore, a reduction 
in major histocompatibility complex (MHC-II) expression has been observed in both human and 
murine macrophages, leading to a reduction in antigen-presentation capacity and cross-talk with 
the adaptive immune system [100, 101]. An increase in prostaglandin E2 production by 
macrophages has been postulated as a possible explanation for the reduction in MHC-II 
expression [102]. Toll-like receptors (TLRs) including TLR-1, TLR-2, and TLR-4, important 
mediators for PAMPs and DAMPs, are also reported to decrease on aged peritoneal and splenic 
macrophages, perhaps contributing to the susceptibility of the elderly to bacterial, mycotic, and 
viral infections [103, 104]. 
Classically activated “M1” macrophages are very efficient at producing pro-
inflammatory cytokines, nitric oxide, and performing phagocytosis. With aging, phagocytosis 
has been reported to decrease, perhaps associated with a reduction in the cellular receptors or 
responsiveness to cytokines [97, 105, 106]. Furthermore, macrophage senescence and quiescence 
induced in vitro has been reported to lead to a reduction in phagocytosis in response to 
biomaterials [107]. In addition, decreases in nitric oxide and superoxide production by aged 
macrophages have been reported in rats [108]. Alternatively activated “M2” macrophages are 
crucial for clearing helminth infections, and have important roles in the resolution of 
inflammatory reactions, including new matrix deposition and anti-inflammatory cytokine 
production. Changes in “M2” macrophage function are less well documented in the literature. 
However, “M2” macrophages have been found to accumulate in aged skeletal muscle and result 
in the detrimental replacement of muscle fibers with fibrotic tissue over time [53]. Advanced age 
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may also impair the ability of macrophages to polarize to either M1 or M2 phenotypes. The gene 
signature of macrophages isolated from bone marrow and polarized to M1 or M2 phenotypes 
was mostly unchanged between young and aged mice, with the exception of increased Fizz-1 
(M2 marker) expression on aged cells [52]. However, macrophages isolated from mouse spleen 
had a reduction in both “M1” and “M2” gene expression patterns when stimulated with 
polarizing cytokines, suggesting deficits in polarization capacity [52].  
While less well documented than the adaptive immune system, changes in innate immune 
function have a significant impact on the host response to infection, biomaterials and the normal 
wound healing process. Further studies that systemically examine the effect of aging on the 
innate immune response to biomaterials are necessary to further the development of 
biocompatible and bioactive materials.  
Several studies have identified that tissue-resident macrophages, but not bone marrow 
derived macrophages, become impaired with aging [52, 106].  Recent work from our group also 
demonstrates minimal differences between young and aged bone marrow derived macrophage 
functions, including nitric oxide production and phagocytosis [109]. Interestingly, when bone 
marrow derived macrophages are pre-exposed to degradation products from young and aged 
extracellular matrix or “tissue cues”, differences in function arise following polarization with 
M1-inducing cytokines [110]. Taken together, these studies suggest that tissue micro-
environments dictate a large portion of the observed immunosenescence of macrophages.  
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1.3 EXTRACELLULAR MATRIX 
1.3.1 Extracellular matrix physiology 
The extracellular matrix comprises the structural components of a tissue outside of the cells 
[111]. These structural molecules provide not only biomechanical support for the cells it 
contacts, but also provides biochemical cues that maintain homeostasis or promote regeneration 
during injury [112, 113]. The main extracellular matrix components include collagens, elastin, 
fibrillins, laminins, proteoglycans and glycosaminoglycans [114]. Extracellular matrix ligands 
are also recognized by integrins, cellular membrane receptors that allow cells to attach to and 
migrate across the ECM [115]. 
As extracellular matrix is produced by cells and the ECM in turn influences cell behavior, 
their co-dependent relationship has been termed “dynamic reciprocity” [116]. A variety of cell 
surface receptors, including integrins, discoidin domain receptors, hyaluronan receptors, and cell 
surface proteoglycans, provide cell signaling from various extracellular matrix molecules [117-
120]. Many extracellular matrix proteins, such as thrombospondins, SPARC, tenascins and 
periostin, have well characterized signaling effects on cells [121]. Growth factors bind to 
extracellular matrix proteins and glycosaminoglycans as well as signal through integrins [122]. 
Cleavage of ECM proteins by MMPs or other proteases creates peptides known as matrikines, 
which have signaling properties in inflammation and disease [123]. Therefore, intact ECM can 
maintain tissue homeostasis while its degradation during injury can control inflammation. 
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1.3.2 Extracellular matrix as a biomaterial 
Bioengineering techniques have allowed for the isolation of the extracellular matrix from tissues 
for use as a biomaterial [124]. A collection of processes called decellularization, using enzymes, 
detergents, acids or bases, and hyper or hypotonic solutions, allow for the removal of cellular 
material while preserving the extracellular matrix and associated proteins [125]. The resulting 
biomaterial can be used as an inductive template to instruct cells toward wound healing 
phenotypes [126]. Extracellular matrix biomaterials have been used successfully in the functional 
reconstruction of many tissues, including tendon, meniscus, muscle, heart, esophagus, bladder 
and skin [127-137]. Functional reconstruction is defined as the remodeling of ECM into new, 
host-derived site appropriate tissue. Extracellular matrix products have been commercialized by 
a number of companies for use in a wide variety of surgical, reconstructive and wound healing 
applications [138-141]. 
Extracellular matrix scaffolds have been processed into a variety of platforms including 
sheets, tubes, powders, and gels [142-145]. Single and multi-laminate ECM sheets as well as 
powders have found use in reconstruction applications such as wound healing, corneal repair, 
and tumor reconstruction [146-148]. Tubes have been used for valve reconstruction and aorta 
repair [149, 150]. ECM hydrogels have recently gained interest in applications such as 
myocardial repair, stroke and meniscus repair [151-153]. The biomechanical and signaling 
properties of extracellular matrix scaffolds can be adapted to many applications for functional 
reconstruction. 
Recently, extracellular matrix has been investigated for its potential as a scaffold for 
three-dimensional organ engineering. As the structural component for any tissue, ECM serves as 
the optimal platform for bioengineering an organ. Decellularization of vascularized organs has 
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been a major strategy for organ engineering which would then proceed with recellularization of 
the “ghost” organ with host cells or stem cells [154]. Efficient reperfusion of cells and recreation 
of tissue-cellular architecture remain problematic with this approach. Solubilized ECM has also 
been adapted to 3D bioprinting efforts in order synthetically create artificial tissues and organs 
[155]. Adapting large, insoluble ECM macromolecules to soluble bio-inks has complications for 
recreating organs found in normal physiology. Spatial resolution and engineering the complexity 
of both cells and matrix normally found in an organ. 
1.3.3 Extracellular matrix biomaterials as model microenvironments 
Just as extracellular matrix biomaterials can be used as scaffolds for 3D organ engineering, ECM 
can also model the microenvironment of an organ to study biological phenomena [156]. The 
effects of altered ECM microenvironments have been studied in aging, cancer, fibrosis, 
homeostasis, regeneration and disease [157-161]. Decellularization techniques allow the harvest 
of ECM for the purpose of modeling its effect upon various cellular functions [162]. Use of 
ECM peptides in controllable polymer gels offers investigation of specific changes in the ECM, 
but does not fully recapitulate the reality of ECM changes with disease or age [163]. 
Understanding how changes in the ECM directly affect cell function proves difficult as there are 
numerous components, each which can change in concentration, degradation, architecture or 
modification with oxidation or glycation. The process of decellularization itself can modify 
extracellular matrix through denaturation, degradation or oxidation. Therefore, the act of ECM 
extraction, while useful in understanding its effects, clouds the ability to accurately preserve its 
native properties. 
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1.3.4 Extracellular matrix changes with aging 
Muscle ECM comprises approximately 10% of total muscle weight and is organized into three 
sections: endomysium (surrounding muscle fibers), perimysium (surrounding muscle fascicles), 
and epimysium (surrounding the entire muscle) [164]. Muscle connective tissue is primarily 
composed of collagen I whereas muscle basement membrane is composed of collagens I, III and 
VI in the outer reticular lamina and collagen IV and laminin in the inner basal lamina [165]. 
Muscle ECM shows increased collagen deposition with age with an increase in collagen I and 
decrease in collagen III [166-168]. Collagen IV is increased whereas laminin decreases with age 
in the basal lamina [169]. Collagen accumulation is assumed to be due to decreased degradation 
rather than increased synthesis, which is corroborated by decreased levels of MMP-2 [170, 171]. 
Thickening of the basal lamina has been shown to effect the interaction between satellite cells 
and myofibers [172]. Reduced collagen turnover leads to accumulation of glycation end-products 
(AGEs) and accumulation of ECM degradation products within the tissue which can interfere 
with normal tissue interactions [172, 173]. Aging ECM changes may also lead to satellite cell 
senescence or induced differentiation through stiffer matrix [166, 174]. A recent study showed 
that aged muscle extracellular matrix promoted a fibrogenic phenotype in muscle stem cells, 
which could, in part, explain the fibrosis commonly observed in aged muscles [9]. 
Few studies tying compositional changes in aging tissue to age related changes in the host 
response have been performed.  However, Tottey, et al. demonstrated that source animal age was 
linked to changes in both the compositional make up and physical properties of decellularized 
tissue scaffolds composed of small intestinal submucosa (SIS) [175].  Briefly, small intestinal 
submucosa was harvested from 3, 12, 26, and 52 week old pigs and decellularized using a 
peracetic acid washing procedure.  The resultant tissue was then tested mechanically and 
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subjected to compositional testing for growth factors, collagen, and glycosaminoglycan content.  
The results showed a trend toward increasing tissue thickness, reduced tensile modulus, and 
resistance to collagenase degradation with aging.   Compositional analysis showed changes in 
bFGF and VEGF content with age including increases in both growth factors between 3 and 26 
weeks with decreased content thereafter.  Analysis of glycosaminoglycan content showed a 
steady drop in content with aging from the 3 to 52 week old source animals.  These changes were 
associated with changes in the mitogenesis, metabolism and migration of perivascular progenitor 
cells exposed to the materials [175].   
A follow-up study utilized the same decellularized small intestinal extracellular matrix as 
an implant in a well-described model of partial thickness abdominal wall defect repair [176].  
The results of this study demonstrated that scaffolds derived from younger animals (3 and 12 
weeks) were associated with significantly improved remodeling (i.e. formation of innervated 
skeletal muscle bundles) of the abdominal skeletal muscle as compared to 26 or 52-week old 
source tissues and untreated and autograft treated controls.  Investigation of the early host 
response revealed that the materials derived from younger animals (3 and 12 weeks) were also 
associated with a decreased ratio of M1:M2 macrophages within the site of implantation as 
compared to 26 or 52-week old source tissues and untreated and autograft treated controls [176].   
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1.4 AGING MODIFICATIONS OF EXTRACELLULAR MATRIX 
1.4.1 Glycation 
Advanced glycation end products, a heterogeneous group of over 20 different molecules, are 
formed through the non-enzymatic glycation of long-lived proteins, lipids, or nucleic acids [177, 
178]. AGE formation in vivo tends to be a progressive process that occurs with increasing age or 
following certain lifestyle choices, such as diets high in glucose or exposure to environmental 
toxins [177, 179]. AGEs are capable of protein cross-linking, resulting in the reduced ability of 
cellular machinery to degrade damaged proteins, in turn leading to tissue stiffening and 
dysfunction [180]. AGEs can also promote formation and accumulation of reactive oxidative 
species (ROS) through the blockade of the 20S subunit of the intracellular proteasome [179, 
181]. Since the 20S subunit is typically responsible for the degradation of oxidized intracellular 
proteins, blockade of this intracellular machinery by AGEs, coupled with reduced antioxidant to 
oxidative species ratios in aged individuals, allows for a feed-forward loop of oxidative species 
formation, subsequently resulting in enhanced AGE formation in vivo [177, 181, 182].   
Additionally, AGEs have been shown to promote inflammatory processes through several 
distinct signaling pathways, with the receptor for advanced glycation end products (RAGE) 
pathway being one the best characterized [177]. RAGE is a pattern recognition receptor of the 
immunoglobulin receptor family and is widely expressed across a variety of cell types, including 
macrophages [183], T-lymphocytes [184], B-lymphocytes [185], dendritic cells [186], 
endothelial cells [187], fibroblasts [188], smooth muscle cells [183], and neuronal cell [177, 189, 
190]. Additionally, RAGE is able to bind a variety of ligands in addition to AGEs, such as 
lipopolysaccharide, calgranulin/S100 family ligands, or high mobility group box protein 1 [177, 
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185]. Since RAGE signaling is dependent on both cell and ligand type, RAGE signaling tends to 
be complex and studied in a context dependent manner [185].  
In macrophage populations, ligand binding to RAGE has been shown to induce M1, pro-
inflammatory macrophage states through the upregulation of MHC-II expression on the cell 
surface and secretion of pro-inflammatory cytokines [191, 192]. While it has not been 
determined definitively how ligand binding to RAGE impacts M2, pro-remodeling states in 
macrophages, some data exists that suggests RAGE-ligand binding promotes the down-
regulation of M2 genes [193]. However, a recent study has shown that AGE-mediated RAGE 
activation has no impact on M2 marker expression[194]. Thus, further studies will need to be 
performed to fully elucidate how RAGE signaling can impact M2 gene and surface marker 
expression. Additionally, while the effects of RAGE-ligand binding have been fairly well 
elucidated in macrophage populations, the specific signaling pathways utilized in these cell 
populations have not. RAGE signaling pathways in monocyte and macrophage populations has 
been shown to be dependent on both the RAGE-bound ligand as well as the extracellular 
microenvironment [185]. For example, monocyte RAGE stimulation with AGEs resulted in 
signaling through PKC, ERK1/2, p38 – but not JNK – to activate master inflammatory regulator 
gene NF-κB [195]. However, under hypoxic conditions Chang et. al. demonstrated that 
monocyte RAGE stimulation did not signal through this pathway but rather led to the 
translocation of PKCβII and subsequent JNK activation, resulting in downstream Egr-1 
activation [196]. Additionally, macrophages have been shown to signal through p38, p44/42, 
JNK, and MAPK pathways [191]. Thus, one can see the importance of ligand and extracellular 
environment in determining the RAGE signaling propagation pathway. 
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1.4.2 Oxidation of extracellular matrix 
Radical oxygen species (ROS) are naturally produced through normal biological functions and 
are increasingly produced during inflammation [197]. These elevated levels of ROS, while 
beneficial for pathogen clearance, can lead to oxidative damage to cells and proteins in affected 
tissues. Because extracellular matrix proteins are long-lived, modifications from oxidative stress 
can accumulate leading to altered function, structure or degradation. In vitro models of oxidative 
stress have proven that ECM molecules are modified through oxidation as measured by increases 
in protein carbonyl content [198]. This increased oxidation led to increased degradation by 
MMP-2 [198]. Protein oxidation could be a cause for increased collagen degradation with aging 
or accumulation of ECM fragments within aged tissues. ROS also have impacts on signaling 
pathways for degradative enzymes, leading to the upregulation of MKK and MAPK which lead 
to elevated MMP-1 expression [199]. 
1.4.3 Lysyl oxidase cross-linking 
Collagen crosslinking is enzymatically accomplished by the lysyl oxidase family of copper-
dependent oxido-deaminases. These enzymes work by modifying the lysyl residues in collagen 
and elastin resulting in the formation of crosslinks between polypeptides that cannot be reduced 
[200]. Lack of LOX-mediated crosslinks leads to abnormal collagen fibril formation with 
increased distribution of fiber diameters and irregular profiles [200]. Allosteric inhibition of 
LOXL2 led to promotion of a pathologic microenvironment characterized by reduced fibroblast 
activation, demoplasia and endothelial cell activation, as well as decreases in growth factor and 
cytokine production including TGF-β [201]. LOX family gene expression has been observed to 
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decrease with aging which has implications for ECM remodeling and signaling [202-204]. 
Reduced or altered crosslinking has implications for tissue function and biomechanics as well as 
the response to tissue injury. 
1.5 CHANGES WITH AGING OF ECM BIOMATERIALS 
As described previously, the extracellular matrix in known to change with age [9, 161, 205, 206]. 
When extracellular matrix biomaterials are derived from different aged animals, the resultant 
material properties are shown to be altered with source animal age [175]. These alterations in 
small intestine submucosa properties with source animal age affected the host response to these 
materials when implanted into a partial thickness abdominal muscle injury [176]. This alteration 
in host response was associated with a promotion of enhanced pro-inflammatory macrophage 
response with increased ECM source animal age. However, this previous study did not 
investigate the direct effects of age-related changes in the ECM upon macrophage phenotype and 
function. The direct effects of ECM source animal age upon macrophages was tested in Chapter 
2 where murine bone marrow-derived macrophages were exposed to extracellular matrix 
degradation products derived from 12, 26 and 52-week old pigs. 
As discussed in Chapter 1.4, there are many factors that can cause changes in the 
extracellular matrix with aging. Among these hypotheses include oxidation and increased cross-
linking from non-enzymatic glycation or lysyl oxidase activity [198]. Growth factors, which 
often interact and are sequestered within the extracellular matrix, change in both secretion and 
content with aging [207]. Lipids also accumulate in aged tissues which can alter the ability to 
regenerate following muscle injury [208]. Chapter 3 discusses investigation of the effects of  
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growth factor or lipid extracts from different source animal age small intestine submucosa 
materials upon macrophage polarization. 
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2.0  EFFECT OF SOURCE ANIMAL AGE UPON MACROPHAGE RESPONSE TO 
SMALL INTESTINE SUBMUCOSA 
This chapter is modified from the following published work: 
LoPresti ST, Brown BN. Effect of Source Animal Age upon Macrophage Response to 
Extracellular Matrix Biomaterials. J Immunol Regen Med. 2018 Mar;1:57-66. doi: 
10.1016/j.regen.2018.03.004. Epub 2018 Apr 25. 
2.1 INTRODUCTION 
While ECM and other natural scaffolds possess advantages of inherent bioactivity, they are often 
criticized for their variability.  One potential source of variability is the age of the donor animal 
or cadaver from which the tissues are harvested.  The extracellular matrix has been shown to 
vary in composition with the age of an organism [175].  For example, muscle ECM shows 
increased deposition of collagen I and decreased collagen III with age [166-168]. Collagen IV is 
increased whereas laminin decreases with age in the basal lamina [169], a key component of 
many ECM-based scaffold materials [209]. Increased deposition and reduced collagen turnover 
leads to accumulation of glycation end-products (AGEs) and associated crosslinks which can 
interfere with normal cell-tissue interactions [172, 173]. ECM changes may also lead to stem cell 
 22 
senescence or induced differentiation through stiffer matrix [166, 174]. These aging-related 
changes have been suggested to affect the ability to regenerate tissue following injury. 
It is logical, therefore, that differences observed in native tissues would persist in ECM 
scaffolds following decellularization and may have implications for their effectiveness following 
implantation.  A recent study showed that small intestinal submucosa (SIS) derived from 52 
week old pigs promoted less constructive remodeling and increased collagen deposition when 
implanted in to a rat abdominal wall defect model compared to SIS derived from 12 and 26 week 
old pigs [176].  This response was also associated with increased pro-inflammatory (M1) 
macrophage polarization with increased source animal age, suggesting these poorer outcomes 
were due to alteration in macrophage phenotype.   
The current study sought to examine the impact of changes in ECM scaffolds with 
different source animal age upon macrophage polarization responses.  In order to accomplish this 
an in vitro primary cell model of macrophage polarization to ECM scaffolds was utilized to 
understand these age-related changes in ECM. Murine bone marrow-derived macrophages were 
chosen as a model system to reduce variability in the host immune responses due to genetic 
and/or environmental factors. As aging is a multifactorial condition, genetically similar mice 
with similar environments and diets were necessary to eliminate comorbidities associated with 
aging such as obesity, diabetes, and cardiovascular disorders that could be present in blood 
drawn from young and aged humans [210-213]. Additional studies can take advantage of murine 
genetic models in order to understand pathways involved in the macrophage response to 
biomaterials. Nevertheless, future studies involving human monocyte-derived macrophages will 
be necessary to assess the response to such materials in humans. 
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In order to assess the effect of aging upon extracellular matrix biomaterials, small 
intestine submucosa was chosen as a model scaffold. Small intestine submucosa is commercially 
available through Cook Medical for a variety of surgical and reconstructive applications [214-
217]. A common animal source for the derivation of small intestine submucosa (SIS) 
biomaterials is the pig [218]. A previous study investigating the effect of source animal age upon 
the remodeling of extracellular matrix biomaterials also used porcine small intestine submucosa 
as a source [176]. This study found that when implanted into a rodent model of abdominal wall 
partial thickness defect repair, that SIS of increasing source animal age caused an increased pro-
inflammatory response and increased collagen deposition, indicative of fibrosis.  
2.2 METHODS 
2.2.1 Scaffold preparation 
Jejunum were harvested from 12 week, 26 week, and 52 week-old Landrace pigs immediately 
following euthanasia (Tissue Source, Lafayette, IN). The animals were of similar genetic 
heritage, diet and immunization history.  Small intestine submucosa (SIS) extracellular matrix 
biomaterials were prepared from these tissues as previously described [129].  Briefly, the tissues 
were rinsed with water and the mesenteric tissues were removed.  Tissues were cut 
longitudinally then mechanically delaminated to remove the tunica serosa, tunica muscularis 
externa, and the luminal tunica mucosa, including most of the lamina propria.  After 
delamination, the tunica submucosa and the basilar layer of the tunica mucosa including the 
muscularis mucosa and the stratum compactum of the lamina propria remained. The material was 
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further decellularized using mechanical agitation with an orbital shaker at 300 rpm in a solution 
of 0.1% (v/v) peracetic acid (Rochester Midland Corporation, Rochester, NY).  Tissues were 
then rinsed multiple times with saline and deionized water.  Decellularized scaffolds were frozen 
at -80°C and then lyophilized.  The resultant scaffolds were considered “intact ECM scaffolds.” 
Scaffolds were digested at a concentration of 10 mg/mL in an acid-pepsin solution (pH 2) under 
constant magnetic stir for 48 hours. These digested scaffolds were considered “ECM degradation 
products.” 
2.2.2 Scaffold characterization 
Hydrated native tissue and decellularized scaffolds were fixed in 10% neutral buffered formalin 
(NBF) and then embedded in paraffin.  Sections of these scaffolds were stained separately with 
hematoxylin & eosin or DAPI to confirm removal of nuclei.  Proteinase K digests of native and 
decellularized scaffolds underwent phenol: chloroform: isoamyl alcohol (25:24:1) extraction for 
DNA and were resuspended in 1X TE buffer.  DNA extracts were separated using 
electrophoresis on a 2% agarose gel in 0.5X TBE buffer to confirm reduction of DNA content 
and fragmentation of remnant DNA in decellularized scaffolds compared to native controls. 
DNA extracts were also quantified for double-stranded DNA content using a PicoGreen assay 
(Thermo) according to manufacturer’s instructions. Endotoxin content was assayed using the 
Pierce LAL Chromogenic Endotoxin Quantification kit (Thermo) according to manufacturer 
instructions. 
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2.2.3 Growth factor ELISA quantification 
Urea heparin extracts were performed on lyophilized native and decellularized SIS samples as 
previously described [219]. Briefly, 100 mg of lyophilized tissue was extracted using 3 mL urea-
heparin extraction buffer (2M urea, 50mM Tris Base, 5 mg/mL heparin, 10mM N-
Ethylmaleimide, 5mM benzamidine, 1mM PMSF in DI H2O). Samples were agitated overnight 
at 4°C. Samples were centrifuged at 10,000 xg for 10 min at 4°C. Supernatants were collected, 
volumes recorded, and stored at -80°C until time of assay. Extraction procedure was repeated 
once more to ensure complete extraction. Growth factor ELISAs were purchased from R&D 
Biosystems for basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), and 
heparin-binding EGF-like growth factor (HB-EGF). Urea-heparin extracts were assayed for 
growth factor content using the ELISA assays above according to manufacturing instructions. 
2.2.4 Artificial glycation of small intestine submucosa ECM 
In order to determine the effect of glycation upon small intestine submucosa, positive controls 
for glycation were created through in vitro glycation protocols previously described [220]. 
Young (12 week) SIS were artificially glycated by incubating lyophilized scaffolds in 50, 250 or 
500 mM ribose with 44mM NaHCO3 and 25mM HEPES in 1XPBS for 5 days. Following 
glycation scaffolds were washed in 1X PBS, frozen at -80°C and lyophilized. 
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2.2.5 Assessment of age-related biomarkers in small intestine submucosa 
Periodic acid-Schiff stain was performed on paraffin sections of SIS to detect levels of 
polysaccharides, glycoproteins, glycolipids, and mucins as previously described. Paraffin 
sections were deparaffinized and rehydrated to water and then oxidized with 0.5% periodic acid 
solution for 5 mins. Following water washes, slides were incubated in Schiff’s reagent for 15 
minutes. Slides were washed in warm water then counterstained with hematoxylin for 1 minute. 
Slides were then dehydrated and mounted with a resinous mounting media and coverslipped. 
Slides were imaged using brightfield microscopy. 
Protein oxidation was tested by staining tissue sections. Paraffin sections were 
deparaffined and then rehydrated to water. Sections were stained with 1mg/mL 2,4-
dinitrophenylhydrazine in 1N HCl for 1 hour. Sections were then washed 3 times for 3 minutes 
in 1X PBS. Sections were then dehydrated, cleared with xylenes then mounted in resinous 
mounting media then coverslipped. Slides were imaged using brightfield microscopy. 
Advanced glycation end-product content in extracellular matrix was assessed via 
immunohistochemical staining. Briefly, paraffin sections were deparaffinized and rehydrated to 
water. Antigen retrieval was performed using 10mM citric acid pH 6 0.05% Tween20 for 20 
mins at 95-100 °C. Slides were washed twice with 1X TBST for 5 mins then twice with 1XPBS 
for 3 mins. Endogenous peroxidase activity was blocked by incubating slides in 0.3% hydrogen 
peroxide for 30 mins. Slides were washed 3 times in 1X PBS for 3 minutes. Slides were blocked 
for non-specific antibody binding with a blocking buffer made of 2% donkey serum/1% bovine 
serum albumin/0.1% Tween-20 for 1 hour at room temperature. Primary antibodies were 
incubated overnight at 4 °C diluted in blocking buffer. Slides were washed 3 times for 3 minutes 
with 1XPBS. Slides were then incubated with biotinylated secondary antibodies diluted in 
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blocking buffer (goat anti-rabbit 1:200 (Vector)). Slides were was again 3 times for 3 minutes 
with 1XPBS. Slides were incubated with VectaShield ABC Reagent for 30 mins then washed 
again 3x3mins with 1XPBS. Staining was developed by incubating sections with 4% DAB. 
Sections were washed then mounted with resinous mounting media and coverslipped. Slides 
were images on a brightfield microscope at the same settings. 
Advanced glycation end-product mass content was quantified using an OxiSelect™ 
Advanced Glycation End Product (AGE) Competitive ELISA Kit (Cell BioLabs). Papain 
digested SIS were assayed for AGE content according to manufacturer instructions. 
2.2.6 Microarchitecture and biomechanical analysis 
Microarchitecture was assessed via scanning electron microscopy. Hydrated decellularized small 
intestine submucosa was processed for scanning electron microscopy according to standards 
established by the University of Pittsburgh Center for Biologic Imaging (CBI). Samples were 
fixed in 2.5% glutaraldehyde in 0.1 M PBS (pH 7.4) for 1 hour. ECM was then washed with 3 
changes 0.1 M PBS for 15 minutes each. Lipid fixation was then performed using 1% OsO4 in 
0.1 M PBS for 60 minutes. Samples were again washed with 3 changes of 0.1 M PBS for 15 
minutes each. Samples were then dehydrated in graded series of alcohol (in PBS) for 15 minutes 
each: 30% ethanol, 50% ethanol, 70% ethanol, 90% ethanol, 3x 100% ethanol. Samples were 
then chemically dried using hexamethyldisilazane (HMDS) for 15 minutes and then allowed to 
dry in a fume hood overnight. Samples were then sputter coated according to CBI protocol. 
Samples were imaged at 2500X on a JSM 6335F SEM. 
Biomechanical properties of decellularized small intestine submucosa using uniaxial 
tensile mechanical testing under constant strain on an Instron mechanical testing system.  
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Samples were cut using a dogbone template and then mounted using screw clamps. Hydrated 
samples underwent 10 loading cycles to 0.5 N of tensile force under a constant strain rate before 
being stretched to failure 
2.2.7 Bone marrow-derived macrophage isolation 
Bone marrow-derived macrophages were harvested from 2 month or 18-20 month-old C57/BL6 
mice as previously described [221].  Briefly, femurs and tibiae were harvested and separated 
from muscle and connective tissue.  Bones were cut at either end to expose bone marrow.  Sterile 
syringe and needles were used to flush out bone marrow using macrophage differentiation media 
(DMEM/10% FBS/10% L-929 Supernatant/1% PenStrep/2% MEM non-essential amino 
acids/1% HEPES/0.1% 55μM β-2 mercaptoethanol).  Bone marrow lysate was reconstituted in 
media and filtered through a sterile cell filter.  Cells were cultured for 7 days in media to 
differentiate them into macrophages, changing differentiation media every 2 days. 
2.2.8 Macrophage Treatment 
Following 7 days of differentiation culture as described above, macrophages were treated with 
acute polarizing regimens to distinguish phenotypes over 24 hours.  Naïve macrophage (M0) 
controls were treated with basal media for 24 hours.  M1 (20 ng/mL IFN-γ and 100 ng/mL LPS) 
and M2 (20 ng/mL IL-4) polarizing cytokines were used to create positive controls for classical 
pro- and anti-inflammatory macrophages.  ECM degradation products were neutralized and 
diluted to 250 μg/mL in macrophage media to isolate biochemical effects of degradation 
products and prevent structural moieties from forming.  Pepsin buffer (1 mg/mL pepsin in 0.01 
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M HCl) diluted in macrophage media was used as a control.  Another set of treatment groups 
involved 24-hour exposure of ECM degradation products followed by 24-hour treatment with 
either the M1 or M2 treatment regimen, referred to as ECM→M1 or ECM→M2, respectively. 
2.2.9 Indirect immunofluorescent antibody labeling 
Cells were fixed with 2% paraformaldehyde (PFA) for 30 minutes then washed in 1XPBS.  Cells 
were incubated in blocking buffer (2% donkey serum, 1% bovine serum albumin (BSA), 0.1% 
Triton X-100, 0.1% Tween-20) for 1 hour at room temperature.  Primary antibodies were diluted 
in this blocking buffer as follows and incubated overnight at 4 °C: F4/80 (1:200, Abcam 6640), 
iNOS (1:100, Abcam 3523), Arginase-1 (1:200, Abcam 91279), Fizz1 (1:200, Peprotech 500-
P214), CCR2 (1:200, Abcam 21667), CX3CR1 (1:200, Abcam 8021), MHC-II (1:100, Abcam).  
F4/80 is a marker of macrophage differentiation. iNOS and MHC-II are classical M1 
macrophage markers whereas Arginase-1 and Fizz1 are classical M2 macrophage markers. 
CCR2 is a chemokine receptor associated with macrophage migration whereas CX3CR1 is a 
fractalkine receptor associated with tissue-resident macrophages. Cells were washed in 1XPBS 
then incubated in the appropriate fluorescently-labeled secondary antibody solution in blocking 
buffer for 1 hour at room temperature (donkey anti-rat Alexa Fluor 488, Invitrogen, 1:200; 
donkey anti-rabbit Alexa Fluor 488, Invitrogen, 1:300).  Cell nuclei were counterstained with 
DAPI.  Cells from five young (2 month) and aged (18 month) mice were imaged nine times in 
the center of each well at 10X magnification using automated position capture function to 
remove bias from subjective image location acquisition. This set of 9 images per well was 
counted as one biological replicate and was repeated in cells from n=5 mice for a total of 5 sets 
of 9 images per group. All imaging was performed on an Axio observer T1 microscope. Mean 
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fluorescence intensity of cells was analyzed using Cell Profiler software (Broad Institute). 
Briefly, DAPI images were used by the program to identify cell nuclei then FITC images were 
used to identify cell borders around the identified nuclei. The mean fluorescent intensity was 
calculated by averaging the pixel intensities (scale of 0 to 1) across the entire cell area. Mean 
fluorescence intensity values were averaged for all imaged cells in each well. 
2.2.10 Phagocytosis assay 
Following treatments, cells were assayed for phagocytic ability using Vybrant Phagocytosis 
Assay Kit (Invitrogen).  Cells were incubated in FITC-labeled dead E. Coli particles for 2 hours 
in the cell culture incubator.  Following washing, the cells were fixed with 2% PFA for 30 
minutes then washed with 1X PBS.  Cells were counterstained with DAPI then imaged and 
analyzed as described above. 
2.2.11 Taqman gene expression assay 
Following treatments, macrophages (n=5 biological replicates from 5 young (2 month) and 5 
aged (18 month) mice) were harvested for RNA using Qiagen RNEasy MiniPrep RNA Isolation 
Columns following standard protocol.  RNA was quantified using a NanoDrop Lite 
Spectrophotometer (Thermo).  cDNA templates were created from 1 μg of RNA using Invitrogen 
High Capacity RNA-to-cDNA kits (Thermo).  Taqman Gene Expression Assays (Thermo) were 
performed for the following commonly reported M1 and M2 macrophage markersgenes: Nos2 
(Mm00440502_m1), IL1b (Mm00434228_m1), IL12b (Mm01288989_m1), TNFa 
(Mm00443258_m1), MHC-II (Mm01181326_m1), Arg (Mm00475988_m1), Fizz1 Retlna 
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(Fizz1) (Mm00445109_m1), Mrc1 (Mm01329362_m1), IL10 (Mm01288386_m1), and PPARg 
(Mm00440940_m1). 
2.2.12 Nitric Oxide Assay 
Following treatments, 50 μL of supernatant from macrophages were transferred into a fresh 
plate.  Nitric oxide content was assayed using a Greiss Reagent system.  Briefly, 50 μL of 
sulfanilamide (1% in 5% phosphoric acid) was added to supernatants for 10 minutes.  Then, 50 
μL of 0.1% N-1-napthylethylenediamine in water was added to the mixture for an additional 10 
minutes.  The absorbance at 540 nm was measured using a BioTek SYNERGY HTX 
spectrophotometer. 
2.2.13 Seahorse metabolic analysis 
XF96 well plates were coated with CellTak (Corning) and then seeded with macrophages as 
previously described.  Following treatments as described above, metabolic stress tests were 
performed to assay metabolic activity of the cells using a Seahorse XF96 Metabolic Assay 
System. Basal extracellular acidification and oxygen consumption rates were taken for 30 min. 
Cells were stimulated with oligomycin (2 µM), FCCP (0.5 µM), 2-deoxyglucose (100mM) and 
rotenone/antimycin A (100 µM) to obtain maximal respiratory and control values. Spare 
respiratory capacity is measured as the difference between basal OCR values and maximal OCR 
values obtained after FCCP uncoupling. 
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2.2.14 Statistical Analysis 
Quantitative results were analyzed using a two-way ANOVA (treatment, age) with Tukey post-
hoc analysis using GraphPad PRISM 7 software. Significance was determined at a p-value less 
than 0.05. 
2.3 RESULTS 
2.3.1 Confirmation of decellularization 
Hematoyxlin & eosin staining of native and decellularized small intestinal submucosa samples 
confirmed decellularization (Figure 1). Outer intestinal musculature and inner luminal mucosa 
were removed in decellularized samples as previously described [222]. 
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Figure 1: Hematoxylin & eosin staining of native and decellularized small intestine submucosa. 
Images taken at 10X magnification. Scale bars indicate 100 µm. 
 
Nuclear removal was confirmed through visual observation in H&E (Figure 1) and DAPI 
staining (Figure 2).  
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Figure 2: DAPI fluorescence staining of native and decellularized small intestine submucosa. 
Images taken at 20X magnification. Scale bars indicate 100 µm. 
 
DNA fragmentation was confirmed through DNA agarose gel electrophoresis (Figure 3A). DNA 
extracts from native samples show large continuous bands indicative of large DNA fragments. 
Extracts from decellularized samples show significant removal of DNA material, with remnant 
DNA existing as lower molecular weight (Figure 3B). This is indicative of effective removal and 
fragmentation of any remnant DNA. Results from PicoGreen DNA quantification (Figure 3B) 
showed that scaffolds were effectively decellularized [223]. Effective and similar levels of 
decellularization confirm that DNA content should not cause differences in immune responses 
between different source age samples. 
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Figure 3: DNA agarose gel electrophoresis (A) and PicoGreen dsDNA quantification (B).  
Data shown as mean ± S.D. Statistical significance reported as *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001 
2.3.2 Analysis of ECM Composition 
SIS scaffolds of different source animal age were analyzed for content of major extracellular 
matrix structural proteins, specifically collagens and glycosaminoglycans. Hydroxyproline 
content was assessed to approximate collagen composition in SIS scaffolds (Figure 4A). In 
native small intestine submucosa, hydroxyproline content significantly increased with source 
animal age. However, in decellularized scaffolds, there was no significant difference in 
hydroxyproline content. Glycosaminoglycan content was assessed using dimethylmethylene blue 
dye (Figure 4B). Native small intestine submucosa showed a significant increase in 
glycosaminoglycan content with increasing source animal age. However, no trend appeared with 
glycosaminoglycan content in decellularized scaffolds of different source animal age.  
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Figure 4: Biochemical assessment of mass content of hydroxyproline and sulfated GAGs. 
Data shown as mean ± S.D. Statistical significance reported as *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
 
Endotoxin content was also assessed using an LAL Endotoxin Assay. Pepsin digests of native or 
decellularized small intestine submucosa were diluted 1:25 and assayed using the LAL 
Endotoxin kit according to manufacturer instructions. Native tissues were taken from the 
mechanically delaminated small intestine submucosa as to not include results from the mucosa or 
muscularis layers. However, our results show that endotoxin content did not differ in ECM 
degradation products (Figure 5). This suggests that any changes in the immune response to these 
biomaterials was not due to alterations in endotoxin content. 
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Figure 5: LAL Chromogenic Endotoxin quantification of LPS content in SIS degradation products. 
Data shown as mean ± S.D. Statistical significance reported as *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
 
Growth factors laden within extracellular matrix scaffolds can contribute to the overall 
biochemical microenvironment created by the scaffold.  Analysis of growth factor content 
change with source animal age is important to the overall characterization of ECM’s effect on 
macrophage phenotype. Due to previous work showing ECM scaffolds of different animal 
source age affected both skeletal muscle regeneration and macrophage phenotype, growth factors 
were selected that are known to affect both of these phenomena and have also been found in 
whole small intestine tissue [224-226]. Native small intestine tissue showed significant increases 
in bFGF and HB-EGF. However, no significant changes in content were observed following 
decellularization (Figure 6A-C). 
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Figure 6: Growth factor ELISA quantification of urea extracts from small intestine submucosa. 
Data shown as mean ± S.D. Statistical significance reported as *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
2.3.3 Assessment of age-related biomarkers 
Paraffin sections of decellularized SIS and SIS artificially glycated with ribose were stained with 
Periodic Acid Schiff stain in order to determine levels of polysaccharides and mucosubstances 
such as glycoproteins, glycolipids or mucins. This was performed in order to potentially detect 
glycation level changes with aging ECM. There were not large changes in Periodic Acid Schiff 
staining intensity with aging though a brighter section on the inside of 52 week old SIS was 
detected. Artificial glycation of SIS resulted in progressively brighter periodic acid Schiff 
staining (Figure 7). 
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Figure 7: Periodic acid-Schiff stain of different aged SIS and artificially glycated SIS. 
Images taken at 10X magnification. Scale bars indicate 100 µm. 
 
Staining of tissue with DNPH did not produce a noticeable signal alone (Figure 8). There was 
some particulate matter that stained dark in 52 wk SIS but it is unclear the cause of this. Other 
types of assays for protein carbonyl may be better suited for detection in extracellular matrix 
scaffolds. 
 
Figure 8: DNPH staining of different aged small intestine submucosa ECM. 
Images taken at 10X magnification. Scale bars indicate 100 µm. 
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Immunohistochemical staining of small intestine submucosa did not reveal large changes in AGE 
staining (Figure 9). 
 
 
Figure 9: Immunohistochemical staining for advanced glycation end-products. 
Images taken at 10X magnification. Scale bars indicate 100 µm. 
 
Assessment of advanced glycation end-product content via ELISA revealed a significant 
reduction in AGE content from 12 week SIS to 26 and 52 week SIS. Artificial glycation of SIS 
resulted in numerical increase AGE content with increased concentration of ribose used to 
glycate the SIS (Figure 10). 
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Figure 10: ELISA for advanced glycation end-products. 
Data shown as mean ± S.D. Statistical significance reported as *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
2.3.4 Biomechanical assessment 
Visual assessment of scanning electron microscopy (SEM) images showed there was more fiber 
alignment in 12 week SIS than in 52 week SIS (Figure 11). Quantitative assessment should be 
performed in order to confirm this observation. 
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Figure 11: Scanning electron microscopy images of small intestine submucosa at 2500X. 
Scale bars indicate 10 µm. 
 
Tensile mechanical testing of small intestine submucosa revealed differences in mechanical 
properties in both circumferential and longitudinal directions. Fifty two week SIS had 
significantly lower peak stress in both the longitudinal and circumferential directions. There was 
no difference in peak strain in either direction. The elastic modulus of 52 week SIS was 
significantly less than 12 week SIS in both directions. Twenty-six week SIS had significantly 
higher toughness than 12 or 52 week SIS in the longitudinal direction. In the circumferential 
direction, 52 week SIS had less toughness than 26 week SIS (Figure 12). 
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Figure 12: Uniaxial tensile mechanical testing performed under constant strain rate. 
Data shown as mean ± S.D. Statistical significance reported as *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
2.3.5 Immunofluorescent antibody labeling 
Differentiation into a macrophage phenotype was confirmed with antibody immunolabeling for 
F4/80, a commonly reported macrophage marker in mice. All treatment groups displayed 
staining for F4/80 with M1 treatment resulting in significant increases in F4/80 labeling (Figure 
13A). Macrophages treated with ECM degradation products were stained for classical 
differentiation markers of macrophage phenotype. Staining for iNOS, a classical M1, pro-
inflammatory marker, showed upregulation in M1 controls and downregulation in M2 controls 
(Figure 13B). Macrophages treated with ECM degradation products showed slight iNOS 
activation. Increasing source animal age resulted in significantly decreased iNOS surface marker 
expression with increasing age in macrophages from 2 month mice (Figure 13B). Macrophages 
derived from 18 month mice did not have a significant decrease in iNOS expression between 12 
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and 52 week ECM but ECM groups in 18 month macrophages had significantly higher iNOS 
expression over 2 month macrophages (p<0.0001) (Table 1). Staining for Arginase-1, a marker 
for M2, alternative activation, showed large upregulation in M2 controls and slight 
downregulation in M1 controls (Figure 13C). ECM-treated macrophages showed no differences 
in Arginase-1 surface marker expression compared to M0 controls. There were no significant 
changes in Arginase-1 immunoexpression with source animal age (Figure 13C). 
Fizz1, a marker for alternative macrophage activation, showed increased labeling in M2 
controls and decreased labeling in M1 controls (Figure 13D). Fizz1 expression of ECM-treated 
macrophages was intermediate, neither pro- nor anti-inflammatory. Source animal age 
significantly decreased Fizz1 expression from 12 week to 52 week SIS. Fizz1 expression was 
significantly higher in macrophages derived from 18 month mice compared to 2 month old mice 
(p<0.0001) (Table 1). 
CCR2, a chemokine receptor for CCL2, is classically a marker for invading 
macrophages. CCR2 showed decreased surface marker expression in M1 controls (Figure 13E). 
There were no significant differences in CCR2 immunolabeling based on source animal age of 
ECM. However, 18 month macrophages responded to ECM with increased CCR2 
immunoexpression compared to 2 month macrophages (p = 0.0463) (Table 1). CX3CR1, a 
fractalkine receptor, is a marker for tissue-resident macrophages. There were no significant 
changes in fractalkine receptor expression in cytokine controls or ECM treatment (Figure 13F). 
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Figure 13: Immunofluorescent antibody labeling of bone marrow macrophages treated with ECM. 
Data shown as mean ± S.D. Statistical significance reported as *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
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Table 1: List of p-values for age of macrophages and age of ECM source animal. 
 
 
 
In order to determine whether ECM degradation product exposure altered the ability of 
macrophages to polarize, macrophages were treated with ECM degradation products for 24 hours 
then treated with M1 or M2 cytokine regimes for the subsequent 24 hours. 52 week SIS 
significantly increased iNOS immunoexpression in ECM→M1 groups over IFN-γ/LPS 
treatments in 2 month old macrophages and 12 week SIS treatments in 18 month old 
macrophages (Figure 14A). Arginase-1 immunoexpression was significantly upregulated with 12 
week pre-treatment with subsequent IL-4 treatment compared to M2 controls (Figure 14B). In 18 
month macrophages, 52 week SIS caused a significant increase in Arginase-1 immunoexpression 
over 12 week SIS with IL-4 post-stimulation. The only significant change in Fizz1 
immunoexpression was a significant increase in Fizz1 in all ECM pre-treatments with IFN-γ/LPS 
post-stimulation over M1 controls in the 2 month macrophage group (Figure 14C). MHC-II 
immunoexpression was significantly decreased with 26 or 52 week SIS pre-stimulation over M1 
and 12 week SIS pretreatment samples in 2 month old macrophages (Figure 14F). SIS from 26 
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and 52 week SIS only decreased MHC-II expression compared to M1 stimulation in 18 month 
old macrophages. 
 
 
Figure 14: Immunofluorescent antibody labeling of macrophages treated with ECM then cytokines. 
Data shown as mean ± S.D. Statistical significance reported as *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
2.3.6 Taqman gene expression analysis 
Transcriptional levels of classical pro-inflammatory and anti-inflammatory markers and 
cytokines were assayed in 24 hour macrophage RNA extracts using Taqman gene expression 
assays (Figure 15). Pro-inflammatory markers NOS2, IL1b, IL12b, and Tnfa showed large 
increases in fold expression change in M1 treatment over naïve M0 macrophages. The anti-
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inflammatory gene targets Arg1, Fizz1, IL10, and Mrc1 showed significant increases in IL-4-
stimulated M2 macrophages. Fifty two week SIS treatment resulted in significant increases of 
IL-1ra expression over 12 and 26 week SIS treatment in 2 month old macrophages. Eighteen 
month old macrophages treated with 52 week SIS resulted in significant increases in Fizz1 
expression over 12 week SIS treatment. 
 
Figure 15: Taqman gene expression analysis of macrophages treated with ECM. 
Data shown are log10 of fold expression changes and are plotted on a scale where +1 
indicates 10x where x is the power of the highest fold change for each gene target and -1 
indicated 10-x. 
 
Gene expression assays were also conducted in challenge experiments where macrophages were 
exposed to ECM degradation products for 24 hours then challenged with M1 or M2 polarizing 
cytokines for an additional 24 hours (Figure 16). Pro-inflammatory (M1) controls showed large 
fold expression increase in iNOS, IL-12β, IL-1β, MHC-II, TNF-α, and IL-10. Anti-inflammatory 
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(M2) controls showed large fold expression increase in Arginase-1 and Fizz1 and smaller 
increases in Mrc1, PPARγ, MHC-II and IL-1β with decreases in TNFα and IL-10. ECM pre-
treatment did not alter expression of any genes following M1 or M2 treatment.  
 
Figure 16: Taqman gene expression of macrophages treated with ECM then cytokines. 
Data shown are log10 of fold expression changes and are plotted on a scale where +1 
indicates 10x where x is the power of the highest fold change for each gene target and -1 
indicated 10-x. 
2.3.7 Nitric oxide production 
Nitric oxide was assayed in the supernatants of macrophages treated with ECM degradation 
products (Figure 17). The stable form of nitric oxide, nitrite, was identified using the Greiss 
reagent system. Results showed an increase in nitric oxide production in M1 controls but no 
increase in M2 controls. ECM treatment showed limited levels of nitric oxide production. There 
were no significant differences in nitric oxide production from macrophages treated with ECM 
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alone. ECM pre-treatment followed by M1 stimulus increased nitric oxide production in 12 week 
SIS samples compared to M1 controls and 52 week SIS pre-treatment. 
 
Figure 17: Greiss reagent system assay of nitrite content from macrophage supernatants. 
Data shown as mean ± S.D. Statistical significance reported as *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
2.3.8 Phagocytosis 
To assess phagocytic function, Vybrant Phagocytosis Beads produced from FITC-labeled E. coli 
bacteria particles were used.  Phagocytic activity increased in pro-inflammatory controls but not 
in anti-inflammatory controls (Figure 18). ECM degradation products did not significantly 
change baseline phagocytosis or phagocytosis following cytokine regimens. 
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Figure 18: Vybrant FITC-labeled E. Coli phagocytosis assay on macrophages treated with ECM. 
Data shown as mean ± S.D. Statistical significance reported as *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
2.3.9 Seahorse metabolic analysis 
Pro-inflammatory (M1) macrophages exhibited significantly less ATP production and coupling 
efficiency (Figure 19). There were not significant changes in metabolism due to ECM treatment 
or ECM source animal age. 
 52 
 
Figure 19: Seahorse metabolic analysis of mitochondrial metabolic parameters. 
Data shown as mean ± S.D. Statistical significance reported as *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
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Figure 20: Seahorse metabolic analysis of glycolytic metabolic parameters. 
Data shown as mean ± S.D. Statistical significance reported as *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
2.4 DISCUSSION 
The present study investigated the response of macrophages to extracellular matrix (ECM) 
degradation products within an aging context. Specifically, this study investigated porcine small 
intestine submucosa (SIS) scaffolds that differ in only the variable of source animal age (the age 
of the animal from which it was derived). Previous work has shown that these scaffolds, when 
implanted into a rat abdominal wall reconstruction model, elicited different potentials for muscle 
healing [176]. This previous study showed that increasing source animal age resulted in 
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increased fibrosis and decreased skeletal muscle formation, which was related to increased pro-
inflammatory macrophage phenotype at early time-points.  In order to identify macrophages as 
being able to respond to these age-related changes, the present study utilized an in vitro model of 
macrophage response to ECM biomaterials. Results showed that ECM biomaterials caused the 
greatest shifts in macrophage phenotype when examined in combination with inflammatory 
cytokine polarization. The lack of robust macrophage response to ECM scaffolds alone is logical 
as the ECM is naturally occurring and involved in the homeostasis of tissues.  
There are currently over 50 extracellular matrix-based products registered with the FDA, 
many of which are derived from animal sources [227]. Due to known differences in composition 
of biologic materials due to individual organism variabilities, it is important to understand what 
characteristics of donor animals have effects on resultant biomaterial properties and their 
response upon implantation. Quality compliance of source animal facilities (SAFs) is regulated 
under FDA guidance “Source Animal, Product, Preclinical, and Clinical Issues Concerning the 
Use of Xenotransplantation Products in Humans” which ensures that animals used for clinical 
products are infection and disease free. However, factors such as age are not included in this 
guidance and could potentially have an effect on the performance of medical devices derived 
from aged animals. Understanding how changes in the extracellular matrix changes with source 
animal age could lead to reduced variability in xenogeneic biomaterials and improved outcomes. 
It is well documented that there are changes with age in extracellular matrix composition 
of many tissues. Aged colon exhibits increases in collagen content and decreases in strength 
[228]. Macrophages have been shown to respond differently to different collagen subtypes with 
collagen I increasing CCL18, IL-1ra, CCL2, CD204 and p-Akt expression whereas collagen III 
only increased CCL18 and IL-1ra [229]. Therefore, changes in extracellular matrix composition 
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with age could alter the macrophage response to biomaterials derived from different aged source 
animals, as shown in this study. This could compromise normally beneficial host responses and 
remodeling outcomes downstream of implantation. Furthermore, the influence of ECM on 
responses to inflammatory cytokines suggest the ECM environment may play a role in the nature 
and progression of the host inflammatory responses to injury and infection. Biochemical 
analyses for hydroxyproline and glycosaminoglycan content were unable to detect changes in 
decellularized ECM scaffolds. Therefore, more rigorous analysis including mass spectrometry is 
needed to understand changes in composition of specific components within aged ECM. 
The importance of changes in animal tissue product composition is most important with 
regard to how these changes affect the host response following implantation. A recent study has 
shown that aged animals elicited an altered macrophage response to polypropylene mesh 
implanted subcutaneously compared to young controls [230]. Results in this study show that 
bone marrow-derived macrophages from young and aged mice have similar abilities to polarize 
to M1 and M2 profiles in vitro. This suggests that changes in the macrophage response to 
implantable biomaterials cannot be explained by macrophage-intrinsic changes with age alone. It 
is logical to infer that the aged local microenvironment, consisting of the extracellular matrix and 
cellular signals, could be responsible for these changes in responses to biomaterials. These in 
vivo results further findings in this paper that aged ECM microenvironments affect macrophage 
phenotypes which could lead to altered immune responses. 
There are documented changes in macrophage populations and phenotypes in aged 
organisms. Peritoneal macrophage populations increased in the percentage of monocyte-derived 
and mature macrophages. Aged peritoneal macrophages also exhibited increased pro-
inflammatory cytokine IL-1b and IL-6 expression when stimulated with GM-CSF or IL-4. Aged 
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macrophages also exhibited a decreased nitric oxide/urea ratio [231]. Aged splenic macrophages 
exhibited decreased expression of IL-6, iNOS, IL-1b and TNFa when stimulated with LPS. Aged 
splenocytes also had reduced M2 markers when stimulated with IL-4 compared with young 
controls [52]. Aged macrophages have also been shown to have decreased MHC-II expression 
following IFN-y treatment, suggesting onset of immunosenescence [100]. Our results showed 52 
week ECM reduced MHC-II immunoexpression following IFN-y/LPS suggesting aged ECM 
may contribute to this immunosenescent phenotype. Further elucidation of these mechanisms is 
necessary to determine how aged ECM causes changes in macrophage phenotype. 
Treatment of macrophages with aged ECM in vitro results in similar alterations in 
phenotype compared to young ECM, reduced iNOS and Fizz1 immunoexpression. Aged ECM 
treatment with IFN-y/LPS stimulus increased iNOS immunoexpression and reduced nitric oxide 
production at 24 hours. This could suggest that aged ECM incites a delayed iNOS response as 
nitric oxide production is a result of the cumulative production in media over 24 hours whereas 
immunolabeling assays protein level at 24 hours only. This suggests that age-related changes in 
the ECM may contribute to the altered immune responses observed in aged wound healing.  
Previous studies have noted that the aging microenvironment is responsible for 
alterations in macrophage populations. Aging muscle exhibits an increase in M2a macrophage 
populations that could be the cause of increased fibrosis [53]. Transplantation of young bone 
marrow cells into aged muscle reduced the number of M2a macrophages, which could be caused 
by altered phenotypes in aged macrophages or be a result of the shift toward myeloid lineages in 
aged bone marrow [53]. These changes in aged muscle are also corrected by transfection of 
nNOS, suggesting that reduced nitric oxide in aged muscle could be a factor in this macrophage 
phenotype shift. Blau et al. also suggest that the aging microenvironment impacts the function of 
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muscle stem cells [232]. Some changes were attributed to intrinsic changes in MuSCs with age 
but others have been attributed to the local microenvironment. Age-related changes in the ECM 
microenvironment thus represents a cell-extrinsic mechanism of altered wound healing and 
regeneration in aged individuals. 
Aging has an effect not only on macrophage phenotypes and populations, but also 
macrophage function. Linehan et al. showed that the aged peritoneal microenvironment 
significantly impaired phagocytic function of macrophages independent of intrinsic changes in 
bone marrow macrophage populations [106]. Some of these changes were attributed to changes 
in T and B cell populations and levels of IL-10. Reduced phagocytic function could lead to 
impaired responses to pathogens or delayed debris removal in wound environments. However, 
our results did not show any change in phagocytic function due to aged ECM exposure. Aged 
alveolar macrophages were also shown to have reduced production of nitric oxide [233]. This 
matches our findings that macrophages exposed to aged ECM produced less nitric oxide upon 
IFN-y/LPS exposure. This reduction in macrophage function could impair pathogen immunity 
and alter angiogenic responses. 
The effects of aging have also been well documented in the area of wound healing. 
Wound healing in aged individuals is associated with delayed monocyte infiltration, increases in 
mature macrophages, and impaired macrophage function including reduced phagocytic capacity 
and increased secretion of pro-inflammatory mediators [99, 234, 235]. There are also delays in 
angiogenesis, collagen production and re-epithelialization, all of which are functions that are 
orchestrated by macrophages and their interaction with other cells of the injury response [236, 
237]. In spinal cord injury, macrophages have been shown to have reduced IL-10 expression in 
aged individuals [238]. Macrophages in aged vascular injury exhibited increased IL-18 
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expression which was associated with higher fibrinogen deposition [239]. All these examples 
show the impact of shifts in aged macrophage populations and phenotypes upon normal wound 
healing. Aged microenvironments may be responsible for these shifts in maintained or recruited 
macrophage populations or alterations from expected phenotypic responses. 
 
There were several limitations to the present study. This study only analyzed the effects 
of aging on porcine small intestine submucosa over the ages of 12 to 52 weeks. Not only does 
the extracellular matrix from different organs have different compositions but there are also 
organ-specific changes in this ECM makeup with age. Therefore, these results may not apply to 
ECM biomaterials derived from different sources. Furthermore, an in-depth assessment of what 
changed in these SIS scaffolds was not performed. More work would need to be done to 
understand, at a detailed level, the specific compositional changes and the signaling pathways 
which dictate changes in ECM-treated macrophage phenotype, which are currently unknown. 
Assessment of the presence and change in composition of matrix bound nanovesicles was also 
not completed. Changes in MBV content with age could be a potential mechanism for altered 
responses to these biomaterials [240]. This study also focused on the effects of extracellular 
matrix biomaterials on the phenotypes of macrophages alone. Many other cells participate 
during, before and after the involvement of macrophages during wound healing and biomaterial 
remodeling, including neutrophils, fibroblasts, adaptive immune cells, endothelial cells and stem 
cells. Little investigation has been performed on the synergistic roles of these cells during 
regenerative processes and further work is warranted in order to understand how these cells 
function together. 
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2.5 CONCLUSION 
Extracellular matrix scaffolds vary significantly due to their biological origin, and age effects 
their properties significantly. These changes in ECM structure are recognized by macrophages 
which change both their expression and function in response. Aged ECM degradation products 
alter macrophage phenotype and function both alone and in the presence of polarizing cytokines. 
These findings suggest that age-related changes in the ECM microenvironment have direct 
effects on the immune system. This suggests that age-related changes in wound healing and 
regeneration could be a result, in part, due to alterations in the extracellular matrix. This suggests 
further investigation into the ECM from aged individuals and its direct effect on immune and 
host response cells could help to elucidate mechanisms of altered healing responses in elderly 
populations. 
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3.0  EFFECT OF LIPID AND UREA EXTRACTS FROM AGED SMALL INTESTINE 
SUBMUCOSA UPON MACROPHAGE POLARIZATION 
3.1 INTRODUCTION 
The composition of the extracellular matrix is known to change with age [241-243]. Therefore, it 
is logical to conclude that extracellular matrix biomaterials derived from different aged animals 
will be different. Previous work has shown that small intestine submucosa (SIS) derived from 3-, 
12-, 26-, and 52-week old pigs showed differences in ECM and growth factor composition [175]. 
The in vivo host response to these different source animal age ECM showed increased pro-
inflammatory macrophage responses with increased ECM source animal age [176]. Extracellular 
matrix degradation products from aged small intestine submucosa were shown to directly alter 
the bone marrow macrophage response [110].  
Changes in growth factor composition is suggested to be one potential mechanism for the 
altered host response to aged extracellular matrix but has yet to be tested directly [244]. There 
are a number of growth factors naturally found in the intestine, including epidermal growth 
factor (EGF), heparin-binding epidermal-like growth factor (HB-EGF), glucagon—like peptide 2 
(GLP2), growth hormone (GH), insulin-like growth factor 1 (IGF-1), granulocyte colony 
stimulating factor (G-CSF), erythropoietin (Epo), intestinal trefoil factor (ITF), keratinocyte 
growth factor (KGF), and hepatocyte growth factor (HGF) [245]. Some reports have shown that 
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certain growth factor levels change with aging and affect lifespan, including IGF-1 [207, 246]. 
Insulin-like growth factor 1 has been shown to be both produced and to maintain M2 
macrophage polarization [247]. Granulocyte-colony stimulating factor (G-CSF) is also known to 
polarize macrophages to an anti-inflammatory phenotype [248]. Production of HB-EGF by IL-4-
stimulated macrophages leads to transactivation of epidermal growth factor receptor (EGFR) 
[249]. Growth factors have previously been extracted from extracellular matrix bioscaffolds 
using urea solubilization [219, 244]. Therefore, a direct effect of ECM-laden growth factors upon 
macrophage polarization can be tested. 
Lipid content in aged porcine extracellular matrix biomaterials is another potential factor 
as pigs rapidly gain mass and fat content as they mature [250]. Fatty acid oxidation has been 
shown to be necessary for an M2 macrophage polarization and is also involved in the 
progression of many diseases including obesity and diabetes [251]. Exposure of macrophages to 
several types of fatty acids has been shown to induce M2 macrophage polarization [252-254].  
3.2 METHODS 
3.2.1 Extracellular Matrix Scaffold Preparation 
Jejunum were harvested from 12 week, 26 week, and 52 week-old Landrace pigs immediately 
following euthanasia (Tissue Source, Lafayette, IN). The animals were of similar genetic 
heritage, diet and immunization history.  Small intestine submucosa (SIS) extracellular matrix 
biomaterials were prepared from these tissues as previously described [129].  Briefly, the tissues 
were rinsed with water and the mesenteric tissues were removed.  Tissues were cut 
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longitudinally then mechanically delaminated to remove the tunica serosa, tunica muscularis 
externa, and the luminal tunica mucosa, including most of the lamina propria.  After 
delamination, the tunica submucosa and the basilar layer of the tunica mucosa including the 
muscularis mucosa and the stratum compactum of the lamina propria remained. The material was 
further decellularized using mechanical agitation with an orbital shaker at 300 rpm in a solution 
of 0.1% (v/v) peracetic acid (Rochester Midland Corporation, Rochester, NY).  Tissues were 
then rinsed multiple times with saline and deionized water.  Decellularized scaffolds were frozen 
at -80°C and then lyophilized.  The resultant scaffolds were considered “whole ECM scaffolds.” 
A Wiley mill with a #60 mesh was used to grind ECM scaffolds into powder. 
3.2.2 Lipid Extraction 
Lipids were extracted from lyophilized ECM scaffolds using a 2:1:1 chloroform:methanol:water 
mixture. Twenty milligrams of lyophilized ECM were added to 2 mL of 2:1:1 
chloroform:methanol:water in a scintillation vial and then agitated on a tube vortexer for 2 hours. 
Scintillation vials were then centrifuged at 3000 rpm for 10 minutes. The organic phase was 
removed and placed in a clean scintillation vial. The organic solvents were then allowed to 
evaporate in a fume hood overnight. Once dry, the scintillation vials were lyophilized to remove 
residual organic solvent. Two milliliters of macrophage media was added to each scintillation 
vial and mixed on a vortexer for 48 hours. 
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3.2.3 Urea Extraction 
Growth factors and soluble proteins were extracted using a urea extraction protocol. Fifty 
milligrams of powdered ECM was added to microcentrifuge tubes and then 1 mL of 2M urea / 
1M Tris-HCl was added to each tube. The tubes were allowed to incubate on a rocker overnight 
at 4 °C. The tubes were centrifuged at 10,000xg for 30 mins and then the supernatant was saved. 
Another 1mL of urea extraction buffer was added to each tube and the tubes were incubated on 
the rocker for another 2 hours. The tubes were centrifuged as before and the supernatant 
combined from the two tubes. Urea soluble fractions were placed into 3kDa dialysis tubing and 
dialyzed against type 1 water for 3 days. Urea insoluble fractions were washed with type 1 water 
3 times via vortexing and then centrifuged to remove the water. Urea soluble fractions were 
adjusted to 10 mg/mL based on original ECM mass added. The urea insoluble fractions were 
frozen at -80 °C and then lyophilized. 
3.2.4 Pepsin digestion of ECM 
Whole ECM powder or urea extracted ECM powder was digested at a concentration of 10 
mg/mL in an acid-pepsin solution (pH 2) under constant magnetic stir for 48 hours. These 
digested scaffolds were considered “ECM degradation products.” 
3.2.5 Fatty acid quantification 
Lipid extracts were analyzed for free fatty acid content using the Free Fatty Acid Quantification 
Kit (Sigma) according to manufacturer instructions. Twenty milligrams of lyophilized ECM was 
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lipid extracted using 2 mL of 2:1:1 chloroform:methanol:water for 2 hours as described above. 
The organic phase was removed and allowed to evaporate overnight. The dried lipids were then 
lyophilized to remove any residual organic solvent. Samples were then diluted in 200 µL Fatty 
Acid Buffer and agitated until dissolved. Fifty microliters of sample or palmitic acid standards 
(0, 2, 4, 6, 8, 10 nmol) were added to a 96 well plate. Two microliters of ACS reagent was added 
to each well and the samples were incubated for 30 mins at 37ºC. Then, fifty microliters of the 
master reaction mix was added to each well and the samples were again incubated for 30 mins at 
37ºC. The absorbance of each well was measured at 570 nm using a spectrophotometer plate 
reader.  Concentrations were calculated based on measurements from the palmitic acid standard 
curve. 
3.2.6 Bone marrow-derived macrophage isolation 
Bone marrow-derived macrophages were harvested from 2 month or 18-20 month-old C57/BL6 
mice as previously described [221].  Briefly, femurs and tibiae were harvested and separated 
from muscle and connective tissue.  Bones were cut at either end to expose bone marrow.  Sterile 
syringe and needles were used to flush out bone marrow using macrophage differentiation media 
(DMEM/10% FBS/10% L-929 Supernatant/1% PenStrep/2% MEM non-essential amino 
acids/1% HEPES/0.1% 55μM β-2 mercaptoethanol).  Bone marrow lysate was reconstituted in 
media and filtered through a sterile cell filter.  Cells were cultured for 7 days in media to 
differentiate them into macrophages, changing differentiation media every 2 days. 
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3.2.7 Macrophage Treatment 
Following 7 days of differentiation culture as described above, macrophages were treated with 
acute polarizing regimens to distinguish phenotypes over 24 hours.  Naïve macrophage (M0) 
controls were treated with basal media for 24 hours.  M1 (20 ng/mL IFN-γ and 100 ng/mL LPS) 
and M2 (20 ng/mL IL-4) polarizing cytokines were used to create positive controls for classical 
pro- and anti-inflammatory macrophages.  ECM degradation products were neutralized and 
diluted to 1 mg/mL in macrophage media to isolate biochemical effects of degradation products 
and prevent structural moieties from forming.  Pepsin buffer (1 mg/mL pepsin in 0.01 M HCl) 
diluted in macrophage media was used as a control.  Another set of treatment groups involved 
24-hour exposure of ECM degradation products followed by 24-hour treatment with either the 
M1 or M2 treatment regimen. 
3.2.8 Indirect immunofluorescent antibody labeling 
Cells were fixed with 2% paraformaldehyde (PFA) for 30 minutes then washed in 1XPBS.  Cells 
were incubated in blocking buffer (2% donkey serum, 1% bovine serum albumin (BSA), 0.1% 
Triton X-100, 0.1% Tween-20) for 1 hour at room temperature.  Primary antibodies were diluted 
in this blocking buffer as follows and incubated overnight at 4 °C: F4/80 (1:200, Abcam 6640), 
iNOS (1:100, Abcam 3523), Arginase-1 (1:200, Abcam 91279), Fizz1 (1:200, Peprotech 500-
P214), CCR2 (1:200, Abcam 21667), CX3CR1 (1:200, Abcam 8021), MHC-II (1:100, Abcam).  
F4/80 is a marker of macrophage differentiation. iNOS and MHC-II are classical M1 
macrophage markers whereas Arginase-1 and Fizz1 are classical M2 macrophage markers. 
CCR2 is a chemokine receptor associated with macrophage migration whereas CX3CR1 is a 
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fractalkine receptor associated with tissue-resident macrophages. Cells were washed in 1XPBS 
then incubated in the appropriate fluorescently-labeled secondary antibody solution in blocking 
buffer for 1 hour at room temperature (donkey anti-rat Alexa Fluor 488, Invitrogen, 1:200; 
donkey anti-rabbit Alexa Fluor 488, Invitrogen, 1:300).  Cell nuclei were counterstained with 
DAPI.  Cells from six young mice were imaged nine times in the center of each well at 10X 
magnification using automated position capture function to remove bias from subjective image 
location acquisition. This set of 9 images per well was counted as one biological replicate and 
was repeated in cells from n=6 mice for a total of 5 sets of 9 images per group. All imaging was 
performed on an Axio observer T1 microscope. Mean fluorescence intensity of cells was 
analyzed using Cell Profiler software (Broad Institute). Briefly, DAPI images were used by the 
program to identify cell nuclei then FITC images were used to identify cell borders around the 
identified nuclei. The mean fluorescent intensity was calculated by averaging the pixel intensities 
(scale of 0 to 1) across the entire cell area. Mean fluorescence intensity values were averaged for 
all imaged cells in each well. 
3.2.9 Phagocytosis assay 
Following treatments, cells were assayed for phagocytic ability using Vybrant Phagocytosis 
Assay Kit (Invitrogen).  Cells were incubated in FITC-labeled dead E. Coli particles for 2 hours 
in the cell culture incubator.  Following washing, the cells were fixed with 2% PFA for 30 
minutes then washed with 1X PBS.  Cells were counterstained with DAPI then imaged and 
analyzed as described above. 
 67 
3.2.10 Nitric Oxide Assay 
Following treatments, 50 μL of supernatant from macrophages were transferred into a fresh 
plate.  Nitric oxide content was assayed using a Greiss Reagent system.  Briefly, 50 μL of 
sulfanilamide (1% in 5% phosphoric acid) was added to supernatants for 10 minutes.  Then, 50 
μL of 0.1% N-1-napthylethylenediamine in water was added to the mixture for an additional 10 
minutes.  The absorbance at 540 nm was measured using a BioTek SYNERGY HTX 
spectrophotometer. 
 
3.3 RESULTS 
3.3.1 Fatty acid content in ECM lipid extracts 
Quantification of free fatty acid content within lipid extracts of small intestine submucosa ECM 
bioscaffolds showed that a significant portion of SIS composition is fatty acids (3-10%)    
(Figure 21). Small intestine submucosa from 26 week old pigs had significantly higher free fatty 
acid content than SIS from 12 week old pigs. Fifty two week old SIS had significantly higher 
free fatty acid content than both 12 and 26 week old SIS. 
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Figure 21: Free fatty acid quantification of lipid extracts from small intestine submucosa ECM. 
Data shown as mean ± S.D. Statistical significance reported as *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
3.3.2 Immunofluorescent antibody labeling 
Macrophages treated with IFN-y and LPS showed an increase in iNOS immunoexpression as 
expected. Extracellular matrix degradation products from 12 and 26 week old pigs had 
significantly less iNOS immunolabeling compared to M1 and M2 controls. Fifty two week old 
SIS was not significantly different than M1 and M2 controls (Figure 22A). Both whole ECM 
degradation products and urea soluble factors from 52 week old SIS promoted significantly 
higher iNOS immunoexpression than their respective fractions from 12 week old SIS (Figure 
22B). Lipid fractions from 52 week old SIS promoted significantly higher iNOS 
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immunoexpression than 12 week SIS lipid extracts with IFN-y/LPS stimulus. Urea insoluble 
fractions from 52 week old SIS promoted significantly more iNOS immunoexpression than 12 
and 26 week old SIS with IFN-y/LPS stimulus (Figure 22C). Whole ECM degradation products 
from 52 week old pigs promoted a significantly decreased iNOS immunoexpression than 12 
week SIS with M2 stimulus (Figure 22D). 
 
Figure 22: Antibody labeling of macrophages treated with ECM extracts for iNOS. 
Macrophages were treated with polarizing cytokines (A), ECM alone (B), ECM then M1 
cytokines (C), or ECM then M2 cytokines (D). Macrophages were then fixed and stained for 
iNOS immunoexpression using indirect fluorescent antibody labeling and mean fluorescence 
intensity was calculated. Data shown as mean ± S.D. Statistical significance reported as *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001. 
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Interleukin-4 stimulation of macrophages resulted in significantly increased arginase-1 
immunolabeling, as expected (Figure 23A). Treatment of macrophages with ECM degradation 
products alone did not result in significant changes in arginase immunolabeling compared to M0 
controls. Whole ECM degradation products from 52 week old SIS did promote significantly 
more arginase-1 immunoexpression than 26 week SIS. Lipid extracts from 52 week old SIS 
promoted significantly less arginase immunoexpression than 26 week old lipid extracts (Figure 
23B). With pro-inflammatory stimulus, there was not significant changes in arginase 
immunoexpression compared to M0 controls. However, soluble and insoluble fractions from 52 
week old SIS did promoted significantly more arginase immunoexpression with M1 cytokine 
treatment (Figure 23C). With IL-4 stimulation, whole and lipid fractions from 52 week old SIS 
promoted more arginase immunoexpression while soluble and insoluble fractions promoted a 
reduction (Figure 23D). 
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Figure 23: Antibody labeling of macrophages treated with ECM extracts for arginase. 
Macrophages were treated with polarizing cytokines (A), ECM alone (B), ECM then M1 
cytokines (C), or ECM then M2 cytokines (D). Macrophages were then fixed and stained for 
arginase immunoexpression using indirect fluorescent antibody labeling and mean fluorescence 
intensity was calculated. Data shown as mean ± S.D. Statistical significance reported as *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001. 
3.3.3 Phagocytosis 
Interleukin-4 stimulation of macrophages promoted a reduction in phagocytosis as expected 
(Figure 24A). ECM degradation products from 12 and 26 week SIS also promoted a significant 
decrease in phagocytosis from M0 and M1 controls to similar levels as M2 controls. Fifty two 
week SIS further reduced phagocytosis from 12 and 26 week SIS (Figure 24A). With basal ECM 
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extract treatment, whole and insoluble 52 week SIS extracts promoted less phagocytosis while 
soluble extracts promoted more (Figure 24B). With pro-inflammatory stimulus, both whole and 
urea insoluble fractions from 52 week SIS reduced phagocytosis compared to 12 week SIS. 
Soluble fraction with M1 cytokines promoted higher phagocytosis with 52 week SIS over 26 
week SIS (Figure 24C). With IL-4 stimulation, whole and insoluble fractions from 52 week SIS 
again reduced phagocytosis while soluble fractions increased it (Figure 24D). 
 
Figure 24: Phagocytic function of macrophages treated with ECM extracts. 
Macrophages were treated with polarizing cytokines (A), ECM alone (B), ECM then M1 
cytokines (C), or ECM then M2 cytokines (D). Macrophages were then incubated with FITC-
labeled E. Coli beads and then fixed and counterstained with DAPI and mean fluorescence 
intensity was calculated. Data shown as mean ± S.D. Statistical significance reported as *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001. 
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3.3.4 Nitric oxide production 
Pro-inflammatory (M1) macrophages produced significantly higher levels of nitric oxide than 
M0 and M1 controls. ECM degradation products from 52 week old SIS promoted higher levels 
of nitric oxide production than 12 week SIS (Figure 25A). With basal ECM extract treatment, 
there was no substantial nitric oxide production from any 12 or 26 week old SIS. Whole, soluble 
and insoluble SIS from 52 week old pigs all promoted higher levels of nitric oxide (Figure 25B). 
With pro-inflammatory cytokine stimulus, 52 week old whole, soluble and insoluble fractions 
promoted less nitric oxide production (Figure 25C). With IL-4 stimulation, soluble and insoluble 
fractions from 52 week SIS promoted more nitric oxide production (Figure 25D). 
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Figure 25: Nitric oxide production from macrophages treated with ECM extracts. 
Macrophages were treated with polarizing cytokines (A), ECM alone (B), ECM then M1 
cytokines (C), or ECM then M2 cytokines (D). Macrophage supernatant was then removed and 
assayed for nitrite content using the Greiss reagent system. Data shown as mean ± S.D. 
Statistical significance reported as *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
3.4 DISCUSSION 
Analysis of different extracts within small intestine submucosa shows that ECM scaffolds are 
more than just insoluble matrix proteins. Small intestine submucosa has a substantial lipid 
content which increases significantly from 26 to 52 weeks. Further analysis of different types of 
lipids present within SIS and how they change with age would be beneficial to understand how 
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this composition is contributing to the host response to ECM biomaterials. While our current 
analysis of the growth factor content in decellularized small intestine submucosa found no 
significant differences, mass spectrometry analysis has shown significant differences in not only 
extracellular matrix proteins but also soluble cellular proteins as well [255]. Proteomic and 
lipidomic analysis of these matrix fractions could reveal more accurately changes in composition 
and help to understand what pathways may be activated because of them. 
3.5 CONCLUSION 
There are many different types of biomolecules within extracellular matrix scaffolds despite 
adequate decellularization. These different classes of biomolecules each affect macrophage 
polarization and function differently. Further investigation into the composition of these different 
components will help to understand extracellular matrix scaffolds and how they influence the 
host response to them. Most dramatic changes were in insoluble fractions of the ECM, 
suggesting that changes to the structural molecules dictate changes in the macrophage response. 
Investigation of modification of structural ECM molecules with glycation or oxidation is the 
most logical explanation for these differences. 
3.6 FUTURE DIRECTIONS 
The results from Chapter 2 and 3 illustrate how extracellular matrix derived from different aged 
animals directly affects macrophage polarization and function. These results have important 
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implication for sourcing of tissues to produce extracellular matrix biomaterials.  Because of these 
implications, previous work was performed using a tissue non-specific and xenogeneic approach, 
which models clinical use of extracellular matrix biomaterials. The direct effects of source 
animal age upon macrophage polarization and function have implications for aging biology. In 
order to test similar questions with aging biology relevance, our approach changed to using 
extracellular matrix in a tissue-specific and allogeneic experimental design. In this way, we 
would be able to investigate whether the natural changes in the extracellular matrix with aging 
would be sufficient to alter the regenerative capacity of an otherwise healthy, young tissue. This 
forms the central basis for the hypotheses formed for this dissertation work. 
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4.0  HYPOTHESIS AND SPECIFIC AIMS 
The central hypothesis for the following work is that aged muscle extracellular matrix (1) 
directly impacts the host response through altered macrophage activation and polarization and 
(2) that these changes are due to accumulation of advanced glycation end-products within the 
aged extracellular matrix. 
4.1 SPECIFIC AIM 1: TO DETERMINE THE EFFECT OF AGED SKELETAL 
MUSCLE EXTRACELLULAR MATRIX UPON MACROPHAGE POLARIZATION 
AND FUNCTION 
Hypothesis: Aged muscle extracellular matrix induces an increased pro-inflammatory 
macrophage response. 
Rationale: Previous studies have shown that aged muscle experiences increased pro-
inflammatory responses during injury [47]. Chronic inflammation has been well characterized in 
elderly individuals [256]. This chronic inflammation has also been associated with the declining 
muscle mass and strength in sarcopenia [257]. 
 78 
4.2 SPECIFIC AIM 2: TO DETERMINE THE EFFECT OF GLYCATION UPON 
THE MACROPHAGE RESPONSE TO MUSCLE ECM 
Hypothesis: Glycation of muscle ECM promotes an enhanced pro-inflammatory macrophage 
phenotype. 
Rationale: Advanced glycation end-products are known to signal through RAGE [177]. This 
receptor signals through the NF-κB transcription factor which mediates pro-inflammatory 
cytokine expression [258]. Macrophages express the RAGE receptor and have been shown to 
respond to AGEs with increased pro-inflammatory responses [194]. 
4.3 SPECIFIC AIM 3: TO DETERMINE THE EFFECT OF AGED AND GLYCATED 
ECM UPON THE HOST RESPONSE FOLLOWING MUSCLE INJURY 
Hypothesis: Aging and glycation of muscle ECM enhances pro-inflammatory macrophage 
response and impairs healing in a model of muscle injury. 
Rationale: Muscle regeneration is impaired in aged individuals [37]. Following exercise, the 
number of pro- and anti-inflammatory macrophages increased in young individuals but not in old 
[47]. Previous studies have shown aged small intestine submucosa created an increased pro-
inflammatory response and increased collagen deposition [176]. 
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5.0  EFFECT OF AGED SKELETAL MUSCLE ECM UPON MACROPHAGE 
POLARIZATION AND FUNCTION 
5.1 INTRODUCTION 
Extracellular matrix acts as the supporting structure of a tissue and dynamically changes in a 
reciprocal relationship with cells of that tissue. ECM changes with aging and disease and can 
affect the responses of cells in these altered states. Therefore, ECM can be used as a model for 
aged microenvironments to more fully understand their effect on cellular function. Skeletal 
muscle strength and healing potential are known to decrease with aging [232]. The immune 
response, which is integral to muscle regeneration, is also dysfunctional with age [259]. 
Macrophage polarization in particular has been shown to be necessary for appropriate skeletal 
muscle healing [51]. There has been no direct investigation to determine whether age-related 
changes in skeletal muscle extracellular matrix influence macrophage polarization and contribute 
to altered host responses observed in aged individuals during skeletal muscle injury. 
 Decellularization techniques have been used for decades now to develop biomaterials for 
a variety of surgical and tissue engineering strategies [260]. These same methodologies can be 
used to harvest the extracellular matrix from skeletal muscle of animals differing in age or 
disease state in order to understand how these factors contribute to altered physiology [261]. 
Previous investigations into changes in aging’s effect on skeletal muscle ECM has relied on 
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histologic analysis of intact muscle tissue only [262]. Therefore, in order to isolate the role of 
extracellular matrix in altered host responses during injury, bioengineering techniques must be 
utilized to separate the ECM from the rest of the skeletal muscle tissue. 
The present study seeks to combine several bioengineering strategies to study the isolated 
effects of aging and glycation of the extracellular matrix upon the macrophage response in vitro. 
While many studies focus on cellular dysfunction during aging, this study seeks to understand 
the isolated role of alterations in the extracellular microenvironment. 
 
5.2 METHODS 
5.2.1 Skeletal muscle extracellular matrix preparation 
Skeletal muscle extracellular matrix was prepared using modified methods previously developed 
[261]. Briefly, abdominal muscle was harvested from 4 month and 18 month old C57BL6/J mice 
(NIA). Muscle was washed in water. Samples were enzymatically digested in 0.2% trypsin/0.2% 
EDTA for 2 hrs at 37 °C with agitation. All subsequent steps were performed on a mechanical 
shaker at 300 rpm. Samples were washed once in water and twice in 1XPBS, 30 mins each. 
Samples were decellularized using 2% sodium deoxycholate for 5 hrs, washed in water and twice 
in 1XPBS for 30 mins each and then decellularized with 2% sodium deoxycholate for 14-16 hrs 
and 1% Triton X-100 for 1 hr. Samples were washed with type 1 water until no bubbles were 
detectable, suggesting detergents had been removed. Samples were either treated with 0.1% 
peracetic acid/4% ethanol for 2 hours. Samples were then washed twice with 1XPBS then twice 
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with water for 30 mins each. Samples used for implantation were terminally sterilized with 
ethylene oxide. ECM degradation products were produced using a 1mg/mL pepsin solution in 
0.01N HCl under constant stir for 48 hrs to create a 10mg/mL ECM digest. 
5.2.2 Skeletal Muscle ECM Characterization 
Hydrated native tissue and decellularized scaffolds were fixed in 10% neutral buffered formalin 
(NBF) and then embedded in paraffin.  Sections of these scaffolds were stained separately with 
hematoxylin & eosin or DAPI to confirm removal of nuclei.  Proteinase K digests of native and 
decellularized scaffolds underwent phenol: chloroform: isoamyl alcohol (25:24:1) extraction for 
DNA and were resuspended in 1X TE buffer.  DNA extracts were separated using 
electrophoresis on a 2% agarose gel in 0.5X TBE buffer to confirm reduction of DNA content 
and fragmentation of remnant DNA in decellularized scaffolds compared to native controls. 
DNA extracts were also quantified for double-stranded DNA content using a PicoGreen assay 
(Thermo) according to manufacturer’s instructions. 
5.2.3 Biochemical Assessment 
ECM scaffold biochemistry was performed to assess hydroxyproline and sulfated 
glycosaminoglycan content. ECM scaffolds were digested at 10mg/mL in a papain solution. 
Sulfate glycosaminoglycan content was assessed using a dimethylmethylene blue (DMMB) 
reagent. Hydroxyproline content was assessed by adding 50 μL 2N NaOH to 50 μL papain 
digests then hydrolyzing at 110 °C for 18 hrs. Samples were neutralized with 5N HCl. One 
hundred microliters of 0.01M copper sulfate, 2.5N NaOH and 6% H2O2 were added. Samples 
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were incubated at 80 °C for 5 minutes then cooled. Four hundred microliters of 3N sulfuric acid 
was added followed by 200 μL of 5% DMAB in propanol. Samples were incubated at 70 °C for 
15 minutes then the absorbance was read at 540 nm. Advanced glycation end-product (AGE) 
fluorescence levels were determined by reading the fluorescence intensity of pepsin-digested 
ECM at excitation of 370nm and emission of 440nm. Protein carbonyl content was quantified 
using a protein carbonyl quantification kit (Cayman Chemical) according to manufacturer 
instructions. 
Paraffin sections were stained with PicroSirius Red as an indicator of collagen content. 
Briefly, slides were deparaffinized and rehydrated to water. Slides were stained in PicroSirius 
Red solution for 1 hour then differentiated in 35% acetic acid for 10 seconds. Slides were 
quickly dehydrated and cleared in xylenes then mounted with resinous mounting media. 
Paraffin sections were stained with Masson’s trichrome as an indicator of collagen 
content. Briefly, slides were deparaffinized and rehydrated to water. Slides were re-fixed in 
Bouin's solution for 1 hour at 56 °C to improve staining quality. Slides were rinsed in running 
tap water for 10 minutes to remove the yellow color. Slides were then stained in Weigert's iron 
hematoxylin working solution for 10 minutes then rinsed in running warm tap water for 10 
minutes then washed in distilled water. Slides were stained in Biebrich scarlet-acid fuchsin 
solution for 10 minutes then washed in distilled water. The stain was differentiated in 
phosphomolybdic-phosphotungstic acid solution for 10 minutes. Slides were transfered directly 
to aniline blue solution and stained for 10 minutes then rinsed briefly in distilled water and 
differentiate in 1% acetic acid solution for 5 minutes then washed in distilled water. Slides were 
dehydrated very quickly and cleared in xylene then mounted with resinous mounting medium. 
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5.2.4 Assessment of advanced glycation end product content 
Fluorescence AGE levels were assessed by pipetting papain digested ECM into 96 well plates. 
Fluorescence intensity levels were assessed on a spectrophotometer (BioTek) for several 
signature AGE wavelengths: excitation = 295 nm emission = 395 nm, excitation = 335 nm 
emission = 385 nm, excitation = 370 nm emission = 440 nm. 
5.2.5 Immunohistochemical staining 
Native and decellularized muscle ECM was fixed in 10% NBF then embedded in paraffin wax. 
Sections were stained using DAB immunohistochemistry for collagen type I, advanced glycation 
end-products, cysteine sulfonate, S-nitro-cysteine, or 3-nitro-tyrosine. Briefly, paraffin sections 
were deparaffinized to water then antigen was retrieved using 10mM citric acid pH 6 0.05% 
Tween20 for 20 mins at 95-100 °C. Slides were washed twice with 1X TBST for 5 mins then 
twice with 1XPBS for 3 mins. Endogenous peroxidase activity was blocked by incubating slides 
in 0.3% hydrogen peroxide for 30 mins. Slides were washed 3 times in 1X PBS for 3 minutes. 
Slides were blocked for non-specific antibody binding with a blocking buffer made of 2% 
donkey serum/1% bovine serum albumin/0.1% Tween-20 for 1 hour at room temperature. 
Primary antibodies were incubated overnight at 4 °C diluted in blocking buffer. Slides were 
washed 3 times for 3 minutes with 1XPBS. Slides were then incubated with biotinylated 
secondary antibodies diluted in blocking buffer (goat anti-rabbit 1:200 (Vector)). Slides were 
was again 3 times for 3 minutes with 1XPBS. Slides were incubated with VectaShield ABC 
Reagent for 30 mins then washed again 3x3mins with 1XPBS. Staining was developed by 
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incubating sections with 4% DAB. Sections were washed then mounted with resinous mounting 
media and coverslipped. Slides were images on a brightfield microscope at the same settings. 
5.2.6 Bone marrow-derived macrophage isolation 
Bone marrow-derived macrophages were harvested from 2 month or 18-20 month-old C57/BL6 
mice as previously described [221].  Briefly, femurs and tibiae were harvested and separated 
from muscle and connective tissue.  Bones were cut at either end to expose bone marrow.  Sterile 
syringe and needles were used to flush out bone marrow using macrophage differentiation media 
(DMEM/10% FBS/10% L-929 Supernatant/1% PenStrep/2% MEM non-essential amino 
acids/1% HEPES/0.1% 55μM β-2 mercaptoethanol).  Bone marrow lysate was reconstituted in 
media and filtered through a sterile cell filter.  Cells were cultured for 7 days in media to 
differentiate them into macrophages, changing differentiation media every 2 days.  
5.2.7 Macrophage Treatment 
Following 7 days of differentiation culture as described above, macrophages were treated with 
acute polarizing regimens to distinguish phenotypes over 24 hours.  Naïve macrophage (M0) 
controls were treated with basal media for 24 hours.  M1 (20 ng/mL IFN-γ and 100 ng/mL LPS) 
and M2 (20 ng/mL IL-4) polarizing cytokines were used to create positive controls for classical 
pro- and anti-inflammatory macrophages.  ECM degradation products were neutralized and 
diluted to 1000 μg/mL in macrophage media to isolate biochemical effects of degradation 
products and prevent structural moieties from forming.  Pepsin buffer (1 mg/mL pepsin in 0.01 
M HCl) diluted in macrophage media was used as a control.  Another set of treatment groups 
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involved 24-hour exposure of ECM degradation products followed by 24-hour treatment with 
either the M1 or M2 treatment regimen. 
5.2.8 Indirect Immunofluorescent Antibody Labeling 
Cells were fixed with 2% paraformaldehyde (PFA) for 30 minutes then washed in 1XPBS.  Cells 
were incubated in blocking buffer (2% donkey serum, 1% bovine serum albumin (BSA), 0.1% 
Triton X-100, 0.1% Tween-20) for 1 hour at room temperature.  Primary antibodies were diluted 
in this blocking buffer as follows and incubated overnight at 4 °C: iNOS (1:100, Abcam 3523) or 
Arginase-1 (1:200, Abcam 91279).  iNOS is a classical M1 macrophage marker whereas 
Arginase-1 is a classical M2 macrophage marker. Cells were washed in 1XPBS then incubated in 
the appropriate fluorescently-labeled secondary antibody solution in blocking buffer for 1 hour at 
room temperature (donkey anti-rat Alexa Fluor 488, Invitrogen, 1:200; donkey anti-rabbit Alexa 
Fluor 488, Invitrogen, 1:300).  Cell nuclei were counterstained with DAPI.  Cells from 2 month 
old mice were imaged nine times in the center of each well at 10X magnification using 
automated position capture function to remove bias from subjective image location acquisition. 
All imaging was performed on an Axio observer T1 microscope. Mean fluorescence intensity of 
cells was analyzed using Cell Profiler software (Broad Institute). Briefly, DAPI images were 
used by the program to identify cell nuclei then FITC images were used to identify cell borders 
around the identified nuclei. The mean fluorescent intensity was calculated by averaging the 
pixel intensities (scale of 0 to 1) across the entire cell area. Mean fluorescence intensity values 
were averaged for all imaged cells in each well. 
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5.2.9 Taqman gene expression assay 
Following treatments, macrophages (n=5 biological replicates from 5 young (2 month) and 5 
aged (18 month) mice) were harvested for RNA using Qiagen RNEasy MiniPrep RNA Isolation 
Columns following standard protocol.  RNA was quantified using a NanoDrop Lite 
Spectrophotometer (Thermo).  cDNA templates were created from 1 μg of RNA using Invitrogen 
High Capacity RNA-to-cDNA kits (Thermo).  Taqman Gene Expression Assays (Thermo) were 
performed for the following commonly reported M1 and M2 macrophage genes: Nos2 
(Mm00440502_m1), IL1b (Mm00434228_m1), IL12b (Mm01288989_m1), TNFa 
(Mm00443258_m1), MHC-II (Mm01181326_m1), Arg (Mm00475988_m1), Retlna (Fizz1) 
(Mm00445109_m1), Mrc1 (Mm01329362_m1), IL10 (Mm01288386_m1), and PPARg 
(Mm00440940_m1). 
5.2.10 Phagocytosis Assay 
Following treatments, 50 μL of supernatant from macrophages were transferred into a fresh 
plate.  Nitrite content was assayed using a Greiss Reagent system.  Briefly, 50 μL of 
sulfanilamide (1% in 5% phosphoric acid) was added to supernatants for 10 minutes.  Then, 50 
μL of 0.1% N-1-napthylethylenediamine in water was added to the mixture for an additional 10 
minutes.  The absorbance at 540 nm was measured using a BioTek SYNERGY HTX 
spectrophotometer. 
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5.2.11 Nitric oxide assay 
Following treatments, 50 μL of supernatant from macrophages were transferred into a fresh 
plate.  Nitrite content was assayed using a Greiss Reagent system.  Briefly, 50 μL of 
sulfanilamide (1% in 5% phosphoric acid) was added to supernatants for 10 minutes.  Then, 50 
μL of 0.1% N-1-napthylethylenediamine in water was added to the mixture for an additional 10 
minutes.  The absorbance at 540 nm was measured using a BioTek SYNERGY HTX 
spectrophotometer. 
 
5.2.12 Arginase Activity Assay 
Following treatments, media was removed and macrophages were lysed in 50μL 0.001% Triton 
X-100 in type 1 H2O with 1X Halt Protease Inhibitors (Thermo). Twenty five microliters of 
lysate was added to 25 μL of arginase activation solution (10mM MnCl2/50mM Tris-HCl, 
pH7.5) and incubated at 55°C for 10 minutes. Samples were allowed to cool and then 50 μL of 
arginine substrate solution (0.5M L-arginine pH 9.7) was added to each well.  Samples were 
incubated at 37°C for 2 hours. A urea standard curve was created via 2 fold serial dilution from 
100 mg/mL to 1.5625 mg/mL with a 0 mg/mL blank in lysis buffer. Five microliters of samples 
or standards were added to a new 96-well plate and 200 μL of urea detection solution (513 mg/L 
primaquine, 100 mg/L phthalaldehyde, 2.5 mol/L sulfuric acid, 2.5 g/L boric acid, 0.03% Brij35) 
was added to each well. Absorbance of samples was analyzed using a plate spectrophotometer at 
430 nm between 5-20 minutes following addition of detection solution. 
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5.3 RESULTS 
5.3.1 Muscle ECM Decellularization Characterization 
Native and decellularized muscle ECM were characterized using hematoxylin & eosin staining 
(Figure 26). Histological assessment showed that skeletal muscle ECM had no presence of 
cellular constituents from muscle fibers and that nuclei were removed. 
 
Figure 26: Hematoxylin & eosin staining of young and aged skeletal muscle and muscle ECM. 
Images taken at 10X magnification. Scale bars indicate 100 µm. 
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Nuclear removal was confirmed with fluorescent DAPI staining of nuclei showing that skeletal 
muscle decellularization was effective (Figure 27). 
 
Figure 27: DAPI fluorescent imaging of native and decellularized skeletal muscle. 
Images taken at 20X magnification. Scale bars indicate 100 µm. 
 
DNA agarose gel electrophoresis confirmed that there was minimal remnant DNA and that any 
DNA was largely fragmented (Figure 28A). PicoGreen quantification of double stranded DNA 
confirmed a significant portion of DNA was removed from decellularized tissues (Figure 28B). 
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Figure 28: DNA gel electrophoresis (A) and PicoGreen dsDNA quantification (B) of muscle ECM. 
Data shown as mean ± S.D. Statistical significance reported as *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
5.3.2 Muscle ECM Biochemical Characterization 
Sulfated glycosaminoglycan content was assessed via DMMB assay. Results showed there were 
no significant differences in sulfated glycosaminoglycan content in either native or 
decellularized skeletal muscle (Figure 29A). Assessment of hydroxyproline content suggested 
there were no significant differences in hydroxyproline content in native skeletal muscle. 
Following decellularization, young skeletal muscle ECM was assessed to have more 
hydroxyproline content than old skeletal muscle ECM (Figure 29B). 
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Figure 29: DMMB sulfated GAG (A) and hydroxyproline quantification (B) of muscle ECM. 
Data shown as mean ± S.D. Statistical significance reported as *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
 
Assessment of free fatty acid content showed there was significantly less free fatty acid content 
in aged skeletal muscle. This is counterintuitive to reports which have shown that there is 
increased fatty acid content in the plasma of aged mice [263]. This reduction in fatty acid content 
may be explained by greater incorporation into triglycerides due to reduced levels of hormone-
sensitive lipase which degrades triglycerides into free fatty acids [264]. Upon decellularization, 
there was a significant reduction in free fatty acid content. There was also no significant 
difference in free fatty acid content between young and aged skeletal muscle ECM (Figure 30). 
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Figure 30: Free fatty acid quantification from lipid extracts of skeletal muscle ECM. 
Data shown as mean ± S.D. Statistical significance reported as *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
 
Advanced glycation end-product (AGE) content was assessed by measuring characteristic 
fluorescence signatures for AGEs in pepsin-digested ECM (ex 370nm em 440nm). Fluorescence 
levels were similar in native samples but reduced in decellularized ECM (Figure 31A). 
Fluorescent AGEs are a subset of AGEs and further work is necessary to determine if they are 
affected by decellularization processes. Quantification of AGE content by ELISA did not reveal 
any differences in AGE content in muscle ECM with age (Figure 31B). 
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Figure 31: Fluorescence level for AGEs in skeletal muscle and muscle ECM. 
Data shown as mean ± S.D. Statistical significance reported as *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
 
In order to determine the level of protein oxidation in young and aged skeletal muscle ECM, a 
DNPH protein carbonyl quantification was performed. There was no difference in protein 
carbonyl content in native skeletal muscle. Upon decellularization, it was determined that there 
was significantly higher protein carbonyl content in young skeletal muscle ECM than in aged 
(Figure 32). This suggests there is not an accumulation of protein oxidation with aging in skeletal 
muscle ECM. It could be possible that decellularization procedures affect this biological 
phenomenon but that has yet to be tested. 
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Figure 32: DNPH protein carbonyl quantification on skeletal muscle and muscle ECM. 
Data shown as mean ± S.D. Statistical significance reported as *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
 
To confirm differences in hydroxyproline content, paraffin sections were stained with PicroSirius 
Red and Masson’s trichrome. PicroSirius Red staining showed increased staining levels in young 
skeletal muscle ECM compared to old (Figure 33). This suggests there is reduced collagen 
content in aged skeletal muscle ECM. 
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Figure 33: PicroSirius Red staining of young and old native and decellularized skeletal muscle. 
Images taken at 10X magnification. Scale bars indicate 100 µm. 
 
Masson’s trichrome staining also showed elevated levels of collagen staining in young skeletal 
muscle ECM (Figure 34). In native sections, collagen staining localized to the external regions 
surrounding the abdominal muscle. 
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Figure 34: Masson’s trichrome stains of young and old native and decellularized skeletal muscle. 
Images taken at 10X magnification. Scale bars indicate 100 µm. 
 
Collagen content was confirmed further through immunohistochemical staining for collagen type 
I. Collagen I IHC also showed reduced levels of collagen in skeletal muscle ECM (Figure 35). 
No differences in collagen I immunohistochemical staining was detected in native skeletal 
muscle by visual inspection. 
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Figure 35: Collagen I immunohistochemistry staining of native and decellularized skeletal muscle. 
Images taken at 10X magnification. Scale bars indicate 100 µm. 
 
Advanced glycation end-product content was further assessed via immunohistochemistry 
staining for AGEs. The antibody used for immunohistochemistry was raised against bovine 
serum albumin (BSA) artificially glycated with glyoxal (Abcam). Immunohistochemical staining 
for AGEs revealed an increase in staining in aged skeletal muscle (Figure 36). Upon 
decellularization, skeletal muscle ECM did not show any substantial staining for AGEs. 
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Figure 36: Immunohistochemical staining for advanced glycation end-products. 
Images taken at 10X magnification. Scale bars indicate 100 µm. 
 
Paraffin sections were also stained for a specific advanced glycation end product, carboxymethyl 
lysine (CML), via immunohistochemistry. There may have been slightly more CML staining in 
young skeletal muscle. Young muscle ECM had higher levels of staining for CML than old ECM 
(Figure 37). However, further quantitative assessment via ELISA would be necessary to be 
conclusive. 
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Figure 37: Immunohistochemical staining for carboxymethyllysine of skeletal muscle ECM. 
Images taken at 10X magnification. Scale bars indicate 100 µm. 
 
Levels of protein oxidation were assessed by immunohistochemistry staining for cysteine 
sulfonate. Aged muscle fibers had higher levels of IHC staining for cysteine sulfonate than 
young muscle fibers, suggesting more protein oxidation (Figure 38). Skeletal muscle ECM did 
not exhibit noticeable changes in cysteine sulfonate IHC staining. 
 100 
 
Figure 38: Cysteine sulfonate IHC staining of native and decellularized skeletal muscle. 
Images taken at 10X magnification. Scale bars indicate 100 µm. 
 
To assess levels of protein nitration, immunohistochemical staining for S-nitro-cysteine was 
performed. There were no observable differences in S-nitro-cysteine staining in native skeletal 
muscle with aging (Figure 39). There appeared to be higher levels of S-nitro-cysteine IHC 
staining in aged skeletal muscle ECM. Quantification via ELISA would be necessary to confirm. 
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Figure 39: S-nitrocysteine IHC staining of native and decellularized skeletal muscle. 
Images taken at 10X magnification. Scale bars indicate 100 µm. 
 
Another marker of protein nitration, 3-nitro-tyrosine (3-NT), was assessed via 
immunohistochemical staining. Native skeletal muscle stained positive for 3-NT. However, there 
was no substantial difference in staining for 3-NT with aging. Decellularized skeletal muscle 
ECM did not have substantial staining for 3-NT; however, aged skeletal muscle ECM stained 
positive around blood vessels (Figure 40). 
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Figure 40: 3-nitro-tyrosine IHC staining of native and decellularized skeletal muscle. 
Images taken at 10X magnification. Scale bars indicate 100 µm. 
5.3.3 Bone marrow macrophage treatment with skeletal muscle ECM 
To assess the effects of skeletal muscle ECM aging upon macrophage polarization, murine bone 
marrow derived macrophages were treated with pepsin-digested skeletal muscle extracellular 
matrix. Pro-inflammatory (M1) macrophage phenotype was assessed via immunofluorescence 
antibody labeling for iNOS. Aged skeletal muscle ECM promoted a higher iNOS 
immunolabeling than young muscle ECM (Figure 41). Both young and aged skeletal muscle 
ECM promoted enhanced iNOS immunolabeling with IFN-γ/LPS stimulus over M1 controls 
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(IFN-γ/LPS alone). However, there were no differences between young and aged skeletal muscle 
ECM with either M1 or M2 stimulus. 
 
 
Figure 41: Immunofluorescence staining of macrophages treated with muscle ECM for iNOS. 
Data shown as mean ± S.D. Statistical significance reported as *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
 
To assess anti-inflammatory (M2) macrophage phenotype, immunofluorescent antibody labeling 
for arginase was performed. Interleukin-4 stimulation resulted in increased immunolabeling for 
arginase-1 as expected (Figure 42). Skeletal muscle ECM did not promote any changes in 
arginase-1 immunolabeling nor was there any difference with aging. Both young and aged 
skeletal muscle ECM with IFN-γ/LPS stimulus promoted more arginase-1 immunolabeling over 
M1 controls. There were no differences in arginase-1 immunolabeling between young and aged 
skeletal muscle ECM with M1 or M2 cytokine stimulus. 
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Figure 42: Immunofluorescent staining of macrophages treated with muscle ECM for arginase. 
Data shown as mean ± S.D. Statistical significance reported as *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
 
To assess the effect of skeletal muscle ECM upon macrophage gene expression, Taqman gene 
expression assays were performed for classical M1 and M2 gene transcripts (Figure 43). 
Interferon-γ and LPS stimulation (M1) promoted increased gene expression of Nos2, Arg1, H2A-
a (MHC-II), Il1b, Ccl2, Il6, Tnfa, and Il10 while downregulating Retlna (Fizz1), Pparg, and 
Tgfb. Interleukin-4 stimulation promoted upregulation of Arg1, Retlna, H2-Aa, Pparg and Ccl2 
while downregulating Tnfa and Il10. Skeletal muscle ECM promoted upregulation of Nos2, 
Arg1, H2-Aa, Il1b, Ccl2, Il6 and Tnfa while downregulating Pparg and Il10. Aged skeletal 
muscle ECM enhanced upregulation of Nos2, H2-Aa, Il1b, Ccl2, Il6 and Tnfa while promoting 
reduced downregulation of Pparg and Il10. 
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Figure 43: Taqman gene expression assays on macrophages treated with muscle ECM. 
Gene expression represented as log10 of fold expression change where 5 indicates 105 
fold expression change compared to M0. 
 
To assess macrophage function, macrophage supernatants were assessed for nitric oxide 
production via the Greiss reagent system. Interferon-γ and LPS stimulation (M1) promoted 
increased nitric oxide production as expected (Figure 44). Skeletal muscle extracellular matrix 
treatment alone did not promote significant nitric oxide production. Extracellular matrix 
treatment with IFN-γ/LPS stimulus significantly enhanced nitric oxide production over M1 
controls. Aged skeletal muscle ECM promoted reduced nitric oxide production compared to 
young with IFN-γ/LPS stimulus. 
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Figure 44: Nitric oxide production from macrophages treated with muscle ECM. 
Data shown as mean ± S.D. Statistical significance reported as *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
 
To assess macrophage phagocytic function, Vybrant FITC-labeled E. Coli particles (Thermo) 
were incubated with macrophages following treatment. M2 macrophages had reduced 
phagocytosis compared to M1 macrophages as expected (Figure 45). Skeletal muscle ECM 
treatment did not alter macrophage phagocytosis in basal conditions or with M1 or M2 cytokine 
stimulus. 
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Figure 45: Vybrant E. Coli phagocytosis of macrophages treated with muscle ECM. 
Data shown as mean ± S.D. Statistical significance reported as *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
5.4 DISCUSSION 
It is well documented that the response to muscle injury in aged individuals is compromised 
[265]. However, the mechanisms governing impairment of elderly repair following muscle injury 
are not fully understood. The regenerative properties of satellite cells (muscle stem cells) is 
known to decline with aging [266]. Some reports suggest this is due to intrinsic changes in 
satellite cell function or number [267-269]. Other studies suggest that there are extrinsic or 
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environmental factors that cause this decline in regenerative potential [39, 270, 271]. Impaired 
immune function with aging, including immunosenescence, has been correlated to aged 
sarcopenia and deficient muscle healing [272]. Macrophages, in particular, are known to be 
important for muscle regeneration and are impacted by inflamm-aging and immunosenescence 
[51, 273]. This paper investigated the effect of age-related changes in muscle ECM 
microenvironments upon the macrophage and host response following muscle injury. 
Characterization of decellularized muscle tissue showed sufficient removal of cells as 
determined by reduction of nuclei, fragmentation of DNA and reduction in levels of double-
stranded DNA. This quality control is necessary to ensure that remnant cellular material is not 
contributing to differences in the macrophage or host response [223]. The main detectable 
changes in the muscle ECM was a reduction in hydroxyproline content and Collagen I 
immunohistochemical staining. This suggests either an alteration in collagen content or 
modification of hydroxyproline residues and collagen fibers. Integrins and other receptors used 
by cells to migrate into the site of injury recognize specific matrix ligands [274]. Altered matrix 
composition or modification could impair interactions between integrins on infiltrating cells and 
the matrix from old tissues. Proteomic analysis would be necessary to fully understand how this 
muscle ECM is changing with age, however. 
Macrophage response to muscle ECM was altered when the ECM was derived from 
young or aged sources. These changes with a basal ECM treatment resulted in enhanced pro-
inflammatory responses seen by enhanced iNOS immunolabeling, nitrite production and gene 
expression of pro-inflammatory cytokines. This result suggests in a basal state, old ECM could 
contribute to the low-grade chronic inflammation observed in aged tissues [275]. With pro-
inflammatory cytokine stimulus, muscle ECM promoted enhanced iNOS immunolabeling. ECM 
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also promoted increased immunolabeling of arginase with pro-inflammatory cytokine treatment. 
Skeletal muscle ECM did not have any effects on anti-inflammatory protein levels and function 
did not change with anti-inflammatory cytokine stimulus. The enhanced nitrite production from 
skeletal muscle ECM suggests that the ECM degradation products may promote a pro-
inflammatory response. 
 
5.5 CONCLUSION 
Aged muscle ECM degradation products promote an enhanced pro-inflammatory response in 
macrophages during basal conditions. This could potentially be from NF-κB signaling but 
further testing would be needed to confirmed with further experiments. Both young and aged 
skeletal muscle ECM promoted enhanced iNOS immunolabeling with IFN-γ/LPS stimulation. 
This suggests degraded muscle ECM can increase pro-inflammatory responses during injury. 
Muscle ECM also increased nitric oxide production following IFN-γ/LPS exposure suggesting 
enhanced pro-inflammatory function as well as protein expression. Overall, muscle ECM acted 
through pro-inflammatory macrophage phenotypes with an enhancement with aged ECM. 
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6.0  EFFECT OF OXIDATION UPON MACROPHAGE RESPONSE TO AGED 
SKELETAL MUSCLE EXTRACELLULAR MATRIX 
6.1 INTRODUCTION 
Radical oxygen species (ROS) are naturally produced through normal biological functions and 
are increasingly produced during inflammation [197]. These elevated levels of ROS, while 
beneficial for pathogen clearance, can lead to oxidative damage to cells and proteins in affected 
tissues. Because extracellular matrix proteins are long-lived, modifications from oxidative stress 
can accumulate leading to altered function, structure or degradation. In vitro models of oxidative 
stress have proven that ECM molecules are modified through oxidation as measured by increases 
in protein carbonyl content [198]. This increased oxidation led to increased degradation by 
MMP-2 [198]. Protein oxidation could be a cause for increased collagen degradation with aging 
or accumulation of ECM fragments within aged tissues. ROS also have impacts on signaling 
pathways for degradative enzymes, leading to the upregulation of MKK and MAPK which lead 
to elevated MMP-1 expression [199]. 
 Oxidative reagents have been used for the decellularization and sanitation of extracellular 
matrix biomaterials, especially peracetic acid (PAA) [276-278]. Peracetic acid is a form of 
stabilized hydrogen peroxide using as a disinfectant and anti-microbial agent [279]. Hydrogen 
peroxide can act as an alarmin to recruit inflammatory cells to the site of injury [280]. Prolonged 
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or enhanced hydrogen peroxide levels, like other ROS, can be responsible for tissue damage 
[197]. Hydrogen peroxide is produced by neutrophils and macrophage during inflammation [281, 
282].  Muscle stem cell proliferation is known to be triggered by ROS such as hydrogen peroxide 
[283]. Hydrogen peroxide can also influence muscle stem cell differentiation [284]. Therefore, 
decellularization of extracellular matrix with hydrogen peroxide could mediate some of these 
effects in macrophage polarization or muscle regeneration. 
6.2 METHODS 
6.2.1 Skeletal muscle extracellular matrix preparation 
Skeletal muscle extracellular matrix was prepared using modified methods previously developed 
[261]. Briefly, abdominal muscle was harvested from 4 month and 18 month old C57BL6/J mice 
(NIA). Muscle was washed in water. Samples were enzymatically digested in 0.2% trypsin/0.2% 
EDTA for 2 hrs at 37 °C with agitation. All subsequent steps were performed on a mechanical 
shaker at 300 rpm. Samples were washed once in water and twice in 1XPBS, 30 mins each. 
Samples were decellularized using 2% sodium deoxycholate for 5 hrs, washed in water and twice 
in 1XPBS for 30 mins each and then decellularized with 2% sodium deoxycholate for 14-16 hrs 
and 1% Triton X-100 for 1 hr. Samples were washed with type 1 water until no bubbles were 
detectable, indicating detergents had been removed. Samples were either treated with 0.1% 
peracetic acid/4% ethanol (+PAA) or with type 1 water (-PAA) for 2 hours. Samples were then 
washed twice with 1XPBS then twice with water for 30 mins each. Samples used for 
implantation were terminally sterilized with ethylene oxide. ECM degradation products were 
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produced using a 1mg/mL pepsin solution in 0.01N HCl under constant stir for 48 hrs to create a 
10mg/mL ECM digest. 
6.2.2 Biochemical Assessment 
ECM scaffold biochemistry was performed to assess hydroxyproline and sulfated 
glycosaminoglycan content. ECM scaffolds were digested at 10mg/mL in a papain solution. 
Sulfate glycosaminoglycan content was assessed using a dimethylmethylene blue (DMMB) 
reagent. Hydroxyproline content was assessed by adding 50 μL 2N NaOH to 50 μL papain 
digests then hydrolyzing at 110 °C for 18 hrs. Samples were neutralized with 5N HCl. One 
hundred microliters of 0.01M copper sulfate, 2.5N NaOH and 6% H2O2 were added. Samples 
were incubated at 80 °C for 5 minutes then cooled. Four hundred microliters of 3N sulfuric acid 
was added followed by 200 μL of 5% DMAB in propanol. Samples were incubated at 70 °C for 
15 minutes then the absorbance was read at 540 nm. 
Paraffin sections were stained with PicroSirius Red as an indicator of collagen content. 
Briefly, slides were deparaffinized and rehydrated to water. Slides were stained in PicroSirius 
Red solution for 1 hour then differentiated in 35% acetic acid for 10 seconds. Slides were 
quickly dehydrated and cleared in xylenes then mounted with resinous mounting media. 
Paraffin sections were stained with Masson’s trichrome as an indicator of collagen 
content. Briefly, slides were deparaffinized and rehydrated to water. Slides were re-fixed in 
Bouin's solution for 1 hour at 56 °C to improve staining quality. Slides were rinsed in running 
tap water for 10 minutes to remove the yellow color. Slides were then stained in Weigert's iron 
hematoxylin working solution for 10 minutes then rinsed in running warm tap water for 10 
minutes then washed in distilled water. Slides were stained in Biebrich scarlet-acid fuchsin 
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solution for 10 minutes then washed in distilled water. The stain was differentiated in 
phosphomolybdic-phosphotungstic acid solution for 10 minutes. Slides were transfered directly 
to aniline blue solution and stained for 10 minutes then rinsed briefly in distilled water and 
differentiate in 1% acetic acid solution for 5 minutes then washed in distilled water. Slides were 
dehydrated very quickly and cleared in xylene then mounted with resinous mounting medium. 
6.2.3 Assessment of advanced glycation end product content 
Fluorescence AGE levels were assessed by pipetting papain digested ECM into 96 well plates. 
Fluorescence intensity levels were assessed on a spectrophotometer (BioTek) for several 
signature AGE wavelengths: excitation = 295 nm emission = 395 nm, excitation = 335 nm 
emission = 385 nm, excitation = 370 nm emission = 440 nm. 
6.2.4 Immunohistochemical staining 
Native and decellularized muscle ECM was fixed in 10% NBF then embedded in paraffin wax. 
Sections were stained using DAB immunohistochemistry for collagen type I, advanced glycation 
end-products, cysteine sulfonate, S-nitro-cysteine, or 3-nitro-tyrosine. Briefly, paraffin sections 
were deparaffinized to water then antigen was retrieved using 10mM citric acid pH 6 0.05% 
Tween20 for 20 mins at 95-100 °C. Slides were washed twice with 1X TBST for 5 mins then 
twice with 1XPBS for 3 mins. Endogenous peroxidase activity was blocked by incubating slides 
in 0.3% hydrogen peroxide for 30 mins. Slides were washed 3 times in 1X PBS for 3 minutes. 
Slides were blocked for non-specific antibody binding with a blocking buffer made of 2% 
donkey serum/1% bovine serum albumin/0.1% Tween-20 for 1 hour at room temperature. 
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Primary antibodies were incubated overnight at 4 °C diluted in blocking buffer. Slides were 
washed 3 times for 3 minutes with 1XPBS. Slides were then incubated with biotinylated 
secondary antibodies diluted in blocking buffer (goat anti-rabbit 1:200 (Vector)). Slides were 
was again 3 times for 3 minutes with 1XPBS. Slides were incubated with VectaShield ABC 
Reagent for 30 mins then washed again 3x3mins with 1XPBS. Staining was developed by 
incubating sections with 4% DAB. Sections were washed then mounted with resinous mounting 
media and coverslipped. Slides were images on a brightfield microscope at the same settings. 
6.2.5 Bone marrow-derived macrophage isolation 
Bone marrow-derived macrophages were harvested from 2 month or 18-20 month-old C57/BL6 
mice as previously described [221].  Briefly, femurs and tibiae were harvested and separated 
from muscle and connective tissue.  Bones were cut at either end to expose bone marrow.  Sterile 
syringe and needles were used to flush out bone marrow using macrophage differentiation media 
(DMEM/10% FBS/10% L-929 Supernatant/1% PenStrep/2% MEM non-essential amino 
acids/1% HEPES/0.1% 55μM β-2 mercaptoethanol).  Bone marrow lysate was reconstituted in 
media and filtered through a sterile cell filter.  Cells were cultured for 7 days in media to 
differentiate them into macrophages, changing differentiation media every 2 days.  
6.2.6 Macrophage Treatment 
Following 7 days of differentiation culture as described above, macrophages were treated with 
acute polarizing regimens to distinguish phenotypes over 24 hours.  Naïve macrophage (M0) 
controls were treated with basal media for 24 hours.  M1 (20 ng/mL IFN-γ and 100 ng/mL LPS) 
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and M2 (20 ng/mL IL-4) polarizing cytokines were used to create positive controls for classical 
pro- and anti-inflammatory macrophages.  ECM degradation products were neutralized and 
diluted to 1000 μg/mL in macrophage media to isolate biochemical effects of degradation 
products and prevent structural moieties from forming.  Pepsin buffer (1 mg/mL pepsin in 0.01 
M HCl) diluted in macrophage media was used as a control.  Another set of treatment groups 
involved 24-hour exposure of ECM degradation products followed by 24-hour treatment with 
either the M1 or M2 treatment regimen. 
6.2.7 Indirect Immunofluorescent Antibody Labeling 
Cells were fixed with 2% paraformaldehyde (PFA) for 30 minutes then washed in 1XPBS.  Cells 
were incubated in blocking buffer (2% donkey serum, 1% bovine serum albumin (BSA), 0.1% 
Triton X-100, 0.1% Tween-20) for 1 hour at room temperature.  Primary antibodies were diluted 
in this blocking buffer as follows and incubated overnight at 4 °C: iNOS (1:100, Abcam 3523) or 
Arginase-1 (1:200, Abcam 91279).  iNOS is a classical M1 macrophage marker whereas 
Arginase-1 is a classical M2 macrophage marker. Cells were washed in 1XPBS then incubated in 
the appropriate fluorescently-labeled secondary antibody solution in blocking buffer for 1 hour at 
room temperature (donkey anti-rat Alexa Fluor 488, Invitrogen, 1:200; donkey anti-rabbit Alexa 
Fluor 488, Invitrogen, 1:300).  Cell nuclei were counterstained with DAPI.  Cells from 2 month 
old mice were imaged nine times in the center of each well at 10X magnification using 
automated position capture function to remove bias from subjective image location acquisition. 
All imaging was performed on an Axio observer T1 microscope. Mean fluorescence intensity of 
cells was analyzed using Cell Profiler software (Broad Institute). Briefly, DAPI images were 
used by the program to identify cell nuclei then FITC images were used to identify cell borders 
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around the identified nuclei. The mean fluorescent intensity was calculated by averaging the 
pixel intensities (scale of 0 to 1) across the entire cell area. Mean fluorescence intensity values 
were averaged for all imaged cells in each well. 
6.2.8 Taqman gene expression assay 
Following treatments, macrophages (n=5 biological replicates from 5 young (2 month) and 5 
aged (18 month) mice) were harvested for RNA using Qiagen RNEasy MiniPrep RNA Isolation 
Columns following standard protocol.  RNA was quantified using a NanoDrop Lite 
Spectrophotometer (Thermo).  cDNA templates were created from 1 μg of RNA using Invitrogen 
High Capacity RNA-to-cDNA kits (Thermo).  Taqman Gene Expression Assays (Thermo) were 
performed for the following commonly reported M1 and M2 macrophage genes: Nos2 
(Mm00440502_m1), IL1b (Mm00434228_m1), IL12b (Mm01288989_m1), TNFa 
(Mm00443258_m1), MHC-II (Mm01181326_m1), Arg (Mm00475988_m1), Retlna (Fizz1) 
(Mm00445109_m1), Mrc1 (Mm01329362_m1), IL10 (Mm01288386_m1), and PPARg 
(Mm00440940_m1). 
6.2.9 Phagocytosis Assay 
Following treatments, 50 μL of supernatant from macrophages were transferred into a fresh 
plate.  Nitrite content was assayed using a Greiss Reagent system.  Briefly, 50 μL of 
sulfanilamide (1% in 5% phosphoric acid) was added to supernatants for 10 minutes.  Then, 50 
μL of 0.1% N-1-napthylethylenediamine in water was added to the mixture for an additional 10 
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minutes.  The absorbance at 540 nm was measured using a BioTek SYNERGY HTX 
spectrophotometer. 
6.2.10 Nitric oxide assay 
Following treatments, 50 μL of supernatant from macrophages were transferred into a fresh 
plate.  Nitrite content was assayed using a Greiss Reagent system.  Briefly, 50 μL of 
sulfanilamide (1% in 5% phosphoric acid) was added to supernatants for 10 minutes.  Then, 50 
μL of 0.1% N-1-napthylethylenediamine in water was added to the mixture for an additional 10 
minutes.  The absorbance at 540 nm was measured using a BioTek SYNERGY HTX 
spectrophotometer. 
6.3 RESULTS 
6.3.1 Biochemical characterization 
In order to understand the effect of peracetic acid upon biochemical content of muscle ECM, 
DMMB sulfated glycosaminoglycan and hydroxyproline assays were repeated. There were no 
significant differences in sulfated glycosaminoglycan content in native skeletal muscle or 
decellularized skeletal muscle ECM treated with PAA (Figure 46A). Removal of PAA from the 
decellularization procedure resulted in significantly more sGAG content in young skeletal 
muscle ECM and a significant reduction in sGAG content in old skeletal muscle ECM (Figure 
46A). Hydroxyproline content was found to be higher in aged skeletal muscle over young. Aged 
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skeletal muscle ECM had reduced hydroxyproline content with or without peracetic acid 
treatment. However, peracetic acid treatment reduced hydroxyproline content levels in young 
skeletal muscle ECM (Figure 46B). 
 
Figure 46: Glycosaminoglycan and hydroxyproline content of muscle ECM with or without PAA. 
Data shown as mean ± S.D. Statistical significance reported as *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001 
 
Confirmation of collagen content with PicroSirius Red staining revealed a reduction in staining 
with peracetic acid treatment. Without peracetic acid treatment, there appeared to be more equal 
staining though still more in young skeletal muscle ECM (Figure 47). 
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Figure 47: PicroSirius Red staining of muscle ECM with or without PAA treatment. 
Images taken at 10X magnification. Scale bars indicate 100 µm. 
(Compare to Figure 33) 
 
Masson’s trichrome staining showed similar trends where young skeletal muscle ECM had 
higher levels of collagen staining, but this effect was more extreme with peracetic acid treatment 
(Figure 48). These observations appear to differ from biochemical quantification assays so 
further investigation would be necessary to reach a conclusive determination. 
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Figure 48: Masson’s trichrome staining of muscle ECM with or without PAA treatment. 
Images taken at 10X magnification. Scale bars indicate 100 µm. 
(Compare to Figure 34) 
 
Immunohistochemical staining for collagen type I showed similar results to PicroSirius Red and 
Masson’s trichrome staining, suggesting the results of those staining methods were indicative of 
true changes in collagen content (Figure 49). 
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Figure 49: Collagen I IHC on muscle ECM with or without PAA treatment. 
Images taken at 10X magnification. Scale bars indicate 100 µm. 
(Compare to Figure 35) 
 
Extracellular matrix content was also assessed via Western blotting in order to determine 
banding and fractionation of matrix proteins. Collagen I, collagen IV and laminin were all 
detected via Western blotting (Figure 50). Collagen I and IV stained brightly on Western blots 
but laminin was dim. Banding patterns for all three proteins were similar with old muscle with 
PAA and young muscle without PAA having strong bands around 40 kDa. Old muscle with PAA 
treatment lost the four distinct bands between 90-200 kDa. 
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Figure 50: Western blotting for collagen I (A), collagen IV (B) and laminin (C) on muscle ECM. 
6.3.2 Assessment of advanced glycation end product content 
To assess advanced glycation end product content, fluorescent signatures for known AGE 
moieties were assessed in papain digested ECM. There was a reduction in fluorescent AGE 
intensity in all three signatures in aged skeletal muscle (Figure 51). Without peracetic acid 
treatment, there was a reduction in fluorescent AGE levels at all three signatures. With peracetic 
acid treatment, there was only a reduction in fluorescent AGEs with an excitation of 370 nm and 
emission of 440 nm. Peracetic acid treatment reduced the fluorescent AGE levels in young 
muscle ECM at all three signatures. Old ECM fluorescent AGE levels were enhanced with an 
excitation of 370 nm and emission of 440 nm and reduced with an excitation of 335 nm and 
emission of 385 nm with peracetic acid treatment. 
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Figure 51: Fluorescence signatures for AGEs in muscle ECM with or without PAA treatment. 
Data shown as mean ± S.D. Statistical significance reported as *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001 
 
Confirmation of AGE levels with immunohistochemistry showed reduction in AGE staining in 
aged skeletal muscle ECM with peracetic acid treatment (Figure 52). Without peracetic acid 
treatment, AGE IHC staining was localized to border regions in aged ECM while it was stained 
throughout in young ECM. 
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Figure 52: IHC for advanced glycation end products on muscle ECM with or without PAA. 
Images taken at 10X magnification. Scale bars indicate 100 µm. 
 
Immunohistochemistry staining for CML showed more intense staining with peracetic acid 
treatment. There were not large changes in CML IHC staining between young and old skeletal 
muscle ECM so further quantitative analysis would be necessary (Figure 53). 
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Figure 53: IHC for carboxymethyllysine on muscle ECM with or without PAA. 
Images taken at 10X magnification. Scale bars indicate 100 µm. 
 
Advanced glycation end-product (AGE) content was also assessed via Western blotting (Figure 
54). The staining for AGEs via Western blotting, however, was weak. 
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Figure 54: Western blotting for AGEs on young and aged muscle ECM ± PAA treatment. 
6.3.3 Assessment of oxidative markers 
Immunohistochemical staining for cysteine sulfonate, a marker of protein oxidation, showed 
staining in both native skeletal muscle and decellularized skeletal muscle ECM (Figure 55). 
There were higher levels of cysteine sulfonate staining in young skeletal muscle. There appeared 
to be more cysteine sulfonate staining in young ECM with peracetic acid but not without 
peracetic acid. 
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Figure 55: IHC for cysteine sulfonate on muscle ECM with or without PAA. 
Images taken at 10X magnification. Scale bars indicate 100 µm. 
 
Immunohistochemistry staining for S-nitro-cysteine showed increased staining in young skeletal 
muscle (Figure 56). There appeared to be reduced S-nitro-cysteine staining with peracetic acid 
treatment compared to without. There was more intense staining for S-nitro-cysteine in the 
border regions of old muscle ECM without PAA treatment. 
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Figure 56: IHC for S-nitro-cysteine on muscle ECM with or without PAA. 
Images taken at 10X magnification. Scale bars indicate 100 µm. 
 
Immunohistochemical staining for 3-nitro-tyrosine stained skeletal muscle positive (Figure 57). 
There was not substantial staining for 3-nitro-tyrosine in any decellularized ECM. Peracetic acid 
treatment did not seem to affect levels of 3-nitro-tyrosine staining. 
 
Figure 57: IHC for 3-nitro-tyrosine on muscle ECM with or without PAA. 
Images taken at 10X magnification. Scale bars indicate 100 µm. 
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6.3.4 Bone marrow macrophage phenotype and function 
To assess the effect of peracetic acid treatment of muscle ECM upon macrophage phenotype, 
murine bone marrow macrophages were treated with the ECM degradation products from young 
or old muscle ECM with or without peracetic acid treatment. iNOS immunolabeling revealed 
increased iNOS protein levels in aged skeletal muscle ECM with or without peracetic acid 
treatment (Figure 58). With peracetic acid treatment, there was no difference in iNOS 
immunolabeling with cytokine treatment (Figure 58A). Without peracetic acid treatment, aged 
skeletal muscle ECM resulted in increased iNOS immunolabeling with either M1 or M2 cytokine 
stimulation (Figure 58B). 
 
Figure 58: Immunofluorescence for iNOS on macrophages treated with mECM ± PAA treatment. 
Data shown as mean ± S.D. Statistical significance reported as *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001 
 
Immunolabeling for arginase-1 resulted in no differences between young and aged skeletal 
muscle ECM in neither basal treatments nor with M1 or M2 cytokine stimulus (Figure 59A). 
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Without peracetic acid treatment, aged skeletal muscle ECM treatment promoted enhanced 
arginase-1 immunolabeling with M1 or M2 stimulus (Figure 59B). 
 
Figure 59: Immunofluorescence for arginase on macrophages treated with mECM ± PAA treatment. 
Data shown as mean ± S.D. Statistical significance reported as *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001 
 
To understand the effects of peracetic acid treatment of skeletal muscle ECM, Taqman gene 
expression assays were performed on RNA extracts from bone marrow-derived macrophages 
treated with young or aged muscle ECM degradation products with or without PAA treatment. 
With peracetic acid treatment, aged skeletal muscle ECM enhanced upregulation of Nos2, H2-
Aa, Il1b, Ccl2, Il6 and Tnfa while promoting reduced downregulation of Pparg and Il10 (Figure 
60). Without peracetic acid, these trends reversed in most markers. Aged muscle ECM reduced 
expression of Nos2, Arg1, H2-Aa, Il1b, Ccl2, Il6 and Tnfa while further downregulating Pparg 
and Il10 compared to young muscle ECM without peracetic acid (Figure 60). 
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Figure 60: Taqman gene expression on macrophages treated with mECM ± PAA treatment. 
Gene expression represented as log10 of fold expression change where 5 indicates 105 
fold expression change compared to M0. 
 
Macrophage function for nitric oxide production was tested using the Greiss reagent system 
(Figure 61). With or without peracetic acid treatment, skeletal muscle ECM enhanced nitric 
oxide production with IFN-γ/LPS stimulus. Aged skeletal muscle ECM reduced nitric oxide 
production with IFN-γ/LPS compared to young regardless of peracetic acid treatment. However, 
peracetic acid treatment increased the nitric oxide production from skeletal muscle ECM with 
IFN-γ/LPS stimulus compared to without PAA. 
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Figure 61: Nitric oxide production on macrophages treated with mECM ± PAA treatment. 
Data shown as mean ± S.D. Statistical significance reported as *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001 
 
The effect of peracetic acid treatment of skeletal muscle ECM upon macrophage phagocytosis 
was assessed using Vybrant FITC-labeled E. Coli particles (Figure 62). With peracetic acid 
treatment, ECM treatment with basal conditions or with cytokine treatment did not change 
phagocytosis from appropriate controls (Figure 62A). Without peracetic acid treatment, ECM 
treatment enhanced phagocytosis with IL-4 stimulation compared to M2 controls (Figure 62B). 
There was no difference in phagocytosis between young and aged skeletal muscle ECM in any 
treatment regimen or with or without peracetic acid treatment. 
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Figure 62: E. coli phagocytosis on macrophages treated with mECM ± PAA treatment. 
Data shown as mean ± S.D. Statistical significance reported as *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001 
6.4 DISCUSSION 
Peracetic acid treatment of extracellular matrix scaffolds normalized the biochemistry and the 
macrophage response to aged muscle ECM. This action could be through the creation of similar 
modifications in both young and aged muscle ECM. Peracetic acid is essentially a stabilized 
form of hydrogen peroxide, which is known to be a potent redox regulator in inflammation, 
regeneration and disease through the modification of biomolecules [285]. These could include 
protein oxidation or lipid peroxidation, both of which can affect the immune response [286, 287]. 
Inflammatory signaling is affected by redox regulation, including NF-ΚB and Nrf2 transcription 
factors, which control pro-inflammatory and anti-oxidant gene transcription respectively [288, 
289].  
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Peroxidation of the extracellular matrix while potentially immunomodulatory and 
beneficial for bioengineering applications could change the native ECM of the aging muscle. 
This would mask the true effect of aged skeletal muscle ECM upon macrophage polarization. 
The extracellular matrix is known to accumulate oxidative modifications with aging [290]. 
Oxidation of ECM is also known to affect the function and phenotype of macrophages [198]. 
Treatment of both young and aged ECM with oxidizing agents could create similar levels of 
oxidation in these materials, removing the differences present before treatment. 
Analysis of young and aged muscle has previously shown changes in the redox state of 
these tissues. Analysis of muscles from elderly subjects has shown an increase in oxidative stress 
[291-293]. This included reduced levels of superoxide dismutase (SOD), an antioxidant enzyme, 
and increased levels of lipid peroxidation [292]. Mass spectroscopy analysis has shown a 
reduction in the content of redox sensitive proteins in aged muscle, indicating a shift in redox 
states of the tissue [294]. Oxidative stress has also been suggested to be a cause for age-related 
muscle mass loss [295]. Therefore, artificial oxidation through peracetic acid treatment may 
induce similar levels of this phenomena that would otherwise have increased presence in aged 
skeletal muscle ECM. 
6.5 CONCLUSION 
Peracetic acid treatment altered the biochemistry of extracellular matrix scaffolds, reducing 
differences in several metrics of matrix content. Peracetic acid treatment had a noticeable effect 
on the macrophage response to muscle ECM, including enhancement of nitric oxide production 
and reduction in iNOS and arginase immunolabeling. These findings suggest peracetic acid 
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treatment of extracellular matrix biomaterials can alter the macrophage response which could be 
beneficial for therapeutic treatment. However, these modifications can complicate the 
investigation of natural changes in the extracellular matrix with physiological events such as 
aging or disease. Further investigation in the effects of aged skeletal muscle ECM will exclude 
peracetic acid treatment to preserve natural changes in ECM biochemistry. 
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7.0  EFFECT OF GLYCATION UPON MACROPHAGE RESPONSE TO SKELETAL 
MUSCLE EXTRACELLULAR MATRIX 
7.1 INTRODUCTION 
Advanced glycation end-products (AGEs) have been implicated in the pathogenesis of tissues 
during aging and diabetes [177]. AGEs result from the non-enzymatic glycation of biomolecules 
including proteins, lipids and nucleic acids [296]. They can produce crosslinks which cause 
increased stiffness and altered degradation [297-299]. AGEs are known to be recognized by the 
receptor for advanced glycation end-products (RAGE) which signals through the NF-κB 
pathway [300]. AGEs have been shown to directly activate pro-inflammatory macrophage 
responses through this pathway [194]. AGEs have also been shown to increase in aged muscle 
tissue [262]. However, glycation of aged muscle ECM itself has not been investigated.  
In order to investigate the mechanism of advanced glycation end-products, in vitro 
glycation of young muscle ECM can be performed [220]. Previous investigation of artificial 
glycation has shown that these modifications increase the stiffness of extracellular matrix 
scaffolds and alter their viscoelastic properties [220]. The stiffness of muscles have been shown 
to increase with aging, which reduces the ability to regenerate following injury [166]. Aged 
muscle extracellular matrix as well has been shown to increase in stiffness due to altered 
anisotropy of ECM fibers [9]. This increase in stiffness could result from glycation of muscle 
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fibers and extracellular matrix. Artificial glycation of extracellular matrix provides a potential 
mechanism for the alterations in the host response following muscle injury in aged individuals. 
This comprises a more physiologically relevant investigation of the role of glycation than current 
studies involving glycated bovine serum albumin, which are limited to blood applications. 
Furthermore, artificial glycation of collagen has been shown to impair enzymatic 
degradation from collagenase [301]. If similar phenomena occur in vivo, glycation would prevent 
the degradation of extracellular matrix in aged tissues.  Extracellular matrix deposition and 
crosslinking is known to increase with aging [241]. MMP activity also increases with age, which 
could be a response to the increased matrix accumulation and crosslinking in aged tissues [241]. 
This increased MMP activity could be responsible for the accumulation of ECM degradation 
products in aged tissues [302]. Aged muscles are known to have increased collagen content, 
which may be due to reduced degradation of the ECM [53]. Collagen accumulation could also be 
due to increased TGF-β signaling promoted by glycation through NF-κB [303]. Glycation could 
be responsible for the many alterations in the extracellular matrix with aging. 
The present study seeks to investigate the direct mechanism of glycation of extracellular 
matrix upon macrophage phenotype and function. As a proposed mechanism in the altered 
responses in aging and diabetes, both aged and diabetic ECM will be used as a control of the 
natural accumulation of these glycation products. Direct evidence of the role of glycation in pro-
inflammatory macrophage phenotype is necessary to fully understand how these aging 
biomarkers affect the ability of aged or diabetic individuals to heal from injury. 
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7.2 METHODS 
7.2.1 Skeletal muscle extracellular matrix preparation 
Skeletal muscle extracellular matrix was prepared using modified methods previously developed 
[261]. Briefly, abdominal muscle was harvested from 4 month and 18 month old C57BL6/J mice 
(NIA). Muscle was washed in water. Samples were enzymatically digested in 0.2% trypsin/0.2% 
EDTA for 2 hrs at 37 °C with agitation. All subsequent steps were performed on a mechanical 
shaker at 300 rpm. Samples were washed once in water and twice in 1XPBS, 30 mins each. 
Samples were decellularized using 2% sodium deoxycholate for 5 hrs, washed in water and twice 
in 1XPBS for 30 mins each and then decellularized with 2% sodium deoxycholate for 14-16 hrs 
and 1% Triton X-100 for 1 hr. Samples were washed with type 1 water until no bubbles were 
detectable, suggesting detergents had been removed. Samples were either treated with 0.1% 
peracetic acid/4% ethanol for 2 hours. Samples were then washed twice with 1XPBS then twice 
with water for 30 mins each. Samples used for implantation were terminally sterilized with 
ethylene oxide. ECM degradation products were produced using a 1mg/mL pepsin solution in 
0.01N HCl under constant stir for 48 hrs to create a 10mg/mL ECM digest. 
7.2.2 In Vitro Glycation 
Young muscle ECM was incubated in 50mM or 250mM solutions of glucose, fructose, or ribose 
with 44mM NaHCO3 and 25mM HEPES in 1XPBS at 37°C for 1 week and then washed 
extensively in 1XPBS and water. 
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7.2.3 High performance liquid chromatography 
High performance liquid chromatography (HPLC) was used to assess advanced glycation end 
product content. Size exclusion chromatography was performed using  
7.2.4 Fourier-transform infrared spectroscopy 
Fourier-transform infrared spectroscopy was performed at the University of Pittsburgh Swanson 
School of Engineering Nanofabrication and Characterization Facility (NFCF). 
7.2.5 Protein carbonyl assay 
Protein carbonyl content was quantified using a protein carbonyl quantification kit (Cayman 
Chemical) according to manufacturer instructions. Pepsin-solubilized ECM was used for 
determination of protein carbonyl content. 
7.2.6 Bone marrow-derived macrophage isolation 
Bone marrow-derived macrophages were harvested from 2 month or 18-20 month-old C57/BL6 
mice as previously described [221].  Briefly, femurs and tibiae were harvested and separated 
from muscle and connective tissue.  Bones were cut at either end to expose bone marrow.  Sterile 
syringe and needles were used to flush out bone marrow using macrophage differentiation media 
(DMEM/10% FBS/10% L-929 Supernatant/1% PenStrep/2% MEM non-essential amino 
acids/1% HEPES/0.1% 55μM β-2 mercaptoethanol).  Bone marrow lysate was reconstituted in 
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media and filtered through a sterile cell filter.  Cells were cultured for 7 days in media to 
differentiate them into macrophages, changing differentiation media every 2 days.  
7.2.7 Macrophage Treatment 
Following 7 days of differentiation culture as described above, macrophages were treated with 
acute polarizing regimens to distinguish phenotypes over 24 hours.  Naïve macrophage (M0) 
controls were treated with basal media for 24 hours.  M1 (20 ng/mL IFN-γ and 100 ng/mL LPS) 
and M2 (20 ng/mL IL-4) polarizing cytokines were used to create positive controls for classical 
pro- and anti-inflammatory macrophages.  ECM degradation products were neutralized and 
diluted to 1000 μg/mL in macrophage media to isolate biochemical effects of degradation 
products and prevent structural moieties from forming.  Pepsin buffer (1 mg/mL pepsin in 0.01 
M HCl) diluted in macrophage media was used as a control.  Another set of treatment groups 
involved 24-hour exposure of ECM degradation products followed by 24-hour treatment with 
either the M1 or M2 treatment regimen. 
7.2.8 Indirect Immunofluorescent Antibody Labeling 
Cells were fixed with 2% paraformaldehyde (PFA) for 30 minutes then washed in 1XPBS.  Cells 
were incubated in blocking buffer (2% donkey serum, 1% bovine serum albumin (BSA), 0.1% 
Triton X-100, 0.1% Tween-20) for 1 hour at room temperature.  Primary antibodies were diluted 
in this blocking buffer as follows and incubated overnight at 4 °C: iNOS (1:100, Abcam 3523) or 
Arginase-1 (1:200, Abcam 91279).  iNOS is a classical M1 macrophage marker whereas 
Arginase-1 is a classical M2 macrophage marker. Cells were washed in 1XPBS then incubated in 
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the appropriate fluorescently-labeled secondary antibody solution in blocking buffer for 1 hour at 
room temperature (donkey anti-rat Alexa Fluor 488, Invitrogen, 1:200; donkey anti-rabbit Alexa 
Fluor 488, Invitrogen, 1:300).  Cell nuclei were counterstained with DAPI.  Cells from 2 month 
old mice were imaged nine times in the center of each well at 10X magnification using 
automated position capture function to remove bias from subjective image location acquisition. 
All imaging was performed on an Axio observer T1 microscope. Mean fluorescence intensity of 
cells was analyzed using Cell Profiler software (Broad Institute). Briefly, DAPI images were 
used by the program to identify cell nuclei then FITC images were used to identify cell borders 
around the identified nuclei. The mean fluorescent intensity was calculated by averaging the 
pixel intensities (scale of 0 to 1) across the entire cell area. Mean fluorescence intensity values 
were averaged for all imaged cells in each well. 
7.2.9 Taqman gene expression assay 
Following treatments, macrophages (n=5 biological replicates from 5 young (2 month) and 5 
aged (18 month) mice) were harvested for RNA using Qiagen RNEasy MiniPrep RNA Isolation 
Columns following standard protocol.  RNA was quantified using a NanoDrop Lite 
Spectrophotometer (Thermo).  cDNA templates were created from 1 μg of RNA using Invitrogen 
High Capacity RNA-to-cDNA kits (Thermo).  Taqman Gene Expression Assays (Thermo) were 
performed for the following commonly reported M1 and M2 macrophage genes: Nos2 
(Mm00440502_m1), IL1b (Mm00434228_m1), IL12b (Mm01288989_m1), TNFa 
(Mm00443258_m1), MHC-II (Mm01181326_m1), Arg (Mm00475988_m1), Retlna (Fizz1) 
(Mm00445109_m1), Mrc1 (Mm01329362_m1), IL10 (Mm01288386_m1), and PPARg 
(Mm00440940_m1). 
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7.2.10 Phagocytosis Assay 
Following treatments, 50 μL of supernatant from macrophages were transferred into a fresh 
plate.  Nitrite content was assayed using a Greiss Reagent system.  Briefly, 50 μL of 
sulfanilamide (1% in 5% phosphoric acid) was added to supernatants for 10 minutes.  Then, 50 
μL of 0.1% N-1-napthylethylenediamine in water was added to the mixture for an additional 10 
minutes.  The absorbance at 540 nm was measured using a BioTek SYNERGY HTX 
spectrophotometer. 
7.2.11 Nitric oxide assay 
Following treatments, 50 μL of supernatant from macrophages were transferred into a fresh 
plate.  Nitrite content was assayed using a Greiss Reagent system.  Briefly, 50 μL of 
sulfanilamide (1% in 5% phosphoric acid) was added to supernatants for 10 minutes.  Then, 50 
μL of 0.1% N-1-napthylethylenediamine in water was added to the mixture for an additional 10 
minutes.  The absorbance at 540 nm was measured using a BioTek SYNERGY HTX 
spectrophotometer. 
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7.3 RESULTS 
7.3.1 Characterization of glycated ECM 
Glycated ECM were pepsin digested for treatment of macrophages. Visual inspection showed 
that high concentration (250 mM) of glycation prevented pepsin digestion of glycated ECM 
(Figure 63). Old muscle ECM degradation products appeared more opaque than young muscle 
ECM while diabetic ECM appeared more translucent. All glycated ECM increased in 
opaqueness compared to young muscle ECM. 
 
Figure 63: Pepsin digests of young, old, diabetic and glycated muscle ECM. 
 
The presence of fluorescent AGEs were detected using size exclusion chromatography (SEC) on 
UV-Visible light (UV-Vis) high performance liquid chromatography (HPLC). Three emission 
spectra were observed for fluorescent AGEs: 335nm, 385nm and 440nm. A standard signal for 
protein, 280nm, was used as a marker for elution of ECM degradation products. HPLC analysis 
of ECM degradation products found positive fluorescence signals at the 280nm and 335nm 
wavelengths (Figure 64). 
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Figure 64: Size exclusion HPLC analysis of muscle ECM for fluorescent AGE signatures. 
 
All extracellular matrix degradation products analyzed had peaks around 5 minutes and another 
set between 10-15 minutes. Young muscle ECM had several peaks at both elution times in the 
280nm emission spectra while having several peaks at 5 minutes and 1 peak at 11 minutes in the 
335nm emission spectra (Figure 65). Old muscle ECM had similar peaks in the 10-15 minute 
range of both emission spectra but lost the peaks at 5 minutes seen in young (Figure 66). 
Diabetic muscle ECM lost the peak at 5 minutes in the 280nm emission spectra but this peak was 
retained at 335nm (Figure 67). Ribosylated, glucosylated and fructosylated ECM all had similar 
peaks to diabetic muscle ECM (Figure 68-Figure 70). 
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Figure 65: Size exclusion HPLC of young muscle ECM degradation products. 
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Figure 66: Size exclusion HPLC of old muscle ECM degradation products. 
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Figure 67: Size exclusion HPLC for diabetic muscle ECM degradation products. 
 
Figure 68: Size exclusion HPLC for ribosylated young muscle ECM degradation products. 
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Figure 69: Size exclusion HPLC of glucosylated young muscle ECM degradation products. 
 
Figure 70: Size exclusion HPLC of fructosylated young muscle ECM degradation products. 
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In order to evaluate presence of functional groups in extracellular matrix, fourier-transform 
infrared spectroscopy (FTIR) was performed on whole decellularized ECM scaffolds (Figure 
71). Young, old and glycated muscle ECM all had similar FTIR spectra expected from a protein-
rich material. Old muscle ECM had two large peaks around 2800-3000 cm-1, which is 
characteristic for –C-H stretch and –C-H aldehydic. Peaks in this range in biological materials is 
typical for presence of lipids [304]. Glycated muscle ECM had a slight reduction in the level of 
peaks in the 2800-3000 cm-1 range compared to young. All samples had two peaks around 1550-
1650 cm-1 indicative of amide bonds from protein. Old muscle ECM had another peak to the left 
of these peaks, which could be a peak associated with the ester bonds in triglycerides which is 
typically found around 1740 cm-1. Old muscle ECM also has a higher peak just right of the two 
amide bond peaks, which could be the peak associated with the –CH2 bending in lipids normally 
found around 1452-56 cm-1. The other two peaks elevated in old muscle ECM between 1200-
1000 cm-1 could be the CO-O-C anti-symmetric stretching found between 1171-1160 cm-1 
associated with phospholipids, triglycerides, and cholesterol esters. The other possibility is the 
PO2- symmetric stretching associated with nucleic acids and phospholipids found at 1083-1078 
cm-1 which is also associated with the C-O stretch from glycogen, polysaccharides and 
glycolipids [304]. All of these data suggest there could be an increased triglyceride or other lipid 
content in old muscle ECM. Glycation of young ECM did not appear to alter the FTIR spectra in 
a significant way. 
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Figure 71: Fourier-transform infrared spectroscopy of decellularized muscle ECM. 
 
In order to assess the levels of protein oxidation in young, old, diabetic or glycated muscle ECM, 
a protein carbonyl assay was performed on ECM pepsin digests. When normalized to protein 
content as assessed by BCA assay, old muscle ECM had a reduction in protein carbonyl content 
while diabetic muscle ECM had an increased content (Figure 72). Artificial glycation of muscle 
ECM with glucose or fructose led to increase in protein carbonyl content to levels similar to 
diabetic muscle ECM. Ribosylated muscle ECM led to higher level of protein oxidation than 
other forms of glycation. 
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Figure 72: Protein carbonyl content of muscle ECM glycated with different reducing sugars. 
Mean values shown. 
 
Assessment of protein carbonyl content in native and decellularized muscle showed that 
glycation significantly increased protein oxidation compared to all other samples. Old and 
diabetic muscle and muscle ECM had lower quantitative levels of protein oxidation compared to 
young muscle or muscle ECM, respectively (Figure 73). 
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Figure 73: Protein carbonyl content of native and decellularized young, old and glycated ECM. 
Data shown as mean ± S.D. Statistical significance reported as *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001 
7.3.2 Macrophage phenotype and function 
Murine bone marrow-derived macrophages were treated with ECM degradation products to 
determine the effect of ECM glycation upon macrophage phenotype and function. To assess pro-
inflammatory (M1) macrophage polarization, macrophages were immunofluorescently labeled 
for iNOS following fixation. Interferon-γ/LPS treatment resulted in significantly higher iNOS 
immunoexpression, as expected (Figure 74A). Old muscle ECM had significantly higher iNOS 
immunolabeling than diabetic muscle ECM (Figure 74A). Ribosylated ECM elicited 
significantly higher iNOS immunoexpression than both young and old ECM while glucosylated 
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ECM reduced iNOS immunolabeling (Figure 74A). With pro-inflammatory cytokine stimulus, 
young muscle ECM significantly reduced iNOS immunolabeling compared to M1 controls, 
diabetic ECM and ribosylated and fructosylated ECM (Figure 74B). High concentrations of 
glycation significantly increased iNOS immunoexpression over all other groups with pro-
inflammatory or anti-inflammatory stimulus (Figure 74B-C). With IL-4 stimulus, young muscle 
ECM significantly increased iNOS immunoexpression over M2 controls and all other ECM 
groups (Figure 74C).  
 
Figure 74: Immunolabeling for iNOS on macrophages treated with glycated muscle ECM. 
Data shown as mean ± S.D. Statistical significance reported as *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001 
 
Anti-inflammatory (M2) macrophages phenotype was assessed via immunolabeling for arginase-
1. Interleukin-4 stimulation induced significantly increased arginase-1 immunoexpression as 
expected (Figure 75A). There were no differences in arginase-1 immunolabeling in any of the 
non-glycated ECM groups. However, high concentrations of ribose and fructose glycation 
resulted in significantly higher arginase-1 immunoexpression (Figure 75A). With pro-
inflammatory stimulus, young, old and diabetic ECM all significantly increased arginase-1 
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immunolabeling over M2 controls (Figure 75B). Diabetic muscle ECM with M1 cytokines 
induced lower arginase-1 immunoexpression than old muscle ECM (Figure 75B). Glucosylated 
ECM and fructosylated ECM at high concentrations significantly increased arginase-1 
immunoexpression over young ECM with M1 stimulus (Figure 75B). With IL-4 stimulus, there 
was no difference between any ECM groups or with M2 controls (Figure 75C). 
 
Figure 75: Immunolabeling for arginase on macrophages treated with glycated ECM. 
Data shown as mean ± S.D. Statistical significance reported as *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001 
 
To assess the effect of ECM glycation upon macrophage function, macrophages were incubated 
with FITC-labeled E. Coli particles to assess phagocytic uptake. Interferon-γ/LPS treatment 
resulted in significantly higher phagocytosis than macrophages treated with IL-4 as expected 
(Figure 76A). Diabetic ECM as well as high concentration glucosylated ECM significantly 
reduced phagocytosis compared to young and old muscle ECM (Figure 76A). Fructosylated 
ECM and high concentration ribosylated ECM both reduced phagocytosis compared to old ECM 
(Figure 76A). With pro-inflammatory cytokine treatment, old and diabetic ECM induced higher 
phagocytosis than M1 controls and young muscle ECM (Figure 76B). Low concentration 
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ribosylation and fructosylation also increased phagocytosis over young ECM with pro-
inflammatory cytokine stimulus. All high concentration glycated ECM reduced phagocytosis 
compared to old muscle ECM with pro-inflammatory cytokine stimulus. With anti-inflammatory 
cytokine stimulus, old and diabetic muscle ECM increased phagocytosis over M2 controls and 
young muscle ECM (Figure 76C). Low concentration glycated ECM all increased phagocytosis 
compared to young ECM with IL-4 stimulus. All types of glycated ECM except low 
concentrations of glucose significantly decreased phagocytosis with M2 stimulus compared to 
old muscle ECM (Figure 76C). 
 
 
Figure 76: E. coli phagocytosis in macrophages treated with glycated ECM. 
Data shown as mean ± S.D. Statistical significance reported as *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001 
 
To further assess the effect of ECM glycation upon macrophage function, nitric oxide production 
was assessed in the supernatants of macrophages following treatment using the Greiss reagent 
system. Pro-inflammatory cytokine stimulus resulted in significantly increased nitric oxide 
production as expected (Figure 77A). Old muscle ECM produced significantly higher nitric 
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oxide than young or diabetic ECM (Figure 77A). Low concentration glycated ECM all increased 
nitric oxide production compared to young ECM while low concentration ribosylation and 
glucosylation increased nitric oxide compared to old ECM (Figure 77A). With pro-inflammatory 
stimulus, neither young, old nor diabetic ECM changed nitric oxide production from M1 controls 
(Figure 77B). Low concentration ribosylation and glucosylation of ECM resulted in higher nitric 
oxide production compared to young muscle ECM with pro-inflammatory stimulus (Figure 77B). 
With anti-inflammatory cytokine stimulus, young muscle ECM increased nitric oxide production 
over M2 controls as well as old and diabetic muscle ECM (Figure 77C). Low concentration 
glycation increased nitric oxide production over young, old and diabetic ECM with anti-
inflammatory cytokine stimulus (Figure 77C). 
 
Figure 77: Nitric oxide production in supernatants of macrophages treated with glycated ECM. 
Data shown as mean ± S.D. Statistical significance reported as *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001 
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7.4 DISCUSSION 
Advanced glycation end-products (AGEs) are associated with many disease states including 
aging and diabetes [305, 306]. Through RAGE signaling, AGEs can cause pro-inflammatory 
responses, cellular dysfunction and tissue damage [307].  While the formation of AGEs has been 
studied extensively in cellular and blood proteins such as albumin, the effect of glycation on 
structural proteins of the extracellular matrix has not been investigated [308]. This study showed 
the direct effects of glycation upon the macrophage response to extracellular matrix. Of the two 
concentrations of reducing sugars tested, the higher concentration of 250mM inhibited the 
degradation of ECM via pepsin. This confirms previous hypotheses that AGEs can inhibit ECM 
turnover [309]. However, due to the fact that aged muscle ECM will solubilize with pepsin 
degradation, these high levels of reducing sugars probably glycated the ECM far beyond 
physiologic levels of normal aging in mice. It is worth noting that the production and 
accumulation of AGEs is a slow process which takes years [310] . 
There were also differences in glycation and macrophage response to the different type of 
reducing sugar used for these experiments. Fructose has previously been shown to glycated more 
rapidly than glucose, while ribose is much stronger than both [311]. Glucose and fructose are 
naturally occurring sugars that are a part of glycolysis as well as being commonly found in the 
diet [312]. Glucose is mainly found in skeletal muscle as glycogen but is rapidly absorbed from 
the bloodstream following exercise [313]. Ribose is a naturally sugar used for the synthesis of 
riboflavin (vitamin B2), RNA, and ATP [314-316]. As muscle uses ATP as an energy source for 
contractility, ribose is freely available for glycation in muscle as well [317]. Therefore, artificial 
glycation by any of these sugars is relevant to normal muscle aging. 
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The effects of ECM glycation upon macrophage polarization was most noticeable in the 
upregulation of iNOS protein levels and nitric oxide production. This response is expected due to 
AGE signaling through the RAGE receptor to trigger an NF-κB transcription profile [318]. iNOS 
is one of many proteins whose transcription is upregulated by NF-κB [319]. High concentrations 
of glycation resulted in high levels of iNOS in both pro- and anti-inflammatory conditions, 
suggesting the dysfunctional macrophage response AGEs can create. Lower levels of glycation 
interestingly elevated nitric oxide production in all cases while higher levels did not. Higher 
levels may create such a dysfunctional environment that prevents normal macrophage function 
while lower levels create a truly pro-inflammatory macrophage environment. 
7.5 CONCLUSION 
This study showed that skeletal muscle extracellular matrix was successfully glycated with 
multiple sugar types. These glycated ECM had a direct effect on macrophage polarization, 
creating a pro-inflammatory or dysfunctional phenotype. This suggests that glycated ECM can 
be used to observe the direct effects of glycated microenvironments upon the regeneration of 
muscle following injury. 
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8.0  EFFECT OF AGED AND GLYCATED MUSCLE ECM UPON HOST RESPONSE 
FOLLOWING MUSCLE INJURY 
8.1 INTRODUCTION 
Extracellular matrix acts as the supporting structure of a tissue and dynamically changes in a 
reciprocal relationship with cells of that tissue. ECM changes with aging and disease and can 
affect the responses of cells in these altered states. Therefore, ECM can be used as a model for 
aged microenvironments to more fully understand their effect on cellular function. Skeletal 
muscle strength and healing potential are known to decrease with aging [232]. The immune 
response, which is integral to muscle regeneration, is also dysfunctional with age [259]. 
Macrophage polarization in particular has been shown to be necessary for appropriate skeletal 
muscle healing [51]. There has been no direct investigation to determine whether age-related 
changes in skeletal muscle extracellular matrix influence macrophage polarization and contribute 
to altered host responses observed in aged individuals during skeletal muscle injury. 
Decellularization techniques have been used for decades now to develop biomaterials for 
a variety of surgical and tissue engineering strategies [260]. These same methodologies can be 
used to harvest the extracellular matrix from skeletal muscle of animals differing in age or 
disease state in order to understand how these factors contribute to altered physiology [261]. 
Previous investigations into changes in aging’s effect on skeletal muscle ECM has relied on 
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histologic analysis of intact muscle tissue only [262]. Therefore, in order to isolate the role of 
extracellular matrix in altered host responses during injury, bioengineering techniques must be 
utilized to separate the ECM from the rest of the skeletal muscle tissue. 
Advanced glycation end-products (AGEs) have been implicated in the pathogenesis of 
tissues during aging and diabetes [177]. AGEs result from the non-enzymatic glycation of 
biomolecules including proteins, lipids and nucleic acids [296]. They can produce crosslinks 
which cause increased stiffness and altered degradation [297-299]. AGEs are known to be 
recognized by the receptor for advanced glycation end-products (RAGE) which signals through 
the NF-κB pathway [300]. AGEs have been shown to directly activate pro-inflammatory 
macrophage responses through this pathway [194]. AGEs have also been shown to increase in 
aged muscle tissue [262]. However, glycation of aged muscle ECM itself has not been 
investigated. In order to investigate the mechanism of advanced glycation end-products, in vitro 
glycation of young muscle ECM can be performed [220]. This comprises a more physiologically 
relevant investigation of the role of glycation than current studies involving glycated bovine 
serum albumin. 
The present study seeks to combine several bioengineering strategies to study the isolated 
effects of aging and glycation of the extracellular matrix upon the macrophage response during 
skeletal muscle injury in vivo. While many studies focus on cellular dysfunction during aging, 
this study seeks to understand the isolated role of alterations in the extracellular 
microenvironment. 
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8.2 METHODS 
8.2.1 Scaffold Preparation 
Skeletal muscle extracellular matrix was prepared using modified methods previously developed 
[261]. Briefly, abdominal muscle was harvested from 4 month and 18 month old C57BL6/J mice 
(NIA). Muscle was washed in water. Samples were enzymatically digested in 0.2% trypsin/0.2% 
EDTA for 2 hrs at 37 °C with agitation. All subsequent steps were performed on a mechanical 
shaker at 300 rpm. Samples were washed once in water and twice in 1XPBS, 30 mins each. 
Samples were decellularized using 2% sodium deoxycholate for 5 hrs, washed in water and twice 
in 1XPBS for 30 mins each and then decellularized with 2% sodium deoxycholate for 14-16 hrs 
and 1% Triton X-100 for 1 hr. Samples were then washed twice with 1XPBS then twice with 
water for 30 mins each. Samples used for implantation were terminally sterilized with ethylene 
oxide. 
8.2.2 Abdominal Wall Partial Thickness Defect Implantation 
Four month old C57BL6/J mice (Jackson) were anesthetized using isofluorane and analgesized 
using Buprenex prior to surgical manipulation. Abdominal skin was incised and abdominal 
muscle exposed. Partial thickness defects (1 cm2 were created in the abdominal muscle by 
removing 2 of the 3 muscle layers. Rehydrated 1 cm2 muscle ECM scaffolds (n=5 per treatment) 
were sutured over the defect using polypropylene sutures. Skin incisions were sutured close 
using PGCL suture. Animals were maintained on Buprenex and Baytril for 3 days post-
operation. ECM was explanted following 3, 7, 14 and 90 days post-implantation. Sections were 
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fixed in 10% NBF for histologic analysis or RNALater Stabilization Solution (Thermo) for gene 
expression analysis. 
 
8.2.3 Histologic Analysis 
Paraffin sections were stained for hematoxylin & eosin as an evaluation of cellularity and 
remodeling. Briefly, slides were deparaffinized and rehydrated to water. Slides were stained in 
Harris hematoxylin for 8 minutes then washed twice for 30 seconds in type 1 water. Hematoxylin 
was differentiated in 5% glacial acetic acid for 1 minute then washed twice for 30 seconds in 
type 1 water. Hematoxylin was blued using Scott’s water for 15 seconds then washed twice for 1 
minute each. Slides were stained with alcoholic eosin for 2 minutes then washed twice in 95% 
ethanol and twice in 100% ethanol for 30 seconds each. Slides were washed twice in xylenes for 
1 minute then mounted with a resinous mounting media. 
Paraffin sections were stained with Alcian blue as an indicator of glycosaminoglycan 
content. Briefly, slides were deparaffinized and rehydrated to water. Slides were stained in 1% 
(w/v) alcian blue/3% acetic acid (v/v) pH 2.5 solution for 30 minutes then washed in running tap 
water for 2 minutes. Slides were counterstained in nuclear fast red solution for 5 minutes then 
washed in running tap water for 1 minute. Slides were dehydrated in 1 change of 95% ethanol 
and 2 changes of 100% ethanol for 3 minutes each. Slides were then cleared in xylenes and 
mounted with a resinous mounting media. 
Paraffin sections were stained with Masson’s trichrome as an indicator of collagen 
content. Briefly, slides were deparaffinized and rehydrated to water. Slides were re-fixed in 
Bouin's solution for 1 hour at 56 °C to improve staining quality. Slides were rinsed in running 
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tap water for 10 minutes to remove the yellow color. Slides were then stained in Weigert's iron 
hematoxylin working solution for 10 minutes then rinsed in running warm tap water for 10 
minutes then washed in distilled water. Slides were stained in Biebrich scarlet-acid fuchsin 
solution for 10 minutes then washed in distilled water. The stain was differentiated in 
phosphomolybdic-phosphotungstic acid solution for 10 minutes. Slides were transfered directly 
to aniline blue solution and stained for 10 minutes then rinsed briefly in distilled water and 
differentiate in 1% acetic acid solution for 5 minutes then washed in distilled water. Slides were 
dehydrated very quickly and cleared in xylene then mounted with resinous mounting medium. 
Paraffin sections were stained with PicroSirius Red as an indicator of collagen content. 
Briefly, slides were deparaffinized and rehydrated to water. Slides were stained in PicroSirius 
Red solution for 1 hour then differentiated in 35% acetic acid for 10 seconds. Slides were 
quickly dehydrated and cleared in xylenes then mounted with resinous mounting media. 
Five images were taken per slide at 20X for quantitation using brightfield microscopy or 
circularly polarized light microscopy for PicroSirius Red. Muscle was quantified for percent 
regenerating muscle fibers by manually counting number of muscle fibers with centralized nuclei 
divided by total number of muscle fibers. Acute timepoints (3, 7, 14d) were stained using 
immunofluorescent antibody labeling. Briefly, slides were deparaffinized then antigen retrieved 
using 10mM citric acid at 95-100°C for 20 mins. Autofluorescence was quenched using a 10mM 
copper sulfate/50mM ammonium acetate (pH5) solution for 20 mins at 37 °C. Sections were 
blocked using 2% donkey serum/1% BSA/0.1% Tween-20 for 1 hour then incubated overnight at 
4 °C  with primary antibodies for F4/80 (1:100 BioRad MCA497), iNOS (1:100 Abcam 3523), 
Arginase-1 (1:200 Abcam 92179) or MyoD1 (1:100 Abcam 203383). Sections were washed in 
PBS then incubated for 1 hour with the appropriate Alexa Fluor 488 donkey antibody at 1:200 
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(Abcam). Sections were washed, counterstained with DAPI then mounted with FluoroGel 
mounting solution. Ninety day explants were stained immunohistochemically for fast & slow 
myosin heavy chain using alkaline phosphatase and DAB solutions, respectively [261]. 
 
8.2.4 Gene Expression Analysis 
Explants were placed in RNALater Stabilization Solution (Thermo) at 4 °C for 2 days then 
solution was aspirated and samples were stored at -80 °C. Samples were thawed and RNA was 
extracted from remodeled ECM using the Fibrous Tissue RNA Extraction Kit according to 
manufacturer protocol (Qiagen). cDNA templates were created from extracted RNA using the 
High Capacity RNA-to-cDNA Kit (Applied Biosystems). Taqman gene expression assays were 
performed for primers described above in the in vitro methods section. 
 
8.2.5 Statistical Analysis 
Quantitative results were analyzed using a two-way ANOVA (treatment, age) with Tukey post-
hoc analysis using GraphPad PRISM 7 software. Significance was determined at a p-value less 
than 0.05. 
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8.3 RESULTS 
8.3.1 Histological evaluation 
The host response to the implanted muscle ECM was observed with hematoxylin & eosin 
staining (Figure 78). The extracellular matrix scaffold is easily detectable in histologic sections 
as the grouping of protein fibers above the muscle injury. At 3 days post implantation, the 
scaffolds appear completely intact and loosely associated with surrounding tissues. There is 
already some cellular infiltration at 3 days but mostly on the border of the implanted ECM. At 7 
days, the bioscaffolds appear to be integrated more with the surrounding tissues as cellular 
infiltration increases. However, remodeling of ECM scaffolds appears minimal at 7 days. By 14 
days, remodeling of ECM is underway as the scaffold appears to be degraded in areas and fully 
infiltrated with host cells. Ninety days post-implantation, the extracellular matrix has been fully 
remodeled into a section of fibrous tissue with cellularity being restored to normal levels. 
Quantification of cellularity shows low levels of cellular infiltration at 3 days. Cellularity peaks 
at 7 days with young muscle ECM promoting significantly more than old or glycated ECM 
(Figure 78A). There was a reduction in cellularity at 14 days; however, young muscle ECM still 
had higher cellularity than old or glycated. By 90 days, cellularity was similar across ECM types 
and had returned to levels below that seen at 3 days. This suggests that old and glycated ECM 
impair the ability of host cells to infiltrate the site of a muscle injury. 
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Figure 78: Hematoxylin & eosin staining of muscle ECM implanted into abdominal muscle injury. 
Images taken at 20X. Scale bars indicate 100 µm. 
 
Glycosaminoglycan production following implantation was assessed via Alcian blue staining 
(Figure 79). There were no differences in GAG content at 3 days. Glycosaminoglycan content 
increased from 3 to 7 days as well as 7 to 14 days then reduced to basal levels by 90 days (Figure 
83C). There was significantly higher glycosaminoglycan production in young muscle ECM 
implants at 7 days over old and glycated ECM (Figure 83C). Young muscle ECM also elicited 
higher glycosaminoglycan production at 14 days over old muscle ECM (Figure 83C). By 90 
days, young muscle ECM had lower glycosaminoglycan content than glycated muscle ECM. 
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Changes in glycosaminoglycan production mirrored changes in cellularity which suggests the 
two are related. However, further investigation would be necessary to understand if one 
phenomena causes the other. 
 
 
Figure 79: Alcian blue staining for muscle ECM implanted over abdominal muscle injury. 
Images taken at 20X. Scale bars indicate 100 µm. 
 
To assess collagen production, explants were stained with Masson’s trichrome (Figure 80). There 
were no differences in any groups in 3 and 7 days post-implantation (Figure 83B). However, all 
groups followed the trend of increasing from 3 to 7 days, decreasing from 7 to 14 days and then 
increasing sharply by 90 days. Glycated muscle ECM groups resulted in significantly higher 
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Masson’s trichrome staining at 14 and 90 days over young and old muscle ECM (Figure 83B). 
This suggests that glycated muscle ECM elicits increased fibrosis. 
 
 
Figure 80: Masson’s trichrome staining of muscle ECM implanted in abdominal muscle injury. 
Images taken at 20X. Scale bars indicate 100 µm. 
 
In order to analyze collagen fiber alignment, PicroSirius red staining was performed on paraffin 
sections (Figure 81). Staining appeared to decrease from 3 to 7 days as the collagen was slowly 
remodeled by host cells. Staining was much brighter at 90 days, similar to Masson’s trichrome 
staining, indicative of increased collagen content and fiber alignment. 
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Figure 81: PicroSirius Red staining of muscle ECM implanted into abdominal muscle injury. 
Images taken at 20X. Scale bars indicate 100 µm. 
 
Muscle regeneration was quantified by counting the number of muscle fibers with centralized 
nuclei versus the number with peripheral nuclei (Figure 82). Quantification of regenerating 
muscle fibers via nuclei centralization showed that there was no substantial muscle fiber 
regeneration occurring 3 days post-injury (Figure 83D). By 7 days, significant muscle 
regeneration was underway as young and aged ECM samples had 50-60% muscle fiber nuclei 
centralization. However, glycated ECM elicited significantly less muscle regeneration at 7 days 
compared to young and old ECM, showing that glycation has an inhibitory effect on both 
inflammation and stem cell activation. Aged muscle ECM did not seem to inhibit muscle 
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regeneration even if there were signs of chronic inflammation. This is counter to reports of 
reduced numbers of regenerating myofibers in aged mice [43]. 
 
Figure 82: Hematoxylin & eosin staining of muscles injured and repaired with muscle ECM. 
Images taken at 20X. Scale bars indicate 100 µm. 
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Figure 83: Quantification of histological stains for muscle ECM reconstruction. 
Data shown as mean ± S.D. Statistical significance reported as *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001 
 
8.3.2 Immunofluorescent staining for macrophage markers 
To understand changes in macrophage infiltration and phenotype during the acute host response 
following injury, immunofluorescent antibody staining was utilized. Presence of macrophages 
was assessed via staining for F4/80, a classical murine macrophage marker (Figure 84). At 7 
days, there was a significantly higher level of F4/80+ macrophages in young muscle ECM over 
glycated muscle ECM (Figure 88A). This suggests that ECM glycation inhibits the infiltration of 
macrophages into the site of muscle injury. By 14 days, F4/80+ macrophage numbers decreased 
in young muscle ECM but remained high in aged muscle ECM groups (Figure 88A). This result 
suggests that aged ECM promotes chronic inflammation through pro-longed macrophage 
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presence. Ninety days post-implantation all groups exhibited reduction in macrophage presence 
to normal levels. 
 
 
Figure 84: Immunofluorescent F4/80 labeling of muscle ECM reconstruction of muscle injury. 
Images taken at 20X. Scale bars indicate 100 µm. 
 
Pro-inflammatory macrophage presence was determined via staining for induced nitric oxide 
synthase (iNOS), a classical M1 macrophage marker (Figure 85). There were no differences in 
the number of iNOS+ cells at 3 days. At 7 days post-implantation, the number of iNOS+ cells 
increased in the young muscle ECM group over aged and glycated muscle ECM, which 
remained at levels similar to 3 days (Figure 88B). By 14 days, young and aged muscle ECM 
reached similar levels of iNOS+ cells while glycated muscle ECM continued to remain at low 
levels. This suggests that aged muscle ECM delays macrophage polarization while glycated 
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muscle ECM completely inhibits it in acute inflammation. By 90 days, all groups exhibited a 
return to levels of iNOS+ cells seen at 3 days. 
 
Figure 85: Immunofluorescence staining for iNOS in muscle ECM reconstruction of muscle injury. 
Images taken at 20X. Scale bars indicate 100 µm. 
 
Anti-inflammatory macrophage presence was determined via Arginase-1 immunofluorescent 
staining (Figure 86). Arginase-1 is a classical murine anti-inflammatory macrophage marker. At 
3 days, there was significantly more Arginase-1+ cells in young muscle ECM over aged and 
glycated ECM (Figure 88C). The number of Arginase-1+ cells continued to increase in the young 
muscle ECM group over the aged and glycated groups, which stayed constant from 3 days. By 
14 days, arginase-1+ cells in young muscle ECM reduced to levels seen in aged and glycated 
muscle ECM groups which continued to stay constant. While young muscle ECM seemed to 
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elicit a normal temporal anti-inflammatory response expected during injury, aged and glycated 
muscle ECM promoted a deficiency in anti-inflammatory macrophage activation. 
 
Figure 86: Immunofluorescent arginase staining on muscle ECM reconstruction of muscle injury. 
Images taken at 20X. Scale bars indicate 100 µm. 
 
8.3.3 Immunofluorescent staining for satellite cell activation 
MyoD staining was performed at acute timepoints to understand how these ECM 
microenvironments and the resulting inflammatory response affected satellite cell differentiation 
(Figure 87). There was no substantial MyoD positive cells at 3 days (Figure 88D). By 7 days, 
aged ECM elicited significantly more MyoD staining while glycated had a reduced staining 
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level. This suggests that aged ECM enhances stem cell differentiation while glycation inhibits it. 
All groups reduced in levels of MyoD+ cells by 14 days. 
 
Figure 87: Immunofluroescent MyoD staining for muscle ECM reconstruction of muscle injury. 
Images taken at 20X. Scale bars indicate 100 µm. 
 
 
 176 
 
Figure 88: Quantification of immunofluorescence staining of ECM reconstruction of muscle injury. 
Data shown as mean ± S.D. Statistical significance reported as *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001 
 
8.3.4 Gene expression analysis 
To understand changes in gene expression during the inflammatory phase following muscle 
reconstruction, RNA was extracted from remodeling ECM at 7 and 14 days then analyzed via 
Taqman gene expression assays (Figure 89). Fold expression change normalized to young 
muscle ECM showed that largely inflammatory gene expression was reduced in aged and 
glycated ECM at 7 days. Aged ECM elicited higher IL-6 and Ccl2 gene expression at 7 days 
suggesting some promotion of increased inflammation (Figure 89A). At 14 days, aged ECM 
elicited a large increase in Fizz1 gene expression and slight increases in Tnfa, Hgf and Igf1. 
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Glycated ECM promoted increases in Ccl2 and Hgf suggesting early promotion of chronic 
inflammation (Figure 89B). Largely, the reduced gene expression seen at 7 days was gone by 14 
days with aged and glycated ECM having similar or higher levels of transcripts at this timepoint. 
 
Figure 89: Taqman gene expression of remodeling ECM in muscle injury at 7 (A) and 14 days (B). 
Gene expression represented as fold expression change where 2 indicates 2 fold 
expression change compared to young ECM. 
 
8.3.5 Evaluation of chronic remodeling 
To understand how muscle ECM affected the repair of abdominal muscle downstream of injury, 
immunohistochemical staining for fast and slow myosin heavy chain was performed (Figure 90). 
Acute muscle injury results in increased slow muscle fiber type and resolution of muscle injury 
results in a return to normal ratios of fast to slow muscle fibers. By 90 days, young and aged 
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muscle ECM groups had similar ratios of fast to slow muscle fibers while glycated muscle ECM 
had a reduced ratio. This suggests that glycated muscle ECM has an unresolved muscle injury 
response at 90 days or has permanently increased the presence of slow muscle fibers. 
 
Figure 90: Fast/slow myosin IHC on 90d explants from ECM reconstruction of muscle injury. 
Images taken at 20X. Scale bars indicate 100 µm. Data shown as mean ± S.D. Statistical 
significance reported as *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 
 
To understand remodeling of the extracellular matrix at 90 days, picrosirius red staining 
was performed (Figure 91). Using imaging under polarized light and a previously described 
algorithm, the presence of red, orange, yellow and green fibers was determined. At 90 days, 
glycated muscle ECM groups had higher levels of red fibers than young and aged groups, which 
is indicative of more thick fibers associated with fibrosis. This result is similar to the increased 
Masson’s trichrome staining found in glycated groups at 90 days. There were no differences in 
the intermediate thickness orange and yellow fibers in any groups. Aged and glycated muscle 
ECM elicited higher levels of green fibers, which are the thinnest detected by picrosirius 
staining. These fibers have low collagen fiber alignment which could indicate more unorganized 
matrix produced in an aged or glycated muscle ECM microenvironment. 
 179 
 
Figure 91: PicroSirius Red staining and analysis of 90d explants from muscle ECM implant. 
Images taken at 20X. Scale bars indicate 100 µm. Data shown as mean ± S.D. Statistical 
significance reported as *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 
 
Macrophage polarization in chronic 90 day explants was evaluated using immunofluorescent 
antibody labeling (Figure 92). Aged ECM had higher levels of F4/80 positive macrophages, 
suggesting chronic inflammation is promoted with aging ECM (Figure 92A). Aged and glycated 
ECM had higher levels of iNOS positive cells which suggests they are promoted pro-
inflammatory signals chronically following injury while young ECM has more resolved 
inflammation (Figure 92B). Aged muscle ECM also promoted higher levels of arginase positive 
cells over glycated muscle ECM (Figure 92C). This suggests that glycated ECM promotes a 
more pro-inflammatory chronic environment while aged muscle ECM elicits a broader range of 
macrophage activation. 
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Figure 92: Analysis of immunofluorescent staining on 90d explants from muscle ECM implants. 
Data shown as mean ± S.D. Statistical significance reported as *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001 
8.4 DISCUSSION 
Explants from acute time-points following muscle injury showed impaired cellular infiltration 
and matrix production within aged and glycated muscle ECM microenvironments. There are 
many reports of impaired neutrophil migration with aging [47, 320, 321], as well as impaired 
macrophage infiltration [47, 322]. Investigation into the cause of impaired immune cell 
infiltration has focused on changes in cellular populations and levels of inflammatory cytokines 
and chemokines. Results from this paper suggest that the aged extracellular matrix 
microenvironment contributes to this altered immune cell infiltration. In addition, aged and 
glycated ECM promoted reductions in glycosaminoglycan content during the acute response 
following injury. GAGs are important orchestrators of the host response as they assist with 
collagen reorganization, growth factor activity, and angiogenesis [323]. Reduced GAG 
production during muscle injury may cause poorer healing downstream. 
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Macrophage infiltration and activation was also impaired in aged and glycated muscle 
environments. Macrophage polarization is known to be important to healthy muscle regeneration 
[51]. Reduction in macrophage response have been shown to impair muscle healing [324]. Aged 
wound healing has been associated with impairments in chemokine signaling and leukocyte 
infiltration [234]. While young microenvironments promoted temporal activation of pro- and 
anti-inflammatory macrophage phenotypes, aged and glycated groups experienced delayed or 
diminished immune activation. This impairment could directly impact the regenerative cascade 
necessary for proper muscle healing. Previous work from our lab has shown the host response to 
biomaterials in aged animals is delayed, which is similar to the results seen here with a delayed 
peak in F4/80+ cells [230]. 
Aging and glycation of muscle ECM also affected metrics of muscle regeneration. Aging 
of ECM seemed to enhance MyoD positive cells while glycation reduced them. Glycation 
reduced both metrics of muscle regeneration. Several studies have shown that aging and 
senescence reduces expression of satellite cell differentiation markers such as MyoD [41, 42]. 
However, there are other reports that aged muscle has increased number of MyoD+ cells 
following injury, as well as increased apoptosis of these activated stem cells [45]. Our data 
suggest this could be due to the effects of glycation but not aging of the ECM. Reports have also 
shown reduced percentages of centralized nuclei in aged muscles following injury [39, 43]. Both 
aged and glycated ECM reduced the percent centralized nuclei in muscle fibers, suggesting they 
could be promoting this reduction in muscle regeneration. 
Chronic remodeling outcomes were impaired by glycated extracellular matrix but not 
aged. This included increased fibrosis as seen by Masson’s trichrome and PicroSirius Red 
staining, as well as increased presence of slow-twitch muscle fibers. Aged muscle experiences 
 182 
fibrosis so glycation of the extracellular matrix with aging could be a cause for this phenotype 
[53]. Intravenous administration of AGEs has previously been shown to increase cardiac fibrosis 
[325]. Previous reports have shown that methylglyoxal modified ECM enhanced myofibroblast 
differentiation, which could lead to fibrosis [326]. Further investigation into the effect of aged or 
glycated ECM upon fibroblast activation would need to be performed. 
Increased presence of slow type muscle fibers has been shown to be an indication of 
injury [327]. Therefore, glycated extracellular matrix may promote an ongoing or unresolved 
inflammatory process at 90 days following injury. Previous reports have shown that diabetic 
patients have increased proportion of slow-twitch muscle fibers, which corroborates the effects 
seen in this study [328]. 
There were several limitations to the study. A comprehensive analysis of the 
compositional changes in the aged muscle extracellular matrix was not conducted. Mass 
spectrometry analysis for composition of extracellular matrix components as well as for the 
presence of glycation crosslinks is necessary to fully understand how muscle ECM changes with 
age. The in vitro glycated ECM was also fabricated using one sugar type and in saline 
conditions, which may not replicate what is happening in vivo. Further the artificial glycation 
was conducted on decellularized ECM which is not exposed during the in vivo setting. 
Therefore, the glycated matrix may not completely mimic the alterations experienced by muscle 
ECM in aged individuals. 
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8.5 CONCLUSION 
Overall, this work provides evidence for a cell-extrinsic mechanism for alterations in the immune 
response and resultant regeneration following muscle injury in aged individuals. This study adds 
further evidence that the extracellular microenvironment, specifically the matrix, directly 
contributes to the aging phenotype in muscle regeneration. This adds another facet to the 
understanding of the causes of muscle dysfunction in aged populations. As sarcopenia and poor 
muscle healing is a symptom experienced by the majority of aged people, this is an important 
issue to fully understand. Furthermore, the cellular changes with aging in both immune and stem 
cell populations may be acquired incrementally over time through dynamic reciprocity. 
Therefore, many facets of muscle tissue could all accumulate aging changes over time while 
each imbuing more aging phenotypes upon each other. 
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9.0  DISCUSSION 
The results presented in this dissertation work have broad applications to both biomaterials and 
aging biology fields. In the biomaterials field, the sourcing of extracellular matrix from 
mammalian tissues is dependent upon the characteristics of the species, organ, aging, health and 
nutrition of the source animal, among other characteristics [176, 329-331]. However, current 
standards for biomaterial sourcing only consider documentation, general health, nutrition and 
transmission of infectious agents [332]. Tissues harvested from abattoirs are commonly of 
“market-weight” which normalizes age [333]. Results from this study as well as others suggests 
that inclusion of animals beyond market-weight age could remove beneficial properties of 
extracellular matrix biomaterials while animals younger than market weight could improve 
regeneration [110, 176]. More rigorous standards concerning the age of animals used for the 
harvest of tissues for biomaterial production could reduce the well-known variability associated 
with biologically-derived materials. 
This dissertation has also provided preliminary evidence for several factors which may 
directly impact the immune cell response to extracellular matrix scaffolds derived from different 
aged animals. The composition of extracellular matrix proteins and modifications of them, as 
well as content of lipids and growth factors are known to change with age [122, 208, 243, 334-
338]. Extraction of these lipid, growth factor or structural components of the extracellular allows 
for investigation of the compositional changes in these different fractions. Our results indicate 
 185 
that these different components have different effects on the host response and these effects 
change with the age of the animal from which the materials are harvested. The relative solubility 
of the growth factors and lipids versus the slower degrading structural matrix molecules could be 
relevant to the different immune cell phenotypes observed inside and at extracellular matrix 
surfaces versus those observed in the periphery of the remodeling zone [109]. 
The skeletal muscle extracellular matrix was found to change with aging; however, many 
of these results were counter to previous investigations of whole tissue. Our results showed there 
were reductions in collagen content, oxidation and glycation in decellularized aged muscle, 
which is opposite of whole tissue analyses [198, 309, 339]. Decellularization of aged tissues may 
remove components of the extracellular matrix which contribute to these aging changes seen in 
whole tissue. Aged tissue has been shown to have increased degraded ECM and oxidized or 
glycated ECM may also lead to more matrix degradation [198, 335, 337]. Further evidence is 
necessary to understand why decellularized and whole tissue analyses of aged skeletal muscle 
ECM differ. 
The investigation of skeletal muscle extracellular matrix aging upon macrophage 
phenotype relates to many studies showing changes in muscle macrophage populations with 
aging.  Aged skeletal matrix promoted increased iNOS and arginase immunoexpression as well 
as reduced nitric oxide production with polarizing cytokines. These results correlate to other 
findings showing increased in both M1 and M2 macrophage population in aged muscle [53, 
340]. Our investigations in vitro involved degraded extracellular matrix, which applies mostly to 
advanced inflammation or chronic responses following inflammation. Further investigation of 
intact matrix in vitro would relate more to physiology during aging without injury. 
 186 
The investigation of the effects of oxidation and glycation upon skeletal muscle 
extracellular matrix reveals distinct effects on their roles in aging and disease. Oxidation of 
extracellular matrix resulted in increased nitric oxide production and reduce iNOS 
immunoexpression. Considering extracellular matrix is known to acquire oxidative changes with 
aging, these studies may suggest a direct effect of ECM oxidation upon macrophage polarization 
[290]. Glycation of extracellular matrix resulted in increased pro-inflammatory macrophage 
responses. This correlates with previous reports that glycation leads to pro-inflammatory 
responses. Further experimentation is needed to confirm the signaling pathways involved in 
these responses. These studies show that the age-related changes in oxidation and glycation of 
the extracellular matrix can directly affect the macrophage response. Previous studies of 
glycation have mainly focused on glycated bovine serum albumin which is less relevant than 
using extracellular matrix materials [341]. 
 Implantation of aged or glycated ECM into a muscle injury showed distinct changes in 
muscle regeneration compared to young ECM. The delays or inhibition in macrophage 
accumulation with aged or glycated ECM correlate to observations in aged or diabetic animals 
[44, 342]. Reduction in iNOS levels in vivo is similar to other studies showing reduced nitric 
oxide activity in aged and diabetic muscle regeneration [343, 344]. The inhibition of arginase 
activation in acute timepoints with aged or glycated ECM could be a cause for the chronic 
inflammation observed in aged or diabetic muscle injury due to delayed immune resolution 
[345]. The direct effects of ECM aging and glycation upon the host response to muscle injury in 
vivo suggests ECM may play a larger role in regenerative decline than previously hypothesized. 
 Implantation of aged or glycated extracellular matrix also affected the processes 
associated with healthy muscle regeneration. Extracellular matrix glycation resulted in reduced 
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muscle fiber nuclei centralization at 7 days. This correlates to reports of impaired stem cell 
accretion with aging or diabetes [232, 346]. The enhancement of MyoD levels at 7 days with 
aged muscle ECM correlates to reports of satellite cell entrapment in an activated phenotype 
without progression to differentiation [347]. The downregulation of most inflammatory targets 
investigated shows aged and glycated ECM replicates the dysfunctional inflammatory gene 
expression observed in aged rodents and humans [340]. Overall, age-related changes in the 
muscle extracellular matrix may be, in part, responsible for aberrant satellite cell activation in 
vivo. 
 The chronic response to implantation of aged or glycated ECM also mirrors the 
remodeling alterations observed with aging and diabetes. The increases in collagen staining at 
chronic time points with glycated muscle ECM shows similarities to the increases in collagen 
accumulation in aged and diabetic individuals [348]. The reduced ratio of fast:slow muscle fibers 
at chronic time points following glycated ECM implantation correlates to shifts in the muscle 
fiber type with sarcopenia and diabetes [349]. Aging and glycation both led to increased 
presence of macrophages and macrophage activation at chronic timepoints. This could explain 
the increased presence of macrophage subtypes in uninjured aged muscles [47, 53]. Aging and 
glycation of ECM affects not only acute inflammation but chronic remodeling and inflammation 
as well. 
 The results presented in this dissertation show that the age-related or glycation 
modifications of muscle extracellular matrix have direct effects upon the inflammatory and 
muscle regeneration processes following injury. Aging of the extracellular matrix alone resulted 
in a partial aging phenotype when implanted into a healthy host. This suggests that extracellular 
matrix aging contributes to the deficiencies observed in aged individuals; however, age-related 
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cellular changes still have a large role in this response. Further work is necessary to understand 
how age-related changes in the extracellular matrix affect the ability to regenerate within an aged 
or diabetic organism. Regardless, these studies lend further evidence towards hypotheses 
centered around a cell-extrinsic mechanism of regenerative declines with aging. 
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10.0  CONCLUSION 
The work presented herein provides concrete evidence that the aging of the extracellular matrix 
has a profound effect upon its properties and upon the resultant host response elicited upon 
implantation. These results have implications for both biomaterial sourcing and aging biology. 
Biomaterial scientists and companies should use source animal age as a quality control criterion 
in order to achieve better, more consistent outcomes from their products. In aging biology, the 
role of extracellular matrix must be considered as an equal contributor to the aging phenotype in 
addition to the aging of stem cells and immune cells. Overall, this work shows that aging of the 
extracellular matrix alone has profound implications for regenerative outcomes. 
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APPENDIX A: FREE RADICAL-DELLULARIZATION OF TISSUES PROMOTES 
ENHANCED ANTI-INFLAMMATORY AND ANTI-OXIDANT HOST RESPONSE 
A.1 INTRODUCTION 
Extracellular matrix biomaterials have been used clinically and pre-clinically in a wide variety of 
applications, including hernia repair, breast reconstruction, skin grafts and wound healing [138-
141]. Typically, extracellular matrix materials are prepared through the decellularization of 
mammalian tissues using detergents, enzymes and/or oxidants [350]. When decellularized and 
prepared properly, extracellular matrix (ECM) biomaterials have been shown to promote 
constructive remodeling, defined as the formation of new site-appropriate host tissue [124]. This 
positive outcome has been correlated with a shift during the acute immune response from a pro- 
(M1) to anti-inflammatory (M2) phenotype (macrophage polarization) [59, 221].  
Oxidative reagents used in decellularization have an interesting correlation with 
macrophage phenotype as reactive oxygen species (ROS) and reactive nitrogen species (RNS) 
are produced by macrophages during inflammation [351]. A common oxidant used in 
extracellular matrix decellularization is peracetic acid, a stabilized form of hydrogen peroxide 
[223, 352-354]. Hydrogen peroxide itself is an important inflammatory mediator and damage 
signal which can modify proteins via cysteine oxidation and lipids via lipid peroxidation [355-
357]. The oxidative modification of extracellular matrix biomaterials by peracetic acid used 
during decellularization may be responsible, in part, for the beneficial host responses observed 
following implantation [251, 358]. In addition, peracetic acid serves as a sterilization step 
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through protein denaturation, cell wall permeabilization, and sulfur oxidation in proteins and 
enzymes which can inactivate bacteria, viruses and spores [359-361]. 
Decellularization of extracellular matrix biomaterials with more potent RNS and ROS 
mediators may further enhance the promotion of an anti-inflammatory phenotype. ROS have 
been shown to promote the polarization of macrophages to an anti-inflammatory phenotype 
[362]. Nitric oxide signaling, which is important in angiogenesis and oxidative burst, also signals 
macrophages to polarize to an anti-inflammatory state via VASP signaling [363-365]. Reactive 
nitrogen species themselves and modification of fatty acids has been shown to reduce pro-
inflammatory macrophage phenotype [366]. Reactive oxygen species have also been shown to 
induce an anti-oxidant oxidative stress pathway via the Nrf2 transcription factor which could be 
beneficial for the treatment of ischemic injuries [367]. Therefore, ROS or RNS decellularization 
methods pose a novel, potential alternative which can enhance or modify the beneficial effects of 
extracellular matrix biomaterials. 
This study investigates the macrophage response to extracellular matrix biomaterials 
decellularized with nitric oxide, hydroxyl radical or both in comparison to a standard method 
using peracetic acid. Bone marrow-derived macrophages were used as an in vitro model of 
macrophage response to assess the direct effect of these scaffolds upon macrophage polarization 
[110]. Degradation products of extracellular matrix were used for in vitro experiments as 
degradation has been shown to be important for constructive remodeling [59]. ECM degradation 
products have also been shown to promote anti-inflammatory macrophage phenotypes in vitro 
[368]. Muscle injury was used as an in vivo model for the assessment of the host response to 
sheets of these materials decellularized using free radical reagents [59, 369, 370]. We 
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hypothesized that decellularization of ECM would promote enhanced anti-inflammatory and 
anti-oxidant macrophage polarization which would enhance healing following muscle injury. 
 
A.2 METHODS 
A.2.1 Scaffold Preparation 
Porcine small intestine was purchased from local slaughterhouse (Thoma Meat Market, 
Saxonburg, PA). Porcine small intestine submucosa was harvested through mechanical 
delamination of the external muscularis and internal mucosa layers. Native submucosa was cut 
into 1 foot lengths and then washed in DI H2O until water was no longer discolored by the tissue. 
Samples were decellularized using standard peracetic acid wash or nitric oxide, hydroxyl radical 
or both at washes for 2 hours [176]. As nitric oxide and hydroxyl radicals will quickly react into 
other reactive nitrogen and oxygen species, decellularization methods will be described as RNS, 
ROS or RNS+ROS as the full range of species present was not characterized. Samples were then 
washed twice with 1XPBS then twice with water for 30 mins each. Decellularized scaffolds were 
frozen at -80 °C and then lyophilized. Samples used for implantation were terminally sterilized 
with ethylene oxide. ECM degradation products were produced using a 1mg/mL pepsin solution 
in 0.01N HCl under constant stir for 48 hrs to create a 10mg/mL ECM digest. 
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A.2.2 Scaffold Characterization 
Hydrated native tissue and decellularized scaffolds were fixed in 10% neutral buffered formalin 
(NBF) and then embedded in paraffin.  Sections of these scaffolds were stained separately with 
hematoxylin & eosin or DAPI to confirm removal of nuclei.  Proteinase K digests of native 
whole small intestine, native submucosa and decellularized scaffolds underwent phenol: 
chloroform: isoamyl alcohol (25:24:1) extraction for DNA and were resuspended in 1X TE 
buffer. Native submucosa was used as a control in addition to whole small intestine as the 
submucosa is the layer used for biomaterial preparation. DNA extracts were separated using 
electrophoresis on a 2% agarose gel in 0.5X TBE buffer to confirm reduction of DNA content 
and fragmentation of remnant DNA in decellularized scaffolds compared to native controls. 
DNA extracts were also quantified for double-stranded DNA content using a PicoGreen assay 
(Thermo) according to manufacturer’s instructions. 
 
A.2.3 Biochemical Analysis 
ECM scaffold biochemistry was performed to assess hydroxyproline and sulfated 
glycosaminoglycan content. Native small intestine, native small intestine submucosa, and 
decellularized ECM scaffolds were digested at 10mg/mL in a papain solution. Sulfate 
glycosaminoglycan content was assessed using a dimethylmethylene blue (DMMB) reagent. 
Hydroxyproline content was assessed by adding 50 μL 2N NaOH to 50 μL papain digests then 
hydrolyzing at 110 °C for 18 hrs. Samples were neutralized with 5N HCl. One hundred 
microliters of 0.01M copper sulfate, 2.5N NaOH and 6% H2O2 were added. Samples were 
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incubated at 80 °C for 5 minutes then cooled. Four hundred microliters of 3N sulfuric acid was 
added followed by 200 μL of 5% DMAB in propanol. Samples were incubated at 70 °C for 15 
minutes then the absorbance was read at 540 nm. Protein carbonyl content, a marker of 
oxidation, was determined using a kit from Cayman Chemical as per manufacturer instructions. 
 
A.2.4 Immunohistochemical Analysis 
Native and decellularized SIS was fixed in 10% NBF then embedded in paraffin wax. Sections 
were stained using DAB immunohistochemistry for markers of nitrosylation or oxidation, 
including S-nitro-cysteine, 3-nitro-tyrosine and cysteine sulfonate. Briefly, paraffin sections were 
deparaffinized to water then antigen was retrieved using 10mM citric acid pH6 0.05% Tween20 
for 20 mins at 95-100 °C. Slides were washed twice with 1X TBST for 5 mins then twice with 
1XPBS for 3 mins. Endogenous peroxidase activity was blocked by incubating slides in 0.3% 
hydrogen peroxide for 30 mins. Slides were washed 3 times in 1X PBS for 3 minutes. Slides 
were blocked for non-specific antibody binding with a blocking buffer made of 2% donkey 
serum/1% bovine serum albumin/0.1% Tween-20 for 1 hour at room temperature. Primary 
antibodies (1:500 S-nitrocysteine (abcam 94930), 1:200 nitrotyrosine (abcam 7048), or 1:100 
cysteine sulfonate (Enzo ADI-OSA-820-D) were incubated overnight at 4 °C diluted in blocking 
buffer. Slides were washed 3 times for 3 minutes with 1XPBS. Slides were then incubated with 
biotinylated secondary antibodies diluted in blocking buffer (goat anti-mouse or goat anti-rabbit 
1:200 (Vector)). Slides were was again 3 times for 3 minutes with 1XPBS. Slides were incubated 
with VectaShield ABC Reagent for 30 mins then washed again 3x3mins with 1XPBS. Staining 
was developed by incubating sections with 4% DAB (Vector). Sections were washed then 
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mounted with resinous mounting media and coverslipped. Slides were images on a brightfield 
microscope at the same settings. 
A.2.5 Macrophage Isolation 
Bone marrow-derived macrophages were harvested from 2 month or 18-20 month-old C57/BL6 
mice as previously described [221].  Briefly, femurs and tibiae were harvested and separated 
from muscle and connective tissue.  Bones were cut at either end to expose bone marrow.  Sterile 
syringe and needles were used to flush out bone marrow using macrophage differentiation media 
(DMEM/10% FBS/10% L-929 Supernatant/1% PenStrep/2% MEM non-essential amino 
acids/1% HEPES/0.1% 55μM β-2 mercaptoethanol).  Bone marrow lysate was reconstituted in 
media and filtered through a sterile cell filter.  Cells were cultured for 7 days in media to 
differentiate them into macrophages, changing differentiation media every 2 days.  
 
A.2.6 Macrophage Treatment 
Following 7 days of differentiation culture as described above, macrophages were treated with 
acute polarizing regimens to distinguish phenotypes over 24 hours.  Naïve macrophage (M0) 
controls were treated with basal media for 24 hours.  M1 (20 ng/mL IFN-γ and 100 ng/mL LPS) 
and M2 (20 ng/mL IL-4) (Peprotech) polarizing cytokines were used to create positive controls 
for classical pro- and anti-inflammatory macrophages.  ECM degradation products were 
neutralized and diluted to 1000 μg/mL in macrophage media to isolate biochemical effects of 
degradation products and prevent structural moieties from forming.  Pepsin buffer (1 mg/mL 
pepsin in 0.01 M HCl) diluted in macrophage media was used as a control.  Another set of 
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treatment groups involved 24-hour exposure of ECM degradation products followed by 24-hour 
treatment with either the M1 or M2 treatment regimen. These experiments were performed to 
assess the effect of ECM exposure upon the ability of macrophages to polarize to classical M1 
and M2 phenotypes. 
A.2.7 Indirect Immunofluorescent Antibody Staining 
Cells were fixed with 2% paraformaldehyde (PFA) for 30 minutes then washed in 1XPBS.  Cells 
were incubated in blocking buffer (2% donkey serum (Lampire), 1% bovine serum albumin 
(BSA) (Sigma), 0.1% Tween-20 (Fisher)) for 1 hour at room temperature.  Primary antibodies 
were diluted in this blocking buffer as follows and incubated overnight at 4 °C: iNOS (1:100, 
Abcam 3523), Arginase-1 (1:200, Abcam 91279), or heme oxygenase-1 (1:200, Abcam 
ab13243).  iNOS is a classical M1 macrophage marker whereas Arginase-1 is a classical M2 
macrophage marker [371]. Heme oxygenase-1 is an anti-oxidant marker upregulated by 
macrophages during oxidative stress [372]. Cells were washed in 1XPBS then incubated in the 
appropriate fluorescently-labeled secondary antibody solution in blocking buffer for 1 hour at 
room temperature (donkey anti-rat Alexa Fluor 488, Invitrogen, 1:200; donkey anti-rabbit Alexa 
Fluor 488, Invitrogen, 1:300).  Cell nuclei were counterstained with 500 nM DAPI (Ebioscience) 
for 10 minutes.  Cells from 2 month old mice were imaged nine times in the center of each well 
at 10X magnification using automated position capture function to remove bias from subjective 
image location acquisition. All imaging was performed on an Axio observer T1 microscope. 
Mean fluorescence intensity of cells was analyzed using Cell Profiler software (Broad Institute). 
Briefly, DAPI images were used by the program to identify cell nuclei then FITC images were 
used to identify cell borders around the identified nuclei. The mean fluorescent intensity was 
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calculated by averaging the pixel intensities (scale of 0 to 1) across the entire cell area. Mean 
fluorescence intensity values were averaged for all imaged cells in each well. 
A.2.8 Phagocytosis Assay 
Following treatments, cells were assayed for phagocytic ability using Vybrant Phagocytosis 
Assay Kit (Invitrogen).  Cells were incubated in FITC-labeled dead E. Coli particles for 2 hours 
in the cell culture incubator.  Following washing, the cells were fixed with 2% PFA for 30 
minutes then washed with 1X PBS.  Cells were counterstained with DAPI then imaged and 
analyzed as described above. 
 
A.2.9 Nitrite Assay 
Following treatments, 50 μL of supernatant from macrophages were transferred into a fresh 
plate.  Nitrite content was assayed using a Greiss Reagent system.  Briefly, 50 μL of 
sulfanilamide (1% in 5% phosphoric acid) was added to supernatants for 10 minutes.  Then, 50 
μL of 0.1% N-1-napthylethylenediamine in water was added to the mixture for an additional 10 
minutes.  The absorbance at 540 nm was measured using a BioTek SYNERGY HTX 
spectrophotometer. 
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A.2.10 Arginase Activity Assay 
Following treatments, media was removed and macrophages were lysed in 50μL 0.001% Triton 
X-100 in type 1 H2O with 1X Halt Protease Inhibitors (Thermo). Twenty five microliters of 
lysate was added to 25 μL of arginase activation solution (10mM MnCl2/50mM Tris-HCl, 
pH7.5) and incubated at 55°C for 10 minutes. Samples were allowed to cool and then 50 μL of 
arginine substrate solution (0.5M L-arginine pH 9.7) was added to each well.  Samples were 
incubated at 37°C for 2 hours. A urea standard curve was created via 2 fold serial dilution from 
100 mg/mL to 1.5625 mg/mL with a 0 mg/mL blank in lysis buffer. Five microliters of samples 
or standards were added to a new 96-well plate and 200 μL of urea detection solution (513 mg/L 
primaquine, 100 mg/L phthalaldehyde, 2.5 mol/L sulfuric acid, 2.5 g/L boric acid, 0.03% Brij35) 
was added to each well. Absorbance of samples was analyzed using a plate spectrophotometer at 
430 nm between 5-20 minutes following addition of detection solution. 
A.2.11 Abdominal Wall Partial Thickness Defect Implantation 
Four month old C57BL6/J mice (Jackson) were anesthetized using isofluorane and analgesized 
using Buprenex prior to surgical manipulation. Abdominal skin was incised and abdominal 
muscle exposed. Partial thickness defects (1 cm2 were created in the abdominal muscle by 
removing the external 2 of the 3 muscle layers. Rehydrated 1 cm2 muscle ECM scaffolds (n=5 
per treatment) were sutured over the defect using 4-0 polypropylene sutures. Skin incisions were 
sutured close using 3-0 PGCL suture. This is a modification of an existing animal model for 
biomaterial host response evaluation [369]. Animals were maintained on Buprenex and Baytril 
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for 3 days post-operation. ECM was explanted following 7 and 90 days post-implantation. 
Sections were fixed in 10% NBF for histologic analysis. 
 
A.2.12 Histologic Analysis 
Paraffin sections at 5μm were stained for hematoxylin & eosin, Masson’s trichrome, Alcian blue, 
Herovici’s polychrome, and PicroSirius Red. Five images were taken per slide at 20X for 
quantitation using brightfield microscopy or circularly polarized light microscopy for PicroSirius 
Red. Acute time-points (7 days) were stained using immunofluorescent antibody labeling. 
Briefly, slides were deparaffinized then antigen retrieved using 10mM citric acid at 95-100°C for 
20 mins. Autofluorescence was quenched using a 10mM copper sulfate/50mM ammonium 
acetate (pH5) solution for 20 mins at 37 °C. Sections were blocked using 2% donkey serum/1% 
BSA/0.1% Tween-20 for 1 hour then incubated overnight at 4 °C  with primary antibodies for 
F4/80 (1:100 BioRad MCA497), iNOS (1:100 Abcam 3523), Arginase-1 (1:200 Abcam 92179), 
or Heme oxygenase-1 (1:100, Abcam 13243). Sections were washed in PBS then incubated for 1 
hour with the appropriate Alexa Fluor 488 donkey antibody at 1:200 (Abcam). Sections were 
washed, counterstained with DAPI then mounted with FluoroGel mounting solution. 
Immunofluorescent stained slides were imaged 5 times per slide at 20X on a Nikon Eclipse TI-U 
and analyzed on Nikon Elements software. Mean fluorescence intensity of cells were analyzed 
using Cell Profiler software as described above. Ninety day explants were stained 
immunohistochemically for fast & slow myosin heavy chain using alkaline phosphatase and 
DAB solutions, respectively [261]. 
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A.2.13 Statistical Analysis 
Quantitative results were analyzed using a two-way ANOVA (treatment, age) with Tukey post-
hoc analysis using GraphPad PRISM 7 software. Significance was determined at a p-value less 
than 0.05. 
 
A.3 RESULTS 
A.3.1 Assessment of decellularization 
Histologic assessment of decellularization showed that all methods resulted in significant 
removal of nuclei (Figure 93A-E). Morphologically, ECM decellularized with PAA seemed to be 
more similar to native morphology whereas FR-decellularized ECM seemed to organize into 
thicker, irregular fiber bundles. Masson’s trichrome staining appeared similar across 
decellularized ECM, suggesting similar levels of collagen content (Figure 93F-J). Alcian blue 
staining was also consistent, suggesting similar glycosaminoglycan content across 
decellularization methods (Figure 93K-O). Cysteine sulfonate staining, a marker of oxidation, 
only appeared to be weaker in the ROS decellularization method (Figure 93P-T). S-nitrocysteine 
immunohistochemistry showed higher staining with RNS and RNS+ROS decellularization 
methods, as expected (Figure 93U-Y). 3-nitrotyrosine immunohistochemistry also showed higher 
staining in RNS and RNS+ROS decellularization methods (Figure 93Z-AD). This suggests a 
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higher presence of nitroxidative protein modifications within RNS and RNS+ROS 
decellularization protocols. 
 
Figure 93: Histologic assessment of decellularized extracellular matrix biomaterials. 
Images taken at 10X. Scale bars indicate 100 µm. 
 
Hematoxylin & eosin (A-E), Masson’s trichrome (F-J) and Alcian blue (K-O) staining of 
histologic sections. Immunohistochemical staining for cysteine sulfonate (P-T), S-nitro-cysteine 
(U-Y), and 3-nitro-tyrosine Z-AD). All images at 10X (Scale bar = 100 μm). 
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A.3.2 Biochemical Analysis 
Biochemical assessment of native and decellularized scaffolds confirmed sufficient removal of 
cellular DNA content. Agarose gel electrophoresis showed significant fragmentation and 
removal of DNA from all decellularization methods (Figure 94A). However, there seemed to be 
higher levels of small DNA fragments in the RNS and RNS+ROS decellularized samples. 
Despite this finding, double stranded DNA quantification showed no significant difference in the 
amount of DNA between any decellularization method (Figure 94B). The dsDNA content in 
decellularization methods was reduced 90-95% from native small intestine and 86-93% from 
native submucosa. All methods resulted in dsDNA content less than 2000 ng/mg dry tissue.  
All decellularization methods resulted in an enrichment in hydroxyproline content. 
However, all FR methods resulted in a significant reduction in hydroxyproline content compared 
to PAA controls (Figure 94C). Similarly, glycosaminoglycan content was enriched with 
decellularization but reduced from PAA to RNS+ROS and ROS scaffolds (Figure 94E). 
RNS+ROS decellularization resulted in significantly higher protein carbonyl content compared 
to PAA controls while ROS scaffolds had higher protein carbonyl content than all other methods 
(Figure 94D). This confirms that FR decellularization methods induced protein oxidation in all 
groups. 
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Figure 94: Biochemical assessment of DNA, hydroxyproline, glycosaminoglycan and protein 
carbonyl content.  
DNA agarose gel electrophoresis of DNA extracts from ECM (A). PicoGreen 
quantification of ds DNA content in ECM (B). Hydroxyproline (C), protein carbonyl (D) and 
DMMB glycosaminoglycan (E) assays for biochemical content. Results presented as mean ± 
S.D. (* represents p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001) 
 
A.3.3 In vitro macrophage response 
Murine bone marrow-derived macrophages were exposed to ECM degradation products in order 
to determine if radical inflammatory species decellularization altered the macrophage response to 
ECM. M1 controls which were exposed to IFN-γ and LPS had higher levels of iNOS 
immunoexpression and nitric oxide production, as well as reduced levels of heme oxygenase-1 
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immunoexpression (Figure 95A, G, J). M2 controls treated with IL-4 had increased levels of 
arginase-1 immunoexpression and increased urea production (Figure 95D, M). ECM controls 
treated with PAA had baseline levels of iNOS, arginase and HO-1 immunoexpression as well as 
no nitric oxide or urea production (Figure 95A, D, G, J, M). All FR-decellularized ECM resulted 
in increased immunoexpression of iNOS, arginase-1 and heme oxygenase-1 compared to PAA 
controls (Figure 95A, D, G). RNS ECM had higher levels of iNOS immunoexpression than 
RNS+ROS ECM (Figure 95A). ROS ECM had lower levels of heme oxygenase-1 than RNS and 
RNS+ROS ECM but was not different than PAA ECM (Figure 95G). 
The effect of ECM exposure upon the ability of macrophages to polarize to extremes is 
important in understanding the mechanism of biomaterial promotion of altered host responses. 
Previous studies have shown that macrophage exposure to different types of extracellular matrix 
biomaterials have altered their phenotype and function following established cytokine 
polarization schemes [110]. Macrophages were exposed to ECM degradation products for 24 
hours then exposed to M1 or M2 cytokines for the subsequent 24 hours. PAA ECM had no effect 
on iNOS immunoexpression with M1 stimulus but all FR ECM resulted in an increased iNOS 
immunoexpression level over M1 controls (Figure 95B). All ECM exposure resulted in 
significant increases in iNOS immunoexpression with IL-4 stimulus over M2 controls (Figure 
95C). FR ECM with IL-4 post-stimulation resulted in a significant increase over PAA controls as 
well (Figure 95C). Arginase immunoexpression was significantly increased with IFN-γ/LPS 
stimulation over M1 controls (Figure 95E). ROS ECM also had significantly less arginase-1 
immunoexpression compared to PAA ECM with M1 stimulation (E). In the M2 stimulation 
group, no ECM treatment had different arginase immunoexpression than M2 controls (Figure 
95F). ROS ECM elicited decreased arginase immunoexpression from PAA and RNS+ROS ECM 
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while RNS ECM was lower than PAA ECM with IL-4 stimulus (Figure 95F). With M1 stimulus, 
all ECM groups resulted in increases in heme oxygenase-1 immunoexpression (Figure 95H). 
RNS and RNS+ROS ECM with M1 stimulus were higher than PAA and ROS ECM (Figure 
95H). With IL-4 stimulus, PAA, RNS and RNS+ROS ECM resulted in significantly higher heme 
oxygenase-1 immunoexpression than M2 controls (Figure 95I). Nitric oxide production with M1 
post-stimulus was higher with PAA, RNS and RNS+ROS ECM (Figure 95K). PAA ECM 
resulted in the highest nitric oxide production with IFN-γ/LPS while RNS and RNS+ROS was 
higher than ROS ECM (Figure 95K). There was not substantial nitric oxide production with any 
IL-4 stimulation condition (Figure 95L). With IFN-γ/LPS stimulus, PAA-treated ECM increased 
urea production over M2 controls and FR-ECM (Figure 95N). With IL-4 stimulus, PAA ECM 
also increased urea production over M2 controls as well as RNS+ROS and ROS ECM (Figure 
95O). 
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Figure 95: Bone marrow macrophage cultures with ECM pepsin digests. 
Immunofluorescence staining for iNOS (A-C), arginase (D-F) and HO-1 (G-I). Greiss 
reagent system assessment of nitric oxide production in macrophage supernatants (J-L). Urea 
production from arginase activity assay (M-O). Results presented as mean ± S.D. (* represents 
p<0.05, ** p<0.01, *** p<0.001, **** P<0.0001). 
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A.3.4 Histological evaluation of in vivo host response 
ECM scaffolds were used to repair a partial thickness defect of the abdominal wall in order to 
assess the host response to FR-decellularized ECM in vivo. This is a standard model which has 
been used extensively to assess the host response and remodeling of ECM scaffolds [59, 369, 
370, 373]. Cellularity was assessed using hematoxylin & eosin staining (Figure 96A-D). RNS 
and ROS ECM exhibited an enhanced cellular infiltration at 7 days compared to PAA controls 
(Figure 96Q). This suggests the RNS and ROS modifications elicit higher levels of cellular 
migration to the wound site. Collagen content as assessed by Masson’s trichrome staining did not 
show large changes at 7 days (Figure 96E-H). There was a significant decrease in Masson’s 
trichrome staining with RNS+ROS ECM from RNS ECM (Figure 96R). Glycosaminoglycan 
content, as assessed by Alcian blue staining, was similar in magnitude across groups (Figure 96I-
L). ROS ECM explants at 7 days did result in significantly higher Alcian blue staining at 7 days 
compared to RNS+ROS ECM (Figure 96S). There was no difference in the percentage of 
centralized nuclei in muscle fibers, indicating there was no difference in the regeneration of 
muscle fibers at 7 days (Figure 96T). Overall, histologic assessment showed a more robust 
cellular infiltration from RNS and ROS ECM without substantial changes in broad ECM 
production. 
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Figure 96: Histological assessment of explants from 7 day ECM repair of abdominal wall defect.  
Representative 20X images of hematoxylin & eosin (A-D), Masson’s trichrome (E-H) 
and Alcian blue (I-L) staining of 7 day explants of remodeling ECM. Masson’s trichrome 
staining of regenerating muscle fibers (M-P). Quantification of cellularity (Q), collagen staining 
(R), glycosaminoglycan staining (S) and percent centralized muscle fiber nuclei (T). Scale bar = 
100 μm) Results presented as mean ± S.D. (* represents p<0.05, ** p<0.01, *** p<0.001, **** 
p<0.0001) 
A.3.5 Evaluation of In Vivo Macrophage Response 
As macrophage phenotype at acute time-points following injury has been shown to predict 
positive remodeling outcomes downstream, explant sections were immunolabeled with 
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antibodies detecting macrophage polarization markers [59]. F4/80 was used as a marker for 
overall macrophage presence within the implant zone at 7 days (Figure 97A-D) [374]. F4/80 
immunolabeling showed an increased presence of F4/80+ cells in FR-ECM repaired mice (Figure 
97Q). This suggests that FR-ECM elicits a more robust macrophage response at acute time-
points. iNOS immunolabeling was performed to detect presence of pro-inflammatory 
macrophages at 7 days post-implant (Figure 97E-H). There were no significant increases in 
iNOS immunolabeling at 7 days (Figure 97R). Arginase-1 immunofluorescent labeling was 
performed to assess presence of anti-inflammatory macrophages at 7 days (Figure 97I-L). ROS 
ECM repair resulted in significantly increased arginase-1+ response over PAA and RNS ECM, 
suggesting an increased anti-inflammatory response (Figure 97S). Heme oxygenase 
immunofluorescent staining was used to assess the presence of anti-oxidant macrophages at 7 
days (Figure 97M-P). All FR-ECM resulted in significantly higher percentage of HO-1+ cells at 
7 days, indicating a robust anti-oxidant response over PAA ECM (Figure 97T). The results from 
macrophage phenotyping indicate that free radical decellularization of ECM results in increased 
macrophage infiltration and increased anti-oxidant macrophage polarization. This response could 
be beneficial to a variety of regenerative and ischemic injury applications.  
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Figure 97: Immuno-labeling of 7 day explants for macrophage polarization markers. 
Representative 20X images of immunofluorescent staining of 7 day explants for F4/80 
(A-D), iNOS (E-H), arginase-1 (I-L) and heme oxygenase-1 (M-P). Cell Profiler quantification 
of immunofluorescent staining for F4/80 (Q), iNOS (R), arginase-1 (S) and heme oxygenase-1 
(T). Scale bars = 100 μm. Results presented as mean ± S.D. (* represents p<0.05, ** p<0.01, *** 
p<0.001, **** p<0.0001) 
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A.3.6 Evaluation of Chronic Remodeling Outcomes 
Explants from ECM repair of abdominal wall defects were taken 90 days post-implantation to 
assess the effect of FR decellularization upon constructive remodeling outcomes. Hematoxylin & 
eosin staining was performed to assess gross morphology and cellularity during chronic 
remodeling (Figure 98A-D). There were no significant differences in cellularity at 90 days, 
suggesting there were no differences in ongoing inflammation (Figure 98Q). There were no 
differences in Masson’s trichrome staining, which suggests that there was no significant 
differences in fibrotic outcomes (Figure 98R). FR-ECM implantation resulted in a significant 
increase in Alcian blue staining at 90 days, indicative of increased glycosaminoglycan deposition 
(Figure 6S). Glycosaminoglycans are important factors in wound healing, which assist with 
growth factor sequestration and activity, capillary growth and collagen formation [323, 375]. 
Picrosirius red staining imaged with circularly polarized light was used to assess collagen 
alignment (Figure 98I-L). RNS ECM had increased levels of red fibers, indicating more highly 
aligned collagen fibrils than the other ECM types (Figure 98U). There were no significant 
differences in any of the other groups of fiber alignment (Figure 98V-X). In order to assess 
quality of muscle healing following regeneration, fast and slow muscle fibers were identified via 
immunohistochemistry (Figure 98M-P). RNS and ROS ECM had significantly lower fast:slow 
muscle fiber ratio at 90 days compared to RNS+ROS ECM (Figure 98T). This could be due to 
unresolved muscle healing as there is an increased presence of slow muscle fibers during acute 
muscle injury [327]. 
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Figure 98: Histologic characterization of chronic 90 day ECM repair of abdominal wall defect.  
Histologic stains of 90 day explants for Masson’s trichrome (A-D), Alcian blue (E-H), 
and polarized light microscopy of PicroSirius red (I-L). Immunohistochemical staining for fast 
(pink) and slow (brown) myosin heavy chain (M-P). Quantification of cellularity (Q), collagen 
(R), glycosaminoglycan (S), and fast/slow myosin fiber ratio (T). Quantification of red (U), 
orange (V), yellow (W) and green (X) fiber types from polarized light-imaged PicroSirius Red 
tissue sections. Scale bars = 100 μm. Results presented as mean ± S.D. (* represents p<0.05, ** 
p<0.01, *** p<0.001, **** p<0.0001). 
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A.4 DISCUSSION 
The present study sought to investigate the feasibility of decellularizing ECM biomaterials using 
radical inflammatory species, as well as the effect of these ECM on macrophage responses in 
vitro and within an in vivo model of abdominal wall repair. The results presented herein suggest 
that reactive nitrogen species, reactive oxygen species or the combination of the two are effective 
reagents for the decellularization of extracellular matrix biomaterials. These reagents also 
functionalized ECM biomaterials with natural nitroxidative and oxidative modifications similar 
to those produced during a normal inflammatory event. These modifications could be useful for 
tailoring ECM biomaterials to have an enhanced inflammatory response that could be beneficial 
in certain wound repair or disease treatment. 
While a basic biochemical assessment was performed, further investigation is necessary 
to understand how these decellularization agents modified the ECM biomaterials. 
Hydroxyproline and glycosaminoglycan content were reduced in free radical decellularization 
methods. It is unclear whether this is due to modification of these biomolecules resulting in lack 
of detection or whether there is more cellular debris within the scaffolds causing reduced 
concentration of ECM as a percentage of total mass. Mass spectrometry analysis would be useful 
in order to determine the retention of different ECM molecules with these methods, but also to 
understand which biomolecules are being modified by these reagents and how. 
Radical inflammatory species-decellularized ECM showed to have an overall antioxidant 
effect upon macrophages in vitro and in vivo.  This appears to be Nrf2-dependent mechanism 
involving heme oxygenase-1 upregulation. However, further mechanistic studies would need to 
be conducted to prove this response. Heme oxygenase-1 induction has been shown to be 
beneficial for many wound healing applications [376]. The delayed upregulation of heme 
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oxygenase in diabetic wounds may benefit from the induction of HO-1 by these biomaterials 
[377]. In muscle, heme oxygenase-1 induction has been shown to improve symptoms from 
muscle dystrophy [378].  Heme oxygenase-1 expression has been shown to prevent muscle 
hypertrophy and prevents uncontrolled muscle acceleration of muscle repair [379].  
The effect of FR-ECM on the reduction of nitric oxide production in pro-inflammatory 
conditions also shows the antioxidant potential of this decellularization method. This can be 
beneficial for preventing further oxidative damage in existing wounds. However, the lack of 
nitric oxide signaling could affect healing if it is not provided by the modifications created 
within the biomaterial. It is not evident if this reduction in nitric oxide production is due to heme 
oxygenase-1 or another antioxidant effect. More testing is needed to understand the direct effect 
of these ECM scaffolds upon the antioxidant effect of macrophages or other cell types. 
Implantation of FR-ECM into an abdominal wound defect model altered the host 
response observed from a standard ECM control. The increased cellular infiltration observed 
with RNS and ROS decellularized ECM suggests that those decellularization methods created 
damage signals that attracted cells to the site of implantation [286]. Reactive oxygen species 
have been shown to induce cellular migration through a number of pathways [380]. This 
increased migration could be beneficial in individuals with compromised immune systems such 
as the elderly or diabetics whose wounds heal more slowly [381, 382]. 
The acute host response to ECM decellularized with RNS or ROS resulted in increased 
presence of F4/80+ macrophages. ROS have been shown to induce a CCL2-dependent migratory 
response in monocytes [383-385]. As macrophage presence is required for proper muscle 
healing, an enhanced recruitment of macrophages to the site of injury could be beneficial for 
individuals with delayed immune cell recruitment [93]. FR-ECM induced increases in both anti-
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inflammatory and anti-oxidant responses as assessed by arginase-1 and heme oxygenase-1 
antibody labeling. ROS have been shown to induce M2 differentiation via late-phase ERK 
activation [362]. ROS also induce HO-1 protein production via Nrf2 activation [367]. These 
results suggest that modification of ECM with RNS or ROS directly triggers an anti-
inflammatory and anti-oxidant response.  
Chronic studies showed no difference in cellularity at 90 days, suggesting there was no 
ongoing inflammation in any of the samples. The lack of difference in collagen staining 
suggesting that no treatment induced fibrosis over the level of control ECM. The increased 
staining for glycosaminoglycans at 90 days in FR-ECM explants is interesting as fetal wounds 
have been shown to have increased GAG content [375, 386]. Previous reports have shown that 
M2 macrophages produce more glycosaminoglycans and lead to more GAG sulfation [365]. 
Therefore, the increased anti-inflammatory macrophage phenotype associated with FR-ECM 
could directly cause an increase in glycosaminoglycan production. However, the method for 
assessing GAG content was Alcian blue which is not stoichiometric. Therefore, the increased 
staining for Alcian blue does not necessarily represent a similar change in magnitude in GAG 
content at 90 days. Further biochemical testing would be needed to confirm the increased 
staining. 
The unique host response induced by modification of extracellular matrix biomaterials by 
RNS, ROS or both lends these materials to be useful for specific applications, such as ischemic 
injury, aging and diabetes. Diabetic wound healing is enhanced by Nrf2 activation and therefore, 
FR-ECM has potential in treating diabetic wounds [387]. Nitric oxide levels are low in patients 
with type II diabetes and nephropathy, which contributes to poor angiogenesis and poor wound 
healing [388]. Reactive oxygen species are recognized to contribute to many stages of wound 
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healing and angiogenesis [389]. The modification of extracellular matrix proteins and lipids with 
ROS and RNS may produce DAMPs that guide the host response towards healing. 
There are several limitation to the current approach. Firstmost, only one concentration of 
reactive oxygen or nitrogen species was used for the decellularization of extracellular matrix 
scaffolds. While a standardized protocol for decellularization using peracetic acid has been 
established, a range of concentrations and durations need to be tested to confirm the optimal 
protocol for an appropriate host response. These materials were also tested in a model of partial 
thickness muscle injury in young mice. In order to understand if these materials benefit the 
healing of ischemic conditions, these materials must be tested in aged and diabetic animals, as 
well as various site-specific ischemic injuries including wound healing, myocardial infarction, 
atherosclerosis and stroke. Further quantification of the alterations in the ECM scaffold 
composition and modification is necessary using genomics, lipidomics and proteomics. How 
these changes in composition directly impact the host response, which was not investigated in 
this study, is important to understand as well. Quantification of the effect on gene expression and 
more quantitative metrics of alterations in extracellular matrix production are necessary to 
understand the host response and chronic remodeling more fully. For the use of these reagents 
upon tissues with higher cellularity, combination protocols with detergents are necessary to 
determine if their effects are similar following detergent cellular removal. 
A.5 CONCLUSION 
Reactive oxygen and nitrogen species can serve as effective reagents for the decellularization of 
extracellular matrix biomaterials. These methods imbue biomolecular modifications that are 
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characteristic of natural inflammatory reactions. The modification of extracellular matrix 
biomaterials with these highly reactive RNS and ROS result in a greater macrophage infiltration 
and a shift toward anti-inflammatory and anti-oxidant macrophage phenotypes in vitro and in 
vivo. Chronic remodeling resulted in enhanced production of glycosaminoglycans which can aid 
in beneficial wound healing responses. 
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APPENDIX B: EFFECT OF EXTRACELLULAR MATRIX SOURCE TISSUE TYPE 
UPON REMODELING OF TEMPOROMANDIBULAR JOINT MENISCUS 
REPLACEMENT DEVICE 
B.1 INTRODUCTION 
The extracellular matrix consists of the myriad secreted proteins, glycosaminoglycan and other 
molecules that provide structural and signaling functions to a tissue. The extracellular matrix 
(ECM) is a heterogeneous, dynamic material that is affected by degradation and synthesis by 
cells and in turn provides signaling cues that affect cell phenotype. Due to this inherent 
relationship with the cells in a tissue, the ECM has been harvested as a natural biomaterial for 
reconstruction of various tissues. When effectively prepared and decellularized, ECM 
biomaterials have been shown to promote constructive remodeling, the site-appropriate 
formation of new functional host tissue [124]. This regenerative capacity has been demonstrated 
in many tissues, including esophagus, skeletal muscle, heart, brain, bone and connective tissue 
among others [390-395]. 
Recently, devices composed of ECM biomaterials have been successfully used to 
reconstruct the temporomandibular joint (TMJ) meniscus. Implantation of an acellular, porcine 
urinary bladder-derived ECM device into a canine model of TMJ meniscus replacement resulted 
in the formation of site-appropriate, functional host tissue at 6 months that mimicked the native 
TMJ disc [396]. A more robust study confirmed these previous findings using a canine, urinary 
bladder ECM device implanted into a porcine model of TMJ meniscus replacement. This study 
showed a robust, hypercellular response at 1 month post-implantation characteristic of an 
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inflammatory response. The response was resolved by 3 months as the scaffold was completely 
remodeled into new host tissue at this time. By 6 months, the new remodeled host tissue 
resembled that of the native TMJ fibrocartilage (cite). 
The extracellular matrix composition is unique to its resident tissue. Therefore, ECM 
biomaterials derived from different tissue types can result in varied cellular responses upon 
implantation. Cells have been shown to have increased proliferation when they were cultured on 
ECM harvested from their source tissue [397, 398]. Stem cells grown or administered on tissue 
specific ECM have shown improved survivability [399]. ECM tissue specificity has become of 
interest in the natural biomaterial field for these reasons. ECM tissue source has been observed to 
affect the ability of ECM scaffolds to promote constructive remodeling phenotypes downstream 
of implantation. When implanted into a rat abdominal wall muscle reconstruction model, faster 
degrading ECM scaffolds such as small intestine submucosa (SIS) and urinary bladder matrix 
(UBM) showed more anti-inflammatory macrophage phenotypes at early time points of 14 days, 
compared to slower degrading scaffolds made from dermis ECM. This was related to better 
constructive remodeling outcomes at downstream time points of 35 days in the faster degrading 
scaffolds [59]. ECM tissue source is important for the remodeling response which plays a large 
role in the success of the TMJ meniscus replacement described above. 
Therefore, the present study investigates the promotion of constructive remodeling when 
the TMJ meniscus replacement device is derived from three different ECM sources: urinary 
bladder, small intestine and dermis. These sources were chosen due to their use in many 
clinically available ECM-based products. Previous TMJ meniscus reconstruction studies were 
performed only with urinary bladder-derived ECM which does not match the tissue type of the 
TMJ fibrocartilage. A comparative study of the effects of ECM tissue source upon constructive 
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remodeling of the TMJ meniscus replacement is important for selecting the best material for 
translating this technology into the clinic. 
 
B.2 MATERIALS & METHODS 
B.2.1 Animal Tissue Harvest 
Skin, small intestine and urinary bladder were obtained from mongrel dogs of age ____ at time 
of euthanasia. Tissues were stored at -20°C until needed for further use. 
B.2.2 Tissue Decellularization 
Small intestine submucosa was prepared as previously described [128]. Briefly, the stratum 
compactum, muscularis mucosa, and tunica submucosa were mechanically delaminated from 
adjacent layers in the small intestine. Remaining tissue was thoroughly washed in type 1 water. 
Following washing, the tissue was decellularized using 0.1% peracetic acid/4% ethanol for 2 
hours then alternatively washed with type 1 H2O and 1X PBS for 15 mins each. All washes were 
performed under mechanical agitation on a rotary shaker at 300 rpm.  
Urinary bladder matrix was prepared as previously described [400]. Briefly, connective 
and adipose tissue were removed from the serosal side of the urinary bladder. Remnant urine was 
washed out with tap water. Urinary bladders were mechanically delaminated to disrupt bonds 
between muscular and connective tissue with the underlying epithelia. The tunica serosa, tunica 
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muscularis externa, tunica submucosa, and most of the tunica muscularis mucosa were 
mechanically removed. Isolated tissues were washed in type 1 H2O thoroughly. Decellularization 
was performed using 0.1% peracetic acid/4% ethanol for 2 hours followed by alternating washes 
in type 1 H2O and 1X PBS. All washes were performed under mechanical agitation on a rotary 
shaker at 300 rpm. 
Dermis was prepared as previously described [219]. Briefly, full-thickness skin was 
delaminated to remove subcutaneous fat, connective tissue, and the epidermis. Dermis was 
decellularized using incubations on a rotary shaker at 300 rpm in the following solutions: 0.25% 
trypsin, 6 hours, 1x; deionized water, 15 minutes, 3x; 70% ethanol, 10-12 hours, 1x; 3% H2O2, 
15 minutes, 1x; deionized water, 15 minutes, 2x; 1% Triton X-100/0.26% EDTA/0.69% Tris, 6 
hours, 1x then overnight, 1x; deionized water, 15 minutes, 3x; 0.1% peracetic acid/4% ethanol, 2 
hours, 1x; PBS, 15 minutes, 2x; deionized water, 15 minutes, 2x. 
Native samples were obtained by processing tissues up to the step before 
decellularization started. This was done to compare the same layers of tissues together. Samples 
to be used for biochemical assessment were lyophilized and powdered. 
B.2.3 TMJ Device Fabrication 
Temporomandibular joint meniscus replacement devices were fabricated as previously described 
[396]. Briefly, decellularized ECM was frozen at -80°C and then lyophilized. Lyophilized ECM 
was powdered using a Wiley mill. Sheets of hydrated ECM (2 for UBM and SIS, 1 for dermis) 
were placed over a mold shaped to the size of a pig TMJ meniscus. Hydrated ECM powder was 
placed into the mold recess. The ECM powder was then covered with additional sheets of 
hydrated ECM (2 for UBM and SIS, 1 for dermis). Implants were wrapped in cheesecloth then 
 222 
vacuum-pressed until sheets were dry. Implants were then frozen and lyophilized until ECM 
powder was fully dry. Devices used for implantation were sterilized using ethylene oxide. 
B.2.4 Histological Assessment 
Fresh native and decellularized tissues were fixed in 10% neutral buffered formalin for 3 days 
prior to being embedded in paraffin wax. Tissue sections were deparaffinized in xylenes 3 times 
for 3 minutes and then rehydrated using decreasing concentrations of ethanol then tap water. 
Slides were stained with hematoxylin & eosin staining to confirm removal of nuclei and 
preservation of native extracellular matrix architecture. Briefly, H&E staining was accomplished 
with 8 minutes Harris hematoxylin, 2 x 30 seconds dH2O, 1 minute 5% glacial acetic acid, 2 x 30 
seconds dH2O, 15 seconds Scott’s H2O, 2 x 1 minute dH2O, 2 minutes alcoholic Eosin, 2 x 30 
seconds 95% ethanol, 2 x 30 seconds 100% ethanol, 2 x 1 minute Xylenes, and then fixed with 
permount. 
B.2.5 DNA Content Analysis 
Paraffin sections mounted on glass slides were deparaffinized and stained with DAPI. This stain 
was used to confirm reduction in nuclei and nuclear material from the decellularized scaffolds. 
Reduction in DNA was quantified using a PicoGreen assay. Briefly, DNA was extracted from 
lyophilized native and decellularized samples using several repetitions of a 25:24:1 phenol: 
chloroform: isoamyl alcohol extraction solution. Samples were precipitated using sodium acetate 
and ethanol and washed in 70% ethanol. DNA pellets were resuspended in Tris-EDTA (TE) 
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buffer. Samples were diluted and combined with PicoGreen reagent and fluorescence intensity 
was measured (excitation = 485 nm, emission = 525 nm). 
B.2.6 DNA Fragmentation Analysis 
Fragmentation of remnant DNA was assessed using an agarose gel. Briefly, a 2% agarose gel 
was created using 0.5X TBE buffer. DNA extracts were diluted with a 6X DNA Loading Buffer 
(Novagen) and compared to a 1kD – 0.1 kD DNA standard curve (Fisher Scientific). Gels were 
imaged on a UV gel imaging machine (_____). 
B.2.7 Hydroxyproline Content Analysis 
Lyophilized native and decellularized samples were digested in papain digestion buffer (0.125 
mg/mL papain; 0.100 M cysteine; 0.100 M Na2HPO4; 0.010 M Na2EDTA) at 50 °C overnight. 
Fifty microliters of digested were added to screw-top microcentrifuge tubes and combined with 
50 μL 2N NaOH and hydrolyzed for 18 hours at 110 °C. Samples were reconstituted with 10.5 
μL dH2O. The following solutions were added to each tube and then thoroughly vortexed after 
each addition: 20 μL 5N HCl, 100 μL 0.1M Cu2SO4, 100 μL 2.5 N NaOH, 100 μL 6% H2O2. 400 
μL of 3N H2SO4 was added to each tube, vortexed and incubated at 80 °C for 5 minutes. 
Following cooling, 200 μL of freshly prepared 5% p-DMAB in n-propanol was added to each 
sample and then incubated at 70 °C for 15 minutes. Samples were transferred to a 96 well plate 
and measured for absorbance at 525 nm. 
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B.2.8 Glycosaminoglycan Content Analysis 
Papain digested samples were pipetted into 96 well plates in triplicate with 50 μL per well. Di-
methyl-methylene blue dye was added to each well at 250 μL per well. The absorbance of each 
well was measured at 540 nm and compared to a standard curve of chondroitin-6-sulfate. 
B.2.9 Protein Gel Electrophoresis 
Powdered ECM or native tissue was digested for 48 hours under constant stir in a 1mg/mL 
pepsin solution in 0.01N HCl to create a 10mg/mL ECM digest. ECM digests were diluted to 
1mg/mL then loaded into a NuPAGETM 4-12% Bis-Tris Protein Gel (Thermo) and then ran until 
protein bands reached end of gel. Gel was stained with Coumassie Blue and then washed with 
water. 
B.2.10 Mechanical Testing 
Uniaxial tensile testing was performed on rehydrated TMJ devices using an Instron mechanical 
testing device. Hydrated extracellular matrix scaffold were stretched under constant strain rate 
until failure. 
B.2.11 Temporomandibular Joint Meniscus Replacement 
Pigs underwent unilateral temporomandibular joint meniscus replacement with ECM TMJ 
meniscus replacement devices as previously described. Remodeled ECM devices were explanted 
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at 1 month and fixed in 10% neutral buffered formalin. Samples were embedded in paraffin wax, 
sectioned and then stained with hematoxylin and eosin. 
B.2.12 Statistics 
All quantitative results were analyzed statistically using a two-way ANOVA with Tukey post-
hoc testing. Significance was indicated if p-value was below 0.05. 
B.3 RESULTS 
B.3.1 Histological Assessment 
Hematoxylin & eosin stains of native tissues revealed characteristic physiology of native tissue 
with intact epidermis and hair follicles in dermis, mucosa and muscularis layers in small intestine 
and detrusor muscle in bladder. Following decellularization, all tissues exhibited removal of 
tissues adjacent to the basement membrane as well as resident cells, leaving behind only 
extracellular matrix (Figure 99). Histological assessment of TMJ meniscus replacement devices 
show highly aligned extracellular matrix sheets devoid of cellular content. 
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Figure 99: Hematoxylin & eosin staining of native canine dermis, small intestine and urinary 
bladder, respective decellularized ECM and TMJ meniscus replacement devices created from these ECM. 
B.3.2 DAPI Nuclear Stain 
Staining of tissue sections with DAPI nuclear stain revealed normal levels of cellular content in 
native samples. Decellularized ECM and TMJ meniscus replacement devices showed reduced 
amounts of DAPI staining indicative of a largely decellularized scaffold (Figure 100). 
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Figure 100: DAPI nuclear staining of native canine dermis, small intestine and urinary bladder, 
respective decellularized ECM and TMJ meniscus replacement devices created from these ECM. 
B.3.3 DNA Quantification and Gel Electrophoresis 
DNA gel electrophoresis showed large amounts of high molecular weight DNA in native tissue 
as expected. DNA extracts from decellularized ECM showed large reductions in levels of DNA 
(Figure 101A). Remnant DNA was also largely fragmented in all ECM. Quantification of 
double-stranded DNA content revealed significant reduction in DNA content in all decellularized 
samples (Figure 101B). 
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Figure 101: Electrophoresis of DNA extracts on a 2.5% agarose gel (A) and PicoGreen double-
stranded DNA quantification of DNA extracts from native and decellularized ECM (B). 
B.3.4 Biochemical Analysis 
Native and decellularized samples were digested in a pepsin/HCl solution and then ran on a 
polyacrylamide gel in order to view protein banding. Small intestine and urinary bladder 
appeared to be most similar in both native and decellularized samples. Dermis had some 
similarities in protein banding most likely associated with collagen protein. DMMB assay of 
sulfated glycosaminoglycan content did not reveal any differences between tissues or as a result 
of decellularization. Hydroxyproline content was enriched in all samples following 
decellularization. However, there were no significant differences in hydroxyproline content 
between any of the tissue types. 
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Figure 102: Polyacrylamide gel electrophoresis of ECM pepsin digests (A), DMMB assay of sulfated 
glycosaminoglycan content (B) and hydroxyproline content (C). 
B.3.5 Biomechanical Analysis 
Uniaxial tensile testing under constant strain rate was performed on rehydrated devices to failure. 
Urinary bladder devices carried the least peak load while dermis devices carried the highest peak 
load. The elastic modulus was similar for small intestine and dermis devices while urinary 
bladder had a significantly lower elastic modulus than both small intestine and dermis. 
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Figure 103: Uniaxial tensile testing under constant strain rate performed on rehydrated devices. 
Peak load (A) and elastic modulus (B) of urinary bladder, small intestine and dermis devices. 
B.3.6 Porcine Model of TMJ Meniscus Replacement 
A porcine model was used to evaluate the potential for these devices made from different source 
tissue to act as a regenerative therapy for TMJ meniscus replacement. Devices were explanted 
after 1 month for histological evaluation. Hematoxylin & eosin staining revealed that all devices 
had reduced cellularity and reorganization of matrix into a tissue resembling that of the native 
TMJ fibrocartilage. However, these samples may suggest that dermis remodels slower than small 
intestine and urinary bladder counterparts. 
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Figure 104: Hematoxylin & eosin staining of 1 month explants from porcine TMJ meniscus 
replacement and native porcine TMJ meniscus. 
B.4 DISCUSSION 
Extracellular matrix biomaterials have been proven to successfully remodel into functional site-
appropriate host tissue in numerous applications and tissues [137, 390, 396, 401]. Extracellular 
matrix is known to be tissue specific, having altered protein composition, structure and 
biomechanics which helps maintain tissue homeostasis [111, 329]. Tissue specific extracellular 
matrix has been shown to enhance tissue specific proliferation and differentiation [397]. 
Therefore, it has been posited that the use of tissue-specific ECM biomaterials for regenerative 
medicine therapies would be beneficial. However, few studies have investigated the comparative 
success of ECM biomaterials derived from different source tissues. This study seeks to determine 
the effect of fabricating ECM devices from different tissues in a recently established therapy for 
temporomandibular joint meniscus replacement. 
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Previous studies have shown that a device fabricated from sheets and powdered urinary 
bladder-derived ECM was successfully used as a replacement therapy for the temporomandibular 
joint meniscus in a canine model [396, 402]. Following 6 months of implantation, the acellular 
device was infiltrated and remodeled into a tissue resembling the fibrocartilage of the native TMJ 
disc. In order to investigate whether this successful result could be replicated with ECM derived 
from other tissues, devices were made from urinary bladder as well as small intestine and dermis 
ECM. These types of ECM have been successful clinically as they have been commercialized 
into FDA-approved medical devices [215, 403, 404]. All of these scaffolds are also derived from 
the basement membrane which is rich in ECM ligands that promote cell adhesion and migration 
[405, 406]. 
This study showed that the TMJ meniscus replacement device was able to be successfully 
fabricated from dermis, small intestine submucosa or urinary bladder ECM. ECM was prepared 
from canine sources in order to preserve xenogenicity in the porcine model used in this study. 
All three types of ECM were successfully decellularized as indicated by hematoxylin & eosin, 
DAPI, agarose gel electrophoresis and PicoGreen assay. This is important to prevent potential 
pro-inflammatory responses from significant amounts of remnant cellular material [223].  
Biochemical analysis of decellularized ECM showed no significant differences in 
sulfated glycosaminoglycan or hydroxyproline content. Further characterization using 
proteomics would be necessary to determine the specific differences in ECM composition. Gel 
electrophoresis of pepsin-digested ECM showed some differences in protein banding in dermis 
samples whereas small intestine and urinary bladder were very similar. This could be due in part 
to the more extensive decellularization procedure necessary to remove the epidermis and remove 
cells from the thicker dermal layer. The dermal decellularization procedure involves trypsin 
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which could cleave certain ECM proteins as well as detergents which could denature these 
proteins as well. This could lead to some differences in the cellular response to the TMJ 
meniscus replacement device. 
Biomechanical analysis of ECM devices showed differences in peak load and elastic 
modulus. UBM devices were weaker under tensile stress in both peak load and modulus 
compared to SIS and dermis. SIS was similar to dermis in modulus but had a lower peak load. 
These biomechanical results suggest that these different ECM biomaterials provide different 
mechanics to the cells that infiltrate them. Engler et al. showed that differences in matrix 
stiffness could lead to changes in stem cell differentiation lineage [407]. Changes in integrin 
ligand density or arrangement could affect cell mechanotransduction. However, the presence or 
spatial profile of integrin ligands was not investigated. As the temporomandibular joint meniscus 
mainly possesses a mechanical function reliant upon its unique fibrocartilage tissue structure, the 
mechanics of the implant before and after remodeling is important [408]. 
Implantation of TMJ meniscus replacement devices into a porcine model of meniscus 
replacement showed similar results across devices derived from different tissues. Explants from 
1 month showed a reduced cellularity and reorganization of the device ECM into a tissue 
resembling native TMJ fibrocartilage. However, further investigation will be necessary to show 
the presence of fibrocartilage specific ECM components. Despite differences in pre-implantation 
device biomechanics, all devices remodeled similarly. Further studies are necessary to 
investigate whether all remodeled devices possess similar biomechanics that are appropriate for 
the TMJ space. This initial data, however, seems to suggest that successful outcomes are 
achievable in the application of TMJ meniscus replacement when acellular devices are derived 
from dermis, small intestine or urinary bladder sources. 
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APPENDIX C: EFFECT OF FIBROBLAST SIGNALING UPON MACROPHAGE 
POLARIZATION 
C.1 INTRODUCTION
The processes of wound healing and fibrosis are governed by well-organized stages in order to 
achieve hemostasis, inflammatory protection, proliferation and restoration of tissue function 
[409]. Disruption or dysregulation of these processes can lead to aberrant or hypertrophic matrix 
deposition which results in fibrotic healing [259]. Major orchestrators of wound healing 
processes include macrophages and fibroblasts [410, 411]. Tissue-resident and monocyte-derived 
macrophages are recruited to wounds, contributing to pro-inflammatory defense, inflammatory 
resolution and recruitment of other cells [412]. Fibroblasts are known to contribute to 
extracellular matrix production needed to protect the wound, release proteases for provisional 
matrix remodeling, and release cytokines necessary for wound healing and angiogenesis [413]. 
Macrophages follow neutrophils to wound sites during the first few days following injury 
and persist for weeks to months. Macrophages help to orchestrate the inflammatory processes 
associated with wound healing and are responsible for proper immune resolution [414]. 
Macrophages are now known to exist in a spectrum of phenotypes known as macrophage 
polarization, existing between M1 and M2 extremes which are characterized as macrophages 
stimulated with interferon gamma and TLR ligands or interleukin-4, respectively [415]. Normal 
wound healing necessitates the timely shift of macrophages from the pro-inflammatory M1 to the 
anti-inflammatory M2 phenotype, leading to inflammatory resolution [416]. However, M2 
macrophage phenotypes have been associated with fibrosis due to their production of pro-fibrotic 
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mediators [417]. Macrophage production of matrix metalloproteinases (MMPs), which degrade 
and remodel matrix components, plays a large role in wound healing and fibrotic outcomes 
[418]. Macrophages secrete chemokines which recruit endothelial cells, stem cells and 
fibroblasts [419]. Based on these conflicting influences, the role of macrophage polarization in 
wound healing and fibrosis is important but not yet fully understood. 
Fibroblasts play an important role in the orchestration of matrix production during wound 
healing and fibrosis. Proliferation of fibroblasts occurs during the transition from pro-
inflammatory to anti-inflammatory responses and as immune cell chemotaxis reduces [420]. 
Fibroblasts produce many matrix components including collagens, fibronectins, tenascin C, 
entactin and laminins [421-423]. These cells also produce a variety of chemokines such as 
CCL2, MIP-1, and IP-10 and growth factors including FGF, PDGF and TGF-β that affect 
macrophages [424, 425]. These factors can influence macrophage polarization and likely 
contribute to a phenotype that cannot be simply explained by classical M1 or M2 cytokine 
stimulus. Additionally, the changes in fibroblast phenotype from resting to activated can also 
influence signaling production which in turn affects their effect on macrophages [426]. 
Fibroblast proliferation during the proliferative phase of wound healing is triggered by many 
factors created during the host response to injury including PDGF, TGF-β, IL-13, eicosanoids, 
and inhibited by PGE-2 [426]. Fibroblast differentiation into myofibroblasts, usually via TGF-β, 
is directly associated with fibrotic outcomes [427]. Understanding how fibroblasts and their 
activation states affect macrophage polarization is important to fully recapitulate normal wound 
healing pathways and to identify the complex pathways that contribute to fibrosis and scarring. 
This study seeks to comprehensively look at the influence of fibroblast signaling upon 
macrophage polarization. Some work has identified important relationships and effects between 
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macrophages and fibroblasts but each have been isolated in approach. One study showed that 
macrophage fibroblast interactions, which are close in normal skin, are interrupted in burn 
wounds [428]. These macrophage fibroblast interactions occur before collagen production and 
could factor into matrix production alterations [429]. Previous work has shown that conditioned 
media from pulmonary fibroblasts alters the production of IL-12 and IL-10 from peripheral 
blood monocytes [430]. These data suggest that juxtacrine, paracrine and cell contact signaling 
could be important mediators of macrophage-fibroblast interactions. They also suggest that 
fibroblasts could play an immunomodulatory role during wound healing, a hypothesis which has 
been posited previously [431-433]. In this study, a robust approach analyzing the paracrine and 
juxtacrine effects of fibroblasts upon macrophage polarization will be performed in order to 
establish pathways of fibroblast immunomodulation during wound healing. 
C.2 MATERIALS & METHODS 
C.2.1 Fibroblast Conditioned Media 
Primary dermal fibroblasts and bone marrow derived macrophages (BMDMs) were isolated from 
wild-type C57BL6/J mice (Jackson Laboratories). Fibroblast cells were cultured in a 5% CO2 
atmosphere, at 37°C in DMEM medium (Corning 10-013 CM) containing normal glucose (4.5 
g/L), 10% fetal calf serum, 1% pen/strep (Gibco 25030-081) and 1% L-glutamate (Gibco 15240-
062) either independently or in Corning 0.4-μm Transwell plates (Sigma CLS3407). Fibroblast 
conditioned media was created from two fibroblast conditions: basal (unactivated) and activated. 
Basal fibroblasts were cells in basic fibroblast media. Activated fibroblasts were stimulated with 
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TGF-β. Cells were stimulated and then fresh media was added to cells for an additional 24 hours 
in order to condition the media with their secreted products (Figure 105A).  
C.2.2 Bone Marrow Macrophage Isolation 
Bone marrow-derived macrophages were harvested from 2 month C57/BL6 mice as previously 
described [221].  Briefly, femurs and tibiae were harvested and separated from muscle and 
connective tissue.  Bones were cut at either end to expose bone marrow.  Sterile syringe and 
needles were used to flush out bone marrow using macrophage differentiation media 
(DMEM/10% FBS/10% L-929 Supernatant/1% PenStrep/2% MEM non-essential amino 
acids/1% HEPES/0.1% 55μM β-2 mercaptoethanol).  Bone marrow lysate was reconstituted in 
media and filtered through a sterile cell filter.  Cells were plated in 96 well plates at a 
concentration of 200,000 cells per well. Cells were cultured for 7 days in media to differentiate 
them into macrophages, changing differentiation media every 2 days. 
 
C.2.3 Macrophage Treatment 
Following 7 days of differentiation culture as described above, macrophages were treated with 
acute polarizing regimens to distinguish phenotypes over 24 hours.  Naïve macrophage (M0) 
controls were treated with basal media for 24 hours.  M1 (20 ng/mL IFN-γ and 100 ng/mL LPS) 
and M2 (20 ng/mL IL-4) polarizing cytokines were used to create positive controls for classical 
pro- and anti-inflammatory macrophages.  Macrophages were also treated with conditioned 
media from fibroblasts for 24 hours (FBCM) (Figure 1B). In order to determine sequential or 
synergistic effects of macrophage polarizing cytokines and the effects of fibroblast conditioned 
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media, cytokines and/or conditioned media were added in different combinations. Conditioned 
media was added for 24 hours, removed and then M1 or M2 macrophage media was added for an 
additional 24 hours (FBCM→M1Mφ and FBCM→M2Mφ, respectively). Basal, M1 or M2 
macrophage media was added for 24 hours, removed and then conditioned media was added for 
an additional 24 hours (M1Mφ→FBCM, M2Mφ→FBCM, respectively) (Figure 1B). 
Conditioned media was also added with M1 or M2 polarizing cytokines simultaneously for 24 
hours (FBCM+M1Mφ or FBCM+M2Mφ) (Figure 
1C).
 
Figure 105: Experimental design for preparation of fibroblast conditioned media (A), sequential 
treatment of macrophages with fibroblast conditioned media and polarizing cytokines (B), and concurrent 
treatment of macrophages with fibroblast conditioned media and polarizing cytokines (C). 
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C.2.4 Transwell Macrophage & Fibroblast Culture 
Macrophages were cultured in 6 well plates and stimulated with either M0, M1 or M2 polarizing 
media. Following stimulation for 24 hours, normal media was added and fibroblasts seeded in 
3μm pore transwells were added to the tops of these wells. Following 24 hours of co-culture, 
media was collected for cytokine analysis and macrophages were harvested for RNA. 
C.2.5 Indirect Immunofluorescent Antibody Staining 
Cells were fixed with 2% paraformaldehyde (PFA) for 30 minutes then washed in 1XPBS.  Cells 
were incubated in blocking buffer (2% donkey serum, 1% bovine serum albumin (BSA), 0.1% 
Tween-20) for 1 hour at room temperature.  Primary antibodies were diluted in this blocking 
buffer as follows and incubated overnight at 4 °C: iNOS (1:100, Abcam 3523) Arginase-1 
(1:200, Abcam 91279). iNOS is a classical M1 macrophage markers whereas Arginase-1 is a 
classical M2 macrophage marker. Cells were washed in 1XPBS then incubated in the appropriate 
fluorescently-labeled secondary antibody solution in blocking buffer for 1 hour at room 
temperature (1:300 donkey anti-rabbit Alexa Fluor 488 (Abcam 150073)).  Cell nuclei were 
counterstained with DAPI.  Six sets of cells were imaged 30 times across each well at 10X 
magnification using automated position capture function to remove bias from subjective image 
location acquisition. This set of 30 images per well was counted as one biological replicate. All 
imaging was performed on an Axio observer T1 microscope. Mean fluorescence intensity of 
cells was analyzed using Cell Profiler software (Broad Institute). Briefly, DAPI images were 
used by the program to identify cell nuclei then FITC images were used to identify cell borders 
around the identified nuclei. The mean fluorescent intensity was calculated by averaging the 
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pixel intensities (scale of 0 to 1) across the entire cell area. Mean fluorescence intensity values 
were averaged for all imaged cells in each well. 
 
C.2.6 Phagocytosis Assay 
Following treatments, cells were assayed for phagocytic ability using Vybrant Phagocytosis 
Assay Kit (Invitrogen).  Cells were incubated in FITC-labeled dead E. Coli particles for 2 hours 
in the cell culture incubator.  Following washing, the cells were fixed with 2% PFA for 30 
minutes then washed with 1X PBS.  Cells were counterstained with DAPI then imaged and 
analyzed as described above. 
 
C.2.7 Taqman Gene Expression Analysis 
Following treatments, macrophages (n=5 biological replicates from 5 young (2 month) and 5 
aged (18 month) mice) were harvested for RNA using Qiagen RNEasy MiniPrep RNA Isolation 
Columns following standard protocol.  RNA was quantified using a NanoDrop Lite 
Spectrophotometer (Thermo).  cDNA templates were created from 1 μg of RNA using Invitrogen 
High Capacity RNA-to-cDNA kits (Thermo).  Taqman Gene Expression Assays (Thermo) were 
performed for the following commonly reported M1 and M2 macrophage genes: Nos2 
(Mm00440502_m1), IL1b (Mm00434228_m1), IL12b (Mm01288989_m1), TNFa 
(Mm00443258_m1), MHC-II (Mm01181326_m1), Arg (Mm00475988_m1), Retlna (Fizz1) 
(Mm00445109_m1), Mrc1 (Mm01329362_m1), IL10 (Mm01288386_m1), and PPARg 
(Mm00440940_m1). 
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C.2.8 Nitric Oxide Assay 
Following treatments, 50 μL of supernatant from macrophages were transferred into a fresh 
plate.  Nitrite, a stable form of nitric oxide, content was assayed using a Greiss Reagent system.  
Briefly, 50 μL of sulfanilamide (1% in 5% phosphoric acid) was added to supernatants for 10 
minutes.  Then, 50 μL of 0.1% N-1-napthylethylenediamine in water was added to the mixture 
for an additional 10 minutes.  The absorbance at 540 nm was measured using a BioTek 
SYNERGY HTX spectrophotometer. 
 
 
C.2.9 Arginase Activity Assay 
Following treatments, media was removed and macrophages were lysed in 50μL 0.001% Triton 
X-100 in type 1 H2O with 1X Halt Protease Inhibitors (Thermo). Twenty five microliters of 
lysate was added to 25 μL of arginase activation solution (10mM MnCl2/50mM Tris-HCl, 
pH7.5) and incubated at 55°C for 10 minutes. Samples were allowed to cool and then 50 μL of 
arginine substrate solution (0.5M L-arginine pH 9.7) was added to each well.  Samples were 
incubated at 37°C for 2 hours. A urea standard curve was created via 2 fold serial dilution from 
100 mg/mL to 1.5625 mg/mL with a 0 mg/mL blank in lysis buffer. Five microliters of samples 
or standards were added to a new 96-well plate and 200 μL of urea detection solution (513 mg/L 
primaquine, 100 mg/L phthalaldehyde, 2.5 mol/L sulfuric acid, 2.5 g/L boric acid, 0.03% Brij35) 
was added to each well. Absorbance of samples was analyzed using a plate spectrophotometer at 
430 nm between 5-20 minutes following addition of detection solution. 
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C.2.10 Cytokine Array 
Fibroblast conditioned media was removed and spun down for 3 minutes at X,000g.  Total 
protein concentration and purity was measured using a Nano drop (A260/A280 ratio).  Equal 
amounts of protein were used for the analysis- using a max volume of the lowest concentrated 
protein sample in a volume of 250 ml.  A Proteome Profiler Antibody Array was used (R&D 
Systems AA006)- Mouse Cytokine Array Panel 1. The Proteome Profiler Mouse Cytokine Array 
Kit, Panel A is a membrane-based sandwich immunoassay. Samples are mixed with a cocktail of 
biotinylated detection antibodies and then incubated with the array membrane which is spotted in 
duplicate with capture antibodies to 40 specific target proteins. Captured proteins were 
visualized using chemiluminescent detection reagents. The signal produced is proportional to the 
amount of analyte bound.  Arrays were analyzed using the Microarray Profiler Plugin for 
ImageJ to quantify the integrated density of the antibody spots on the array. The image was 
Inverted, values were measured, and background (average of values from array dots F23 and 
F24) was subtracted from the values, and normalized to control treatment cells baseline 
cytokines. The identity of the dots was found by referencing the ARY006 R&D product manual. 
C.2.11 Statistical Analysis 
Quantitative results were analyzed using a one-way ANOVA with Tukey post-hoc analysis using 
GraphPad PRISM 7 software. Significance was determined at a p-value less than 0.05. 
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C.3 RESULTS 
C.3.1 Effects of Fibroblast Conditioned Media on Naïve Macrophages 
In order to determine the effects of fibroblast conditioned media upon macrophage gene 
expression, bone marrow macrophages were treated with basal media (M0), IFN-γ/LPS (M1), 
IL-4 (M2) or conditioned media for 24 hours. Taqman gene expression assays were performed 
on these samples for Nos2 and Arg1. . iNOS is a classical M1 macrophage marker, which 
metabolizes arginine to produce nitric oxide. Arginase is a classical M2 marker, which competes 
away arginine from iNOS for the production of polyamines used for collagen synthesis. 
Treatment with IFN-γ/LPS resulted in significantly higher Nos2 gene expression compared to 
M0 and M2 controls as expected (Figure 106A). Conditioned media promoted enhanced 
transcription of Nos2 at 24 hours with basal or activated CM promoting a 4.6 or 2.7 fold increase 
in Nos2 gene expression over M0 control (Figure 106A). Macrophage treatment with IL-4 
resulted in a significant increase in Arg1 gene expression compared to M0 and M1 controls as 
expected (Figure 2B). Macrophage treatment with IFN-γ/LPS resulted in a 108-fold increase in 
Arg1 gene expression. Conditioned media promoted increased Arg1 gene expression with basal 
and activated FBCM inciting a 61- and 1015-fold increase, respectively (Figure 106B). Overall, 
fibroblast conditioned media has a striking activation of anti-inflammatory macrophage 
phenotype with some pro-inflammatory effects as well, suggesting that fibroblasts have a role in 
influencing immune responses during injury. 
To assess the effect of conditioned media upon protein expression, macrophages were 
stained for iNOS and arginase immunoexpression following treatment. M1 macrophages and M2 
macrophages both showed increases in iNOS immunoexpression compared to M0 controls with 
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M1 higher than M2 as well (Figure 2C). Activated conditioned media treatment alone increased 
iNOS immunoexpression from basal CM as well as the M0 baseline (Figure 106C). Interleukin-4 
stimulation produced a significant increase in arginase-1 immunoexpression, as expected from 
M2 macrophages. Stimulation with interferon-y and lipopolysaccharides resulted in a reduced 
immunoexpression compared to M0 controls, as expected from M1 macrophages (Figure 106D). 
Conditioned media treatment alone resulted in significantly lower arginase-1 immunoexpression 
with basal CM compared to activated CM and M0 controls (Figure 106D). Overall, fibroblast 
signaling did not produce a strong M1 or M2 phenotype. Though the effect on phenotype 
appeared to be more pro-inflammatory with activated FBCM increasing iNOS and basal FBCM 
decreasing arginase-1 immunoexpression. 
While treatment with conditioned media produced significant changes in macrophage 
phenotype, we next wanted to prove that these changes also resulted in altered macrophage 
function. Pro-inflammatory (M1) macrophages are known to produce nitric oxide in order to 
produce cytotoxicity in pathogens. Nitric oxide production was indirectly measured through 
presence of the stable end product of nitric oxide, nitrite, using the Greiss reagent system. Nitrite 
content was analyzed in supernatants of macrophages following treatment. Stimulus with IFN-
γ/LPS produced significantly increased nitrite production compared to naïve and IL-4 stimulated 
macrophages, which produced no nitrite (Figure 106E). Conditioned media treatment alone led 
to little nitrite production; however both FBCM groups produced more nitric oxide than M0 
controls. This small increase in nitric oxide production in the sub-micromolar range could elicit 
anti-oxidant pathways that are protective to cells [434]. 
To assess arginase-1 functionality, urea production was measured from macrophage 
lysates following treatment as urea is produced by arginase-1. Interleukin-4 treatment caused a 
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significant increase in urea production compared to M0 and M1 controls as expected (Figure 
106F). Conditioned media treatment alone resulted in a significant increase in urea production 
from activated fibroblasts over basal (Figure 106F). Arginase activity can lead to increased 
proliferation and collagen production [435]. The increased urea production from activated 
FBCM suggests activated fibroblasts could enhance fibrosis through increased arginase activity 
in macrophages. 
Macrophages are classically known as phagocytes which uptake pathogens during injury 
and inflammation. To test changes in macrophage phagocytic function, we cultured macrophages 
with FITC-labeled E. Coli beads for 2 hours following treatments. Stimulus with IFN-γ/LPS 
resulted in significantly higher phagocytosis compared to M0 and M2 controls, as expected 
(Figure 106G). Conditioned media treatment alone had no effect upon phagocytosis. 
Phagocytosis is important in both the clearance of foreign particles during inflammation and 
debris during resolution [436]. The lack of effect on phagocytosis suggests fibroblast signaling 
does not incite a phagocytic phenotype in naïve macrophages regardless of fibroblast activation 
state. 
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Figure 106: Taqman gene expression for iNOS (A) and arginase (B) of bone marrow derived 
macrophages treated with basal media (M0), IFN-y/LPS (M1), IL-4 (M2), or conditioned media for 24 hrs. 
Immunofluorescent antibody labeling of macrophages for iNOS (C). Immunofluorescent antibody labeling 
for Arginase-1 of bone marrow derived macrophages (D). Greiss reagent system detection of supernatant 
nitrite levels at 24 hrs (E). Arginase activity assay for urea production of macrophages (F). Vybrant 
phagocytosis assay on macrophages (G). 
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C.3.2 Effect of Fibroblast Signaling on Pro-Inflammatory Macrophage Polarization 
Following analysis of the effects of fibroblast secretions upon basal macrophage phenotype and 
function, we next analyzed how fibroblast conditioned media affected polarization to pro-
inflammatory M1 extremes. Macrophages were stimulated with fibroblast conditioned media 
concurrently with (FBCM+M1Mφ), prior to (FBCM→M1Mφ), or following (M1Mφ→FBCM) 
IFN-γ/LPS treatment. Co-delivery of FBCM and M1 polarizing cytokines resulted in higher 
iNOS immunoexpression from activated FBCM over basal CM (Figure 107A). Sequential 
delivery of M1 polarizing cytokines then conditioned media resulted in a significant increase in 
iNOS immunoexpression with activated FBCM over basal as well as M1→M0 controls (Figure 
107B). Sequential delivery of conditioned media then M1 polarizing media resulted in 
significantly increased iNOS immunoexpression with activated or basal CM and M1 controls 
(Figure 107C). Fibroblast signaling appears to maintain pro-inflammatory macrophage signaling 
when it occurs simultaneously. Activated fibroblast signaling appears to extend M1 macrophage 
phenotype when following pro-inflammatory response while basal and activated fibroblasts can 
prime macrophages for an enhanced pro-inflammatory response. 
Co-stimulus with CM and M1 cytokines did not change arginase immunoexpression 
(Figure 107D). Stimulation of macrophages with IFN-γ/LPS followed by basal FBCM resulted 
in significantly less arginase positive cells compared to M1 or activated FBCM (Figure 107E). 
There was no alteration in arginase immunoexpression with FBCM→M1Mφ treatment (Figure 
107F). Similarly to iNOS immunoexpression, fibroblast signaling maintained arginase protein 
levels when it was delivered concurrently with M1 cytokines. Opposite to iNOS 
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immunolabeling, arginase immunoexpression was inhibited with basal conditioned media 
suggesting a further promotion of pro-inflammatory responses. 
Activated FBCM enhanced while basal FBCM reduced nitric oxide production when 
delivered simultaneously with M1 cytokines (Figure 107G). Delivery of conditioned media 
following M1 stimulus produced overall lower nitrite production compared to M1 stimulus alone 
while activated was higher than basal (Figure 107H). In M1→CM treatments, activated FBCM 
again enhanced nitric oxide production while basal decreased it (Figure 107I). The nitric oxide 
data is most telling of an inhibition of pro-inflammatory responses by basal fibroblasts and a 
promotion of pro-inflammatory response by activated fibroblast signaling. Interestingly, 
activated fibroblast signaling enhances nitric oxide production when provided simultaneously or 
prior to inflammatory stimulus but reduces nitric oxide when following inflammatory stimulus. 
This spectrum of responses suggests that fibroblast activation can dramatically impact the 
severity and timing of pro-inflammatory responses. 
Urea production with IFN-γ/LPS stimulus was low regardless of stimulation order. With 
simultaneous treatment, basal FBCM reduced urea production compared to M1 macrophages 
while activated FBCM enhanced it (Figure 3J). Stimulus with IFN-γ/LPS then FBCM resulted in 
reduced urea production from basal CM compared to M1 or activated FBCM (Figure 107K). 
Conditioned media treatment then M1 stimulus resulted in a reduction in urea production from 
basal FBCM compared to activated FBCM and M1 controls (Figure 107L). The small changes in 
urea production with M1 cytokines responses suggest fibroblast signaling affect anti-
inflammatory function but nitric oxide effects dominate in pro-inflammatory responses. 
Co-treatment with CM and M1 cytokines resulted in reduction of phagocytosis compared 
to M1 controls in all groups (Figure 107M). Conditioned media treatment following M1 stimulus 
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did not change phagocytosis (Figure 107N). Activated FBCM reduced phagocytosis when 
followed with IFN-γ/LPS stimulus compared to M1 controls (Figure 107O). These results 
suggest that signaling from activated fibroblasts can reduce phagocytic macrophage phenotypes 
but only if it occurs simultaneously or prior to pro-inflammatory signaling.  
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Figure 107: Immunofluorescent antibody labeling for iNOS of bone marrow derived macrophages 
treated with CM+M1 (A), M1→CM (B) or CM→M1 (C). Immunofluorescent antibody labeling for Arginase-
1 of bone marrow derived macrophages treated with CM+M1 (D), M1→CM (E) or CM→M1 (F). Greiss 
reagent system detection of supernatant nitrite levels at 24 hrs with CM+M1 (G), M1→CM (H) or CM→M1 
(I). Arginase activity assay for urea production of macrophages treated with CM+M1 (J), M1→CM (K) or 
CM→M1 (L). Vybrant phagocytosis assay on macrophages treated with CM+M1 (M), M1→CM (N) or 
CM→M1 (O).  
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C.3.3 Effect of Fibroblast Signaling on Anti-Inflammatory Macrophage Polarization 
We next analyzed how fibroblast conditioned media affected polarization to an anti-
inflammatory M2 phenotype. Co-delivery of conditioned media and IL-4 resulted in decreased 
iNOS immunoexpression with basal CM stimulation (Figure 108A). Sequential delivery of M2 
polarizing cytokines then condition media resulted in significant increases in iNOS 
immunoexpression from activated over basal CM and M2→M0 controls (Figure 108B). 
Sequential delivery of conditioned media then M2 polarizing cytokines resulted in significantly 
higher iNOS immunoexpression with activated FBCM over basal FBCM and M2 controls 
(Figure 108C). This data suggests that the presence of fibroblasts prior to anti-inflammatory 
stimulus enhances pro-inflammatory responses while only activated fibroblasts enhance pro-
inflammatory macrophage phenotype following IL-4 signaling. Fibroblast activation in anti-
inflammatory settings may contribute to mixed macrophage phenotypes observed in vivo [437]. 
Simultaneous delivery of FBCM and M2 polarizing cytokines resulted in increased 
arginase-1 immunoexpression from activated FBCM while basal FBCM decreased 
immunoexpression (Figure 108D). M2 cytokine stimulus followed by activated CM resulted in 
significantly higher arginase-1 immunoexpression than basal and M2 controls (Figure 108E). 
Sequential treatment of activated CM then M2 polarizing cytokines resulted in significantly 
increased arginase-1 positive cells over basal and M2 controls (Figure 108F).  Overall, activated 
FBCM tended to increase arginase-1 immunoexpression over basal FBCM with IL-4 stimulus, 
suggesting an enhanced promotion of an anti-inflammatory macrophage phenotype.  
Simultaneous treatment or CM treatment following IL-4 exposure resulted in more nitric 
oxide production compared to M2 controls (Figure 4G, H). However, the nitric oxide levels were 
low in magnitude. There was no significant nitric oxide production in FBCM→M2 groups 
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(Figure 108I). Simultaneous delivery of IL-4 and FBCM resulted in enhanced urea production 
compared to IL-4 alone, while activated FBCM enhanced urea over basal FBCM (Figure 108J). 
Interleukin-4 treatment followed by activated FB CM resulted in significantly higher urea 
production compared to basal treatment as well as M2→M0 controls (Figure 108K). Conditioned 
media treatment prior to IL-4 stimulus resulted in an increased production of urea from activated 
fibroblast conditioned media compared to IL-4 treatment alone while basal FB CM promoted a 
decrease (Figure 108L). TGF-beta fibroblast activation caused relatively increased urea 
production in all treatments suggesting it induces fibroblast phenotypes that enhance anti-
inflammatory macrophage responses. This could lead to a synergistic effect of anti-inflammatory 
macrophages and TGF-β activated fibroblasts to enhance collagen production in fibrosis [438]. 
With conditioned media and IL-4 co-stimulation, basal and activated CM reduced 
phagocytosis from M2 controls (Figure 108M). Activated conditioned media promoted 
reductions in phagocytosis compared to basal CM and M2 controls when condition media was 
provided before or after M2 stimulus (Figure 108N, O). Activated fibroblast signaling may 
further turn down phagocytosis in an anti-inflammatory environment.  
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Figure 108: Immunofluorescent antibody labeling for iNOS of bone marrow derived macrophages 
treated with CM+M2 (A), M2→CM (B) or CM→M2 (C). Immunofluorescent antibody labeling for Arginase-
1 of bone marrow derived macrophages treated with CM+M2 (D), M2→CM (E) or CM→M2 (F). Greiss 
reagent system detection of supernatant nitrite levels at 24 hrs with CM+M2 (G), M2→CM (H) or CM→M2 
(I). Arginase activity assay for urea production of macrophages treated with CM+M2 (J), M2→CM (K) or 
CM→M2 (L). Vybrant phagocytosis assay on macrophages treated with CM+M2 (M), M2→CM (N) or 
CM→M2 (O). 
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C.3.4 Characterization of Fibroblast Conditioned Media 
In order to determine changes in inflammatory protein expression in unactivated versus activated 
fibroblasts, conditioned media was assayed using cytokine arrays. TGF-β activation of 
fibroblasts increased protein expression of the interleukin-1 family, with IL-1ra having the 
highest increase (Figure 109A). The higher levels of IL-1ra suggest an inhibition of interleukin-1 
signaling overall, but further testing would need to be performed. Activated fibroblasts 
upregulated protein expression of a number of class I cytokines with IL-3 (~300 fold) having the 
highest increase (Figure 109B). Interleukin-3 is involved in There were also large increases in 
IL-4 (~10 fold), an anti-inflammatory cytokine, and IL-27 (~7 fold). Fibroblasts stimulated with 
TGF-β increased IFN-γ and IL-10 protein expression to similar levels (Figure 109C). Of the CC 
chemokines tested, only CCL17 had a striking increase in protein expression in activated 
fibroblasts (Figure 109D). CCL17 is a Th2 chemokine, often associated with fibrosis [439]. 
Fibroblast activation led to increases in the CXC chemokines, CXCL10 and CXCL12 (Figure 
109E). CXCL10 is upregulated during fibrosis but has been shown to inhibit fibrotic responses 
[440]. CXCL12 has been shown to promote fibrosis through CXCR4 signaling [441]. 
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Figure 109: Cytokine array of conditioned media from basal or TGF-β activated fibroblasts. Fold 
change in protein levels normalized to basal fibroblasts for interleukin 1 cytokines (A), class 1 
(hematopoietin) cytokines (B), class II (interferon) cytokines (C), CC chemokines (D), CXC chemokines (E) or 
members of other cytokine families (F). 
C.3.5 Bi-directional signaling between fibroblasts and macrophages 
In order to determine real-time communication between macrophages and fibroblasts, fibroblasts 
were cultured in transwells above macrophages polarized to M0, M1 or M2 phenotypes. 
Following 24 hours of culture together, conditioned media from macrophages was collected and 
analyzed using cytokine arrays (Figure 110). Cytokine expression was normalized to M0 
macrophages without fibroblast influence. M1 macrophages alone caused increased levels of IL-
6, IL-10, GM-CSF, and TNFa while decreasing IFN-g, IL-1b, CCL3, CCL4, CXCL2 and 
CXCL12 compare to M0 alone. M2 macrophages alone caused increased levels of IL-1b, GM-
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CSF and TNF-a cytokine expression while decreasing IFN-g, IL-6, IL-10, CCL3, CCL4, 
CXCL1, CXCL2 and CXCL12. Addition of fibroblasts above M0 macrophages caused increases 
in IL-b, IL-6, CXCL2 and TNF-a while reducing IFN-g, IL-10, CCL3, and CCL4 compare to M0 
alone. Addition of fibroblasts above M1 macrophages increased IL-1b, IL-6, CXCL2, GM-CSF 
and TNFa while decreasing IL-10 compared to M1 alone. Addition of fibroblasts above M2 
macrophages increased cytokine expression of IL-6 and CXCL1 while reducing IFN-g, IL-1b, 
CCL3, CCL4, CXCL2, and GM-CSF compared to M2 alone. Addition of fibroblasts seemed to 
enhance pro-inflammatory responses in M0 and M1 macrophages while tuning down pro-
inflammatory responses in M2 macrophages. 
 
Figure 110: Cytokine array analysis of macrophages cultured with and without fibroblasts in 
transwells above. 
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C.4 DISCUSSION 
The host response following injury involves many cells and phases in order to orchestrate proper 
healing. Macrophages are well known orchestrators of the innate inflammatory response while 
fibroblasts orchestrate the proliferative and remodeling phases of wound healing. While much is 
known about how the invasion, activation and resolution of these cell populations affects the 
wound healing process, how they affect each other is largely unknown. This study sought to 
understand how signaling from fibroblasts influences macrophage phenotype and function. 
Therapies targeting an anti-inflammatory response may have varying responses based on the 
cellular microenvironment caused by other host response cells such as fibroblasts. Understanding 
the pathways controlling this interaction is crucial to optimizing therapies or reducing fibrosis. 
Conditioned media from resting, proliferating and activated fibroblasts had profound 
differences on macrophage phenotype and function as assessed by these in vitro assays. 
Cytokines produced by proliferative and activated fibroblasts enhanced macrophage iNOS 
immunoexpression in basal, pro- and anti-inflammatory states, suggesting that fibroblast 
activation can incite or propagate pro-inflammatory phenotypes. Fibroblast activation has been 
associated with pro-inflammatory responses, including from macrophage-derived TNFα, in 
atherosclerosis [442]. In contrast, depletion of macrophages from ischemic heart injury prevents 
fibroblast activation and fibrosis, as well as appropriate healing [443]. While previous studies 
have shown that pro-inflammatory macrophages activate fibroblasts in wound healing, our 
results suggest that fibroblast activation, in turn, can promote inflammation in the absence of 
other signals. 
Anti-inflammatory macrophage immunoexpression was mainly affected by fibroblast 
signaling in basal and IL-4 environments. Interestingly, TGF-β is chiefly produced by 
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macrophages when in an anti-inflammatory state [444]. The reduction in arginase-1 
immunoexpression in naïve macrophages promoted by basal and proliferative fibroblast 
signaling suggests that these signals promote a pro-inflammatory environment. Interestingly, 
basal and proliferative fibroblast signaling reduced arginase immunoexpression when combined 
with IL-4 stimulation, suggesting an inhibitory role in anti-inflammation if fibroblasts are present 
during alternative macrophage activation. The sweeping enhancement of arginase 
immunoexpression when combined with activated fibroblast signaling suggests that 
myofibroblasts can prolong alternative activation, which in turn could prolong fibrosis. 
Gene expression analysis showed that basal fibroblast conditioned media promoted an 
enhanced iNOS expression where activation enhanced arginase gene expression. While all 
conditioned media promoted enhanced iNOS and arginase gene expression, this data suggests a 
spectrum of macrophage phenotypes promoted by the spectrum of fibroblast activation from a 
pro-inflammatory macrophage incited by basal fibroblasts and anti-inflammatory macrophage 
promoted by myofibroblasts. 
Our results suggest that fibroblast signaling not only affects macrophage protein and gene 
expression, but also functional metrics of nitric oxide production and arginase activity. Fibroblast 
conditioned media led to slight production when macrophages were treated with it alone, with 
IL-4 simultaneously or after IL-4 stimulation. Despite these nitric oxide levels being quite low 
compared to pro-inflammatory macrophage levels, nitric oxide is known to have cyto-protective 
activity at nanomolar concentrations [445]. Fibroblast signaling with pro-inflammatory stimulus 
had contrasting effects on nitric oxide production depending on the timing of exposure. 
Conditioned media exposure following pro-inflammatory stimulus reduced nitric oxide 
production suggesting fibroblasts can reduce macrophage cytotoxicity and transition to anti-
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inflammatory activation. Conditioned media exposure before pro-inflammatory stimulus 
inhibited nitric oxide production with basal fibroblasts and enhanced NO production with 
activated fibroblasts. This suggests promotion of distinct phenotypes with the presence of 
difference fibroblast activation states prior to inflammation. Similarly, basal and proliferative 
fibroblast signaling inhibited while activated promoted nitric oxide signaling when provided 
simultaneously with IFN-γ and LPS. This also suggests fibroblast presence as well as its 
spectrum of activation can have strong effects on macrophage function during ongoing 
inflammation as well as influence the transition to anti-inflammatory phenotypes. 
Urea production, an indicator of arginase activity, was also strongly affected by fibroblast 
signaling. Arginase also produces ornithine which is used to form polyamines and L-proline, 
both of which are needed for collagen production. Enhanced arginase activity elicited by 
activated fibroblasts may compound the already fibrotic characteristics of these cells. The 
presence of basal or activated fibroblasts during or activated fibroblasts after IL-4 mediated 
alternative macrophage activation drastically enhances this arginase activity in vitro. These 
specific cellular interactions may be a cause for fibrosis where macrophages and fibroblasts are 
synergistically causing collagen deposition. The presence of basal or proliferating fibroblasts 
prior to alternative activation may prevent this drastic increase in arginase activity and may 
prevent excess collagen production. 
Fibroblast signaling also had effects on the phagocytic function of macrophages, which is 
important in the clearance of debris as well as uptake and presentation of antigens [446]. 
Phagocytosis of apoptotic neutrophils leads to the down-regulation of pro-inflammatory factors 
IL-1β, IL-8, IL-10, GM-CSF and TNFα while increasing TGF-β and PGE-2, factors that lead to 
fibroblast activation [447]. Our data shows that proliferative and activated fibroblast signaling 
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decreases macrophage phagocytosis suggesting that these signals provide a feedback loop 
shifting macrophages from clearance and surveillance to focus on repair and resolution. The lack 
of inhibition of phagocytosis when CM was presented followed by pro-inflammatory stimuli 
suggests fibroblast signaling is not strong enough to inhibit phagocytosis after pathogens are 
already detected. However, simultaneous or previous fibroblast conditioning can steer 
macrophages away from this phenotype. 
Transwell experiments where macrophage and fibroblast signaling was allowed to occur 
in real-time showed interesting effects on cytokine production. The addition of fibroblasts above 
macrophages enhanced several pro-inflammatory cytokines including IL-1β and IL-6 in all 
macrophages while only increasing TNFα in M1 macrophages, suggesting fibroblasts may 
enhance pro-inflammatory responses from macrophages. Fibroblast transwell addition also 
reduced IFN-γ and IL-10 cytokine levels. The increase in CXCL2 levels with fibroblast co-
culture suggests enhanced migratory signals which would lead to higher recruitment of 
inflammatory cells to the site of injury [448]. The decreased levels of CCL3, an inhibitor of stem 
cells, with fibroblast addition may lead to enhanced tissue repair [449]. Overall, fibroblast co-
culture enhanced pro-inflammatory cytokine production indicative of an ongoing injury 
response. 
Macrophage and fibroblast responses are crucial to the inflammatory and remodeling 
processes that occur following injury. Many studies focus on how factors or treatments affect 
one of these cell populations separately. This study highlights how fibroblast signaling can have 
drastically different impacts on macrophage phenotype and function based on fibroblast 
activation state and when fibroblast signaling is presented to these macrophages. More robust 
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analysis of both macrophages and fibroblasts as well as their interactions is necessary to 
understand the response to injury and therapeutic interventions designed to improve outcomes. 
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